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The g-amino-butyric-acid (GABA) is the main inhibitory neurotransmitter in the central nervous system 
(CNS) and exerts its physiological role by binding to the ionotropic GABAA and GABAC receptors and 
the metabotropic GABAB receptor (GABAB-R). The GABAB-R is an obligate heterodimer that belongs 
to class C of guanine-binding proteins (G-protein) coupled receptors (GPCRs). Each monomer, 
GABAB1a/b and GABAB2, is comprised of an extracellular bi-lobed domain connected by a short loop to 
a heptahelical transmembrane domain (7TM). The extracellular domain is called the Venus flytrap 
(VFT) due to the architectural and mechanical resemblance to the carnivorous flower. The GABAB1a/b 
VFT contains the orthosteric GABA binding site, while the 7TM domain of GABAB2 hosts an allosteric 
binding site and is responsible for binding of G-proteins.  
 
Previous studies have shown that the GABAB-R is associated with numerous neurological and 
neuropsychiatric disorders including learning and memory deficits, depression and anxiety, addiction 
and epilepsy. The role of GABAB-R in pathophysiology makes it an exciting target for drug 
interventions, especially since there is only one drug on the market targeting the receptor, the agonist 
baclofen. At present, there are few known available orthosteric GABAB-R ligands and the majority of 
them are analogues or derivatives of GABA. The low structural diversity of known ligands may indicate 
that the conformational space of orthosteric ligands and the orthosteric binding site is not fully explored. 
The complex activation mechanisms of the GABAB-R and concepts such as ligand bias, where activation 
of GPCRs favors one intracellular signaling pathway, and allosteric modulation of signaling effects, 
emphasize the benefits of discovering new orthosteric ligands that can promote advantageous- and/or 
block potential adverse effects, either alone or in combination with allosteric modulators. The three 
dimensional (3D) structure of the full GABAB-R has not been resolved, but nine crystal structures of the 
VFTs co-crystalized with agonists or antagonists have been published. Based on knowledge from other 
class C members, the receptor is presumed to undergo comprehensive structural rearrangements when 
activated, starting from stabilization of the extracellular GABAB1a/b VFT in a closed conformation and 
transduction of the signal to the 7TM of the GABAB2 and binding of G-proteins.  
 
On the background of the limited number of agonist and antagonist, we tested the applicability of both 
classical structure-based and ligand-based methods in a virtual screening (VS) workflow to discover 
novel orthosteric ligands targeting the GABAB-R. The methods found to be reliable were further applied 
in a VS study to retrieve potential candidates from databases of altogether 8.2 million commercially 
available compounds. A total of 34 ligands were bought and tested in a functional cAMP assay using 
Wild Type (WT) Chinese hamster ovary (CHO) cells and CHO-K1 cells stably overexpressing the 
human GABAB-R. All compounds have been tested in the wild type cells, while eight have so far been 
tested in the GABAB-R cells, and two have showed antagonistic properties. In paper 3, classical 
 xii 
molecular dynamics (MD) simulations were used to gain insight into the structural movements of the 
VFT, and investigate potential stable receptor conformations in absence of ligands. Analysis and 
concatenation of the MD trajectories showed reaction coordinates for the open-close transition, but the 
transition could not be observed in individual simulations. Frames were extracted and connected to 
represent motions of the VFT as a path collective variable to study the free energy surface associated 
with the transitions in a Well-Tempered metadynamics stimulations. The results show that the barriers 
between the open/inactive and closed/active conformation is high, indicating that a ligand is needed for 






1.1 Neurotransmission and neurotransmitters 
 
The nervous system can be separated into two major parts based on function and structure, the 
central nervous system (CNS) and peripheral nervous system (PNS). The CNS consists of the 
spinal cord and the brain, while the PNS is a collection of all nerves outside this area and is 
responsible for transmitting signals to the CNS (called afferent or sensory neurons) and from 
the CNS (called efferent or motor neurons) (Costanzo, 2010).  
 
The nervous system is comprised of neurons (nerve cells) that are specialized in receiving and 
conducting electrochemical impulses from other neurons or cells. A neuron consists of a cell 
body, called soma, with dendrites and an axon extending from the soma (Fig. 1). The dendrites 
are branched extensions of the cell body capable of conducting impulses to the cell body, while 
the axon is a long extension of the cell body responsible for communication with other neurons 
by transmitting the received impulses from the dendrites (Barrett and Ganong, 2010).  
 
Figure 1 – An illustration of a network of neurons with typical neuron structures and the chemical 
synapses. Depolarization of a neuron causes an action potential to travel through the axon and causes 







The impulses are electrochemical waves travelling along the axon that can cause a release of 
molecules (ions, neurotransmitters) from terminals of the presynaptic cell into the synaptic 
cleft, that act on the postsynaptic cell (Battista et al., 2015). The impulses are triggered by 
voltage-gated sodium (Na+) channels in the cell membrane of the neuron, and are called action 
potentials. The resting membrane potential of a nerve cell is -70 mV, and the sodium-potassium 
ion pump bound to adenosine triphosphate (ATP) is an important contributor to regulating and 
balancing the membrane potential (Battista et al., 2015). Action potentials occur when a 
stimulus, e.g. a neurotransmitter, causes influx of cations resulting in a more positive cell body, 
and when the current reaches the critical threshold of -55 mV the action potential is triggered 
(Battista et al., 2015). The event activates voltage-gated sodium channels at the axon closest to 
the cell body, which becomes depolarized and sends the signal further down the axon.  
 
The impulses received by dendrites and the transmission conducted by axons are conveyed in 
the synaptic cleft. In the synaptic cleft, the plasma membrane of the presynaptic cell comes into 
close proximity with the membrane of the target neuron (postsynaptic cell) (Fig. 1). There are 
billions of neurons in the brain that communicate via chemical and electrical synapses. 
Electrical synapses are directly coupled by a physical connection between the pre- and 
postsynaptic neuron that allows ions to flow directly from one neuron to another (Pereda, 2014). 
Chemical synapses encompass release of the chemical messengers, neurotransmitters, from the 
presynaptic neuron to a receiving cell or neuron and are the most common type of synapses 
(Barrett and Ganong, 2010; Pereda, 2014).  
 
Neurotransmitters themselves are produced by presynaptic neurons and stored in synaptic 
vesicles. More than 100 different neurotransmitters have been identified and divided into two 
main classes in humans; small-molecule neurotransmitters and neuropeptides (Barrett and 
Ganong, 2010). The small molecule neurotransmitters include amino acid transmitters like 
glycine, γ-aminobutyric acid (GABA), and glutamate, bioaminergic neurotransmitters such as 
dopamine, noradrenaline, adrenaline, histamine and serotonin synthesized from amino acid 
precursors, and purinergic neurotransmitters such as ATP and adenosine. Acetylcholine is also 
a small molecule neurotransmitter. The neuropeptides contain three or more amino acids and 
include substances such as the endorphins (Barrett and Ganong, 2010).  
 
Following release of the neurotransmitters to the synaptic cleft, receptors present on 
surrounding postsynaptic cells can bind neurotransmitters released by presynaptic cells and 





nature of the neurotransmitter as inhibitory or excitatory depends on the target receptor. For 
example acetylcholine gives an excitatory function on neuromuscular junctions causing 
muscles to contract by binding to nicotinic acetylcholine receptors (nAChRs), while giving 
inhibitory effect in the heart causing the heart rate to slow down by binding to muscarinic 
acetylcholine receptors (mAChRs) (Battista et al., 2015). Termination of neurotransmitter 
binding to its receptor is accomplished by removal of neurotransmitters from the synaptic cleft. 
There are three main ways of removal depending on the neurotransmitter; enzymatic 
breakdown, reuptake and diffusion away from the synaptic cleft (Lodish, 2000). Monoamines 
like dopamine, serotonin and noradrenalin are mainly removed by reuptake of the intact 
molecule into the axon terminal that released the monoamines by specialized and selective 
transporter proteins. Acetylcholine and neuropeptides become enzymatically degraded in the 
synaptic cleft. Reuptake of amino acid neurotransmitters like GABA and glutamate is facilitated 
both post- and presynaptically by uptake through transporter proteins, in addition to diffusion 
and uptake by non-neuronal cells (Barrett and Ganong, 2010; Lodish, 2000). 
 
Through binding to its receptor(s), a neurotransmitter can cause ion channels to open or close 
on the postsynaptic cell and thereby increases or decreases the likelihood of the postsynaptic 
neuron to fire an action potential. If the shift in synaptic potential makes the postsynaptic neuron 
less likely to generate an action potential (influx of anions), it is called hyperpolarization or 
inhibitory post-synaptic potential (IPSP), which is often associated with the main inhibitor 
neurotransmitter GABA. Excitatory postsynaptic potential (EPSP) is the depolarizing response 
from opening of channels ensuring influx of cations and sometimes multiple EPSPs are needed 
to trigger the action potential (Barrett and Ganong, 2010). Glutamate is the neurotransmitter 
most often associated with EPSP. A postsynaptic neuron may receive signals from multiple 
neurons of both excitatory and inhibitory character and if the sum of the signals causes the 
membrane potential to reach the threshold potential, the neuron fires and potentially release 
neurotransmitters from presynaptic terminus.  
 
Neurotransmitter receptors can be divided into two broad categories, G-protein coupled 
receptors (GPCRs) and ligand-gated ion channels (ionotropic receptors) (Fig. 2). GPCRs are 
mainly responsible for slower synaptic responses (seconds) because binding of a 
neurotransmitter causes activation of intracellular G-proteins before these can activate 
intracellular signaling cascades and/or ion channels. Ligand-gated ion channels are responsible 





causes immediate conformational changes allowing ions to cross the membrane (Barrett and 
Ganong, 2010; Lodish, 2000).  
 
 
Figure 2 – A simplified representation of slow and fast neurotransmitter receptors at the postsynaptic 
neuron. Binding of a neurotransmitter to a G-protein coupled receptor (blue) can activate intracellular 
effectors affecting ion channels resulting in fluxion of ions across the membrane. Ligand gated ion 
channels (purple) bind neurotransmitters, inducing conformational changes of the receptor and allow 
ions to be translocated through the channel and thereby exhibit a fast responses in the millisecond range. 
 
1.2 GABA and Glutamate in the CNS   
 
GABA is the main inhibitory neurotransmitter in the CNS, while glutamate is the main 
excitatory neurotransmitter. The inhibitory function of GABA is closely regulated with the 
excitatory function of glutamate for maintaining normal brain function.  
 
Glutamate is distributed throughout the brain and spinal cord. Glutamate signaling is conducted 
both by ionotropic and metabotropic receptors (Barrett and Ganong, 2010). Ionotropic 
glutamate receptors mediate fast excitatory transmission and can be divided into 3 different 
classes based on the agonist selectivity; N-methyl-D-aspartate (NMDA) that controls Ca2+ 
influx and kainate (KA) and α-amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid 





metabotropic glutamate receptors (mGluR) are responsible for slow synaptic activation and 
function by recruitment of intracellular heterotrimeric G-proteins and thereby activation of 
secondary signals and downstream signal transduction pathways. There are in total eight 
different mGluRs divided into three groups based on homology, signal transduction pathways 
and ligand binding (Niswender and Conn, 2010). The first group contains mGluRs 1 and 5, 
group 2 includes mGluRs 2 and 3 and the last group includes mGluRs 4, 6, 7 and 8. The 
receptors in these groups couple to different G-proteins and have different functions, most of 
them modulate voltage-gated calcium channels (Niciu et al., 2012; Wierońska and Pilc, 2019). 
 
GABA is synthesized from glutamate by glutamate decarboxylase (GAD). GABA exerts its 
function by binding to the ionotropic GABAA receptor (GABAA-R) and GABAC receptors 
(GABAC-R) and the metabotropic GABAB receptor (GABAB-R). Activation of the ionotropic 
GABAA-R and GABAC-R causes influx of Cl- ions, leading to hyperpolarization of the cell 
(Chebib and Johnston, 1999). The GABAB-R is found on neurons and glia cells and has a 
widespread distribution in the CNS (Gassmann and Bettler, 2012).  
 
1.3 G-protein-coupled receptors 
 
The GABA and glutamate metabotropic receptors are members of the GPCR superfamily of 
receptors that constitutes one of the largest protein superfamilies encoded by the mammalian 
genome (Katritch et al., 2013). GPCRs are involved in extensive physiological signaling 
processes in the human body from detecting external signals such as ions, photons and lipids, 
to signals such as hormones and neurotransmitters (Fredriksson, 2003). GPCRs play a 
substantial role in pathophysiology and are therefore among the most intensively studied drug 
targets  (Hauser et al., 2017). More than 800 GPCRs are encoded by the human genome, which 
comprises 4 % of the total protein-coding genome (Fredriksson, 2003; Pándy-Szekeres et al., 
2018). Approximately half of the GPCRs have sensory functions including mediating olfaction 
and taste, pheromone signaling and light, while the remaining are non-sensory GPCRs (Hauser 
et al., 2017).  
 
All GPCRs are activated by binding of an agonist at an extracellular accessible site, and they 
share the common feature of seven transmembrane spanning (7TM) a helices connected by 
intra- and extracellular loops (Fig. 3). Ligand binding induces a conformational change in the 
intracellular part of the receptors resulting in binding of G-proteins or the adaptor proteins 





arrestins are further responsible for activation, regulation and termination of intracellular 
signaling cascades (Erlandson et al., 2018). The signaling cascades lead to cellular responses 
where individual receptors exhibit unique combinations of signals due to the coupling to 
different G-proteins or arrestins. Constitutive activity without external stimulus present may 
also occur (Hilger et al., 2018; Luckey, 2014).  
 
 
Figure 3 – An overview of the general architecture of the 7 transmembrane domain of a GPCR. The N- 
terminus and three loops (ECL1-3) are located on the extracellular side of the membrane and the C-
terminus with three loops (ICL1-3) are located on the intracellular side.  
Two main classification schemes exist for separating GPCRs into classes based on sequence 
homology and phylogenetic analysis; the clan system and the GRAFS classification 
(Fredriksson, 2003; Kolakowski, 1994). These schemes are partly overlapping by denoting the 
classes A-F or by their prototypical members; class A (Rhodopsin), class B (B1: Secretin and 
B2: Adhesion), class C (Glutamate), class F (Frizzled) and taste 2. Class D and E only exist in 
invertebrates and are encountered by the clan system, while the GRAFS system only includes 
classes identified in humans (Fredriksson, 2003; Kolakowski, 1994). The classes are further 
separated into subclasses based on pharmacological classification of their endogenous ligands 
(Davies et al., 2011; Fredriksson, 2003; Kolakowski, 1994). Class A (rhodopsin family) is the 





and neuropeptides among others (Katritch et al., 2013). Peptide binding GPCRs are the biggest 
family within class A and are mainly receptors for hormone peptides which are important in 
physiological processes such as hormonal homeostasis (Hollenstein et al., 2014; Kobilka, 
2007). Class B (secretin and adhesion family) GPCRs are more diverse with multiple 
physiological functions and are characterized by their long N-terminus that is capable of 
mediating contact with surrounding cells through cell-cell or/and cell matrix interactions 
(Paavola and Hall, 2012). Class C (glutamate family) is composed of 22 GPCRs and includes 
receptors for the main inhibitory and excitatory neurotransmitters GABA (GABAB-R) and 
glutamate (mGluRs), respectively (Munk et al., 2016). In addition to the neurotransmitter 
binding receptors, the class is composed of calcium sensing receptors (CaSR) important for 
calcium homeostasis, pheromone receptors, taste 1 receptors and several orphan receptors 
(Chun et al., 2012).  
 
The architecture of the entire receptor and localization of binding sites vary between the 
different classes of GPCRs. Members of class A have the simplest receptor architecture with 
both the orthosteric and a topologically distinct allosteric binding sites located in the 7TM (Lee 
et al., 2015). In contrast, the class C members have a large extracellular N-terminal that hosts 
the orthosteric binding site in a bi-lobed architecture, while the allosteric site is located within 
the 7TM (Basith et al., 2018; Geng et al., 2013).  
 
1.3.1 GPCR signaling pathways  
 
Agonist binding causes receptor activation and coupling to heterotrimeric G-proteins or 
arrestins that initiate intracellular signaling cascades (Hilger et al., 2018). The G-proteins 
consist of three subunits: Ga, Gb and Gg (Hilger et al., 2018). In the resting state, guanosine 
diphosphate (GDP) is bound to the Ga subunit (Hilger et al., 2018). Coupling of a 
heterotrimeric G-protein to a receptor induces a conformational change in Ga, which causes an 
exchange of the GDP to guanosine triphosphate (GTP), and a switch from inactive to active 
state (Hilger et al., 2018) (Fig. 4). Activation induces downstream effects by dissociation of the 
GTP-bound a subunit from the Gbg dimer, and interactions of Gα and Gbg with effectors 
(Hilger et al., 2018). The effectors include enzymes that modulate secondary messengers or 
ions channels such as calcium channels (Chang et al., 2013). The G-protein remains active as 





ability to hydrolysis of GTP to GDP and re-association of the G-protein subunits (Battista et 









Figure 4 – A simplified scheme of signaling pathways for GPCRs. Activation of a receptor causes 
coupling to G-proteins or Arrestins. The Ga family are shown with their second messengers in addition 
to the targets of the Gbg subunits. GIRK – G-protein Coupled Inwardly Rectifying K+ channel, G-
proteins – Guanine nucleotide binding protein, RGS – Regulators of G-protein signaling, PLC – 
Phospholipase C, AC – Adenylyl Cyclase, GTP – Guanosine Triphosphate, GDP – Guanosine 
Diphosphate, Cdc-42 – Cell division control protein 42, DAG – Diacylglycerol, InsP3 – inositol (1, 4, 
5) triphosphate, AMP – Adenosine monophosphate, ∆V – Voltage change. Rho A - a subfamily of small 
GTPases (modified from Watson, 2015). 
 
G-proteins are separated into four main classes Gas, Gai/o, Gaq/11 and Ga12/13 based on 
sequence homology (Neves, 2002).  Activation of each class is associated with inhibition or 
activation of a particular set of effector proteins. The Gai/o subunit often targets and inhibits the 
enzyme adenylyl cyclase (AC) and thereby formation of the second messenger cyclic adenosine 
monophosphate (cAMP) from ATP and activation of protein kinase A (PKA) (Battista et al., 
2015). This pathway is used by many neurotransmitters such as dopamine, acetylcholine and 
GABA (Gassmann and Bettler, 2012; Neves, 2002). Muscarinic acetylcholine receptors, 
coupled to Gi/o, are located in the heart to produce effects opposing the effects of the b-
adrenergic receptors by decreasing the heart rate. Gas stimulates the AC and thereby the cAMP 
production, and further activation of PKA which regulates ion channels and affect gene 
expression (Gassmann and Bettler, 2012). For instance in cardiac muscles the b-Adrenergic 
receptors are using this pathway, where the cAMP dependent PKA phosphorylates and opens 





The Gq/11 class activates the phospholipase C (PLC) pathway and second messengers such as 
inositol (1, 4, 5) triphosphate (IP3) and diacylglycerol (DAG) (Neves, 2002). IP3 triggers release 
of calcium from endoplasmic reticulum (ER) and can give effects such as smooth muscle 
contraction and increased hormone or transmitter release by depolarization (Battista et al., 
2015). GPCRs that utilize this pathway include some of the muscarinic acetylcholine and 
serotonergic receptors (Battista et al., 2015). DAG activates and regulates one of the six PKC 
types which again can give over 50 different effects including neurotransmitter release, ion 
transport and inflammation (Battista et al., 2015; Neves, 2002). G12/13 interacts via the Rho 
GTPase family, which is a part of the Ras superfamily (Kozasa et al., 2011). The cellular effects 
and interactions with effectors of this class are still under investigation, but there is strong 
evidence that it plays a large role in processes such as cell growth and polarity, apoptosis and 
immunity (Neves, 2002; Suzuki et al., 2009; Syrovatkina et al., 2016). The bg dimer can interact 
with G-protein-coupled receptor kinases (GRK), AC, PLC and multiple ion channels such as 
G-protein-mediated inwardly rectifying potassium channels (GIRK). 
 
Activation of GPCRs can also lead to phosphorylation of intracellular amino acids by GRKs. 
The phosphorylated site can then act as a binding site for arrestins causing G-protein 
independent signaling and receptor desensitization (Hilger et al., 2018). Arrestins activate 
effector proteins such as mitogen-activated protein kinases (MAPKs), which regulate cellular 
processes including proliferation, differentiation and apoptosis, or the cytoplasmic non-receptor 
tyrosine kinases Src (Alberts, 2008). There are also some G-proteins, Gs and Gi that can activate 
Scr (Alberts, 2008). There are four different subtypes of arrestins that are suggested to be highly 
adaptable in terms of changing conformations to engage different downstream effectors (Hilger 
et al., 2018). Recruitment of arrestins also promotes internalization by endocytosis and the 
receptors becomes dephosphorylated and recycled or degraded in lysosomes (Benke, 2012). 
 
1.3.2 Orthosteric and allosteric GPCR ligands  
 
Ligands bind to the orthosteric binding site and act as agonists activating the receptor, or 
antagonists inhibiting the receptor function. The magnitude of agonist activation depends on 
the affinity and efficacy of the agonist. A full agonist is defined as a compound giving 
maximum (100 %) efficacy meaning maximum effect, while agonists with less efficacy are 
called partial agonists (Fig. 5). Inverse agonists exerts the opposite pharmacological effect of 





and Nishtala, 2017). Antagonists can compete with agonists for the binding to the receptor 
(competitive), and in contrast to inverse agonists, antagonists do not turn-off the constitutive 
activity. Most antagonists bind in a reversible manner, but may also bind irreversibly to the 
receptor. In all cases the antagonist reduces the ability of agonists to bind (Salahudeen and 





Figure 5 – Illustration of potential dose-response plots for agonists with different receptor efficacy 







Binding of modulators in the allosteric site can change the receptor efficacy, called efficacy 
modulation, and/or modify of the agonist association or dissociation rate, called affinity 
modulation (Conn et al., 2014; Gilchrist, 2010). Positive allosteric modulators (PAMs) bind to 
the allosteric site and potentiate receptor activation upon binding of an orthosteric agonist. 
Negative allosteric modulators (NAMs) inhibit or reduce responses normally produced by 
agonist, most probably by stabilizing the 7TM domain in an inactive conformation. In addition, 
some ligands binding in the allosteric binding site have intrinsic agonist activity, and are called 
agoPAMs, as they also potentiate the effect of agonists (Conn et al., 2014). Silent allosteric 
modulators (SAM) have no effect on the orthosteric agonists and behaves as a competitive 
antagonists of the allosteric binding site (Burford et al., 2013).    
 
GPCR activation of a specific pathway depends on capability of the agonist to stabilize a 
particular active receptor conformation (Wootten et al., 2018). Agonists exhibiting pathway 
specific selectivity have been identified for several GPCRs, named biased agonists, while the 
phenomena is named biased agonism or functional selectivity (Wootten et al., 2018). Binding 
of an allosteric modulator can also contribute to stabilization of receptor conformations induced 
by the agonist and thereby contributing to activation of a specific signal pathway (Foster and 
Conn, 2017; Smith et al., 2018).  
 
1.3.3 In vitro studies of ligand affinity and activity 
 
In vitro ligand screening and characterization is a compulsory part of drug discovery and 
development, and requires assays for description of ligand activity (for example differentiation 
between agonist, antagonist or PAM, NAM, or SAM) assays for studying different signaling 
pathways for the receptor, and assays measuring affinity and potency. As previously described, 
GPCRs can activate multiple signal pathways, and concepts such as biased signaling needs to 
be taken into consideration when selecting or developing functional assays to avoid rejecting 
potential valuable drug candidates (Zhang and Xie, 2012).  
 
Ligand-binding assays using radioactive ligands are commonly applied, alone or in 
combination with other ligands, in order to resolve which binding site the ligand occupies 
(orthosteric, allosteric), the binding affinity and kinetics among other purposes (Hulme and 
Trevethick, 2010; Miyano et al., 2014). A disadvantage of such  assays is their hazardous nature 





cost expensive (Sykes et al., 2019). Fluorescence-based methods are emerging as an alternative 
to radioligand-based methods as they are not hazardous (Sykes et al., 2019). These types of 
binding studies require a fluorophore to be attached via a linker to the ligand(s) and the signal 
from the probe can then be detected upon ligand binding. A challenge with fluorescence 
labeling is that the molecular weight is increasing and can influence the physicochemical- and 
pharmacological properties of the ligands (Sykes et al., 2019). Time-resolved fluorescence 
resonance energy transfer (TR-FRET) assay is an example of a relatively new fluorescence 
based method that can be applied in a HTS where a distance-dependent transfer of energy from 
a donor (e.g. a tagged receptor) to an acceptor (e.g. a tagged ligand) results in a traceable signal 
(Zhang and Xie, 2012). This technology can be applied for multiple types of studies from 
kinetic measurements to protein-protein interaction, dynamics and trafficking (Vernall et al., 
2014). There are multiple variants ligand binding assays, and they are important tools for 
identification of compounds targeting different GPCR classes, but to determine the functional 
properties and biological responses of ligands, functional assays are necessary (Zhang and Xie, 
2012). 
 
Ligand affinity can also be measured by biophysical techniques such as isothermal titration 
calorimetry (ITC), surface plasmon resonance (SPR) and fluorescence polarization (FP) (Du et 
al., 2016). ITC measures heat exchange during the binding process, and provides characteristics 
such as the affinity, enthalpy and entropy of a reaction. In general, the macromolecule under 
investigation is placed in a chamber in the calorimeter before the ligand is titrated into the 
chamber. The heat released, if the reaction is exothermic, or absorbed during the binding is 
measured and the data is used for calculating binding characteristics (Du et al., 2016). SPR can 
measure kinetics, affinity and specificity in real time without using labels. The optical-based 
method measures changes in the refraction index upon binding to proteins immobilized on a 
sensor surface made up of a thin film of gold on a glass support. As ligands bind to the protein, 
an increase in the refraction index can be measured and after a desired association time, the 
solution without ligands is injected to dissociate the ligand binding complexes. This causes an 
decrease in the refraction index, and the refraction index curves can be used to calculate the 
rate constants (Du et al., 2016). FP  measures kinetics based on the principle that polarized light 
becomes unpolarized over time, and a decrease in molecular weight caused by disassociation 
of the ligand-receptor complex causes the emitted light to depolarize (Lea and Simeonov, 
2011). The method can also be applied for competition binding assays using fluorescence 





concentration of the unlabeled ligand necessary to displace the labelled ligands (IC50 value) (Du 
et al., 2016).    
 
Functional assays can be applied to detect activated G-proteins, G-protein mediated events or 
G-protein independent events (Zhang and Xie, 2012). A GTPgS binding assay can be used to 
determine if a ligand initiates receptor-G-protein coupling and for identifying intrinsic activity. 
In addition, the GTPgS assay can be applied independent of which of the four main G-protein 
families the receptor is interacting with. As activation of a G-protein causes exchange of Ga-
bound GDP to GTP, the radioactive GTPgS is added and binds the Ga subunit and radioactivity 
can be counted (Zhang and Xie, 2012).  
 
The four main families of G-proteins initiate different intracellular responses upon activation 
and the choice of assay is therefore dependent on which family of G-protein the receptor 
recruits. Many G-protein dependent assays are based on detecting the second messenger after 
ligand binding and receptor activation, and thereby require the receptor coupling mechanism to 
be known. cAMP-based assays are frequently used when the GPCR is coupled with Gi/o and/or 
Gs that causes negative or positive stimulation of adenylyl cyclase and thereby affects the 
cellular levels of cAMP which can be detected by the assay (Fig. 4). Labeled cAMP can be 
introduced in the assay to compete with endogenous cAMP, and later be detected by anti-cAMP 
antibody (Zhang and Xie, 2012). There are multiple variants of the cAMP assay both 
radiolabeled and radio-free approaches (Zhang and Xie, 2012). Please see the methods section 
for further description of the cAMP assay applied in this thesis. 
 
GRKs phosphorylate specific intracellular sites of GPCRs and cause recruitment of arrestins 
that promote receptor internalization (Hilger et al., 2018). This processes can be investigated 
both by receptor internalization- and b-arrestin recruitment assays. However, receptor 
internalization can be studied in several ways, but very often specific antibodies binding to an 
extracellular part of the receptor is used. The antibody is co-internalized with the receptor upon 
activation and may be detected by a fluorophore-labeled secondary antibody or by tagging the 
receptor with fluorescent proteins (Zhang and Xie, 2012). b-arrestins are also involved in G-
protein independent signaling and can act as scaffolds that interact with various proteins such 
as the signaling protein Extracellular signal-regulated kinase 1/2 (ERK 1/2), nonreceptor 
tyrosine kinases like Src, and trafficking proteins (Lefkowitz, 2005). Assays targeting b-





commercial recruitment assay for studying the effects of b-arrestin recruitment upon receptor 
activation used b-arrestin tagged with green fluorescence protein (GFP) that emits green 
fluorescence upon light exposure which is monitored by an imaging system (Zhang and Xie, 
2012).  
 
1.3.4 G-Protein coupled receptors as drug targets  
 
Disruption or malfunction of GPCR signaling pathways may lead to a wide range of diseases 
and disorders, and GPCRs are therefore valuable therapeutic targets. Despite 
that approximately 35 % of all marketed U.S Food and Drug Administration (FDA) approved 
drugs target in total 108 unique GPCRs, this number constitutes only a fraction of the GPCRs 
encoded by the human genome (Hauser et al., 2017; Hu et al., 2017). The non-sensory GPCRs 
are targets for the majority of GPCR drugs; however, only a minority of them are currently 
therapeutically exploited. Identification of targets and novel ligands is necessary for treating 
diseases where the existing marketed drugs are giving insufficient effects or extensive side 
effects. 
 
Few marketed drugs that act on GPCRs have been developed using structure-based methods, 
as the number of solved 3D structures of GPCRs until recently was very limited. However, 
advances in structural biology during the last 20 years have increased the number of known 
GPCR 3D structures tremendously. An import breakthrough came in year 2000 with the release 
of the X-ray crystallography structure of bovine rhodopsin (Palczewski et al., 2000), and the 
development and increase in cryogenic electron microscopy (cryo-EM) structures the past 5 
years (Shen, 2018) have given new opportunities within the field. The number of solved GPCR 
structures has dramatically increased since the release of the bovine rhodopsin structure with 
currently 321 resolved structures of the 7TM domain (March 2019). In total, 74 of 321 solved 
receptor complexes are in an active state with an agonist bound. At present, structures of 62 
unique GPCRs are present in the Protein Data Bank (PDB) database (Pándy-Szekeres et al., 
2018). 
 
In addition, the progress in the discovery and development of allosteric modulators of multiple 
GPCRs is advancing drug discovery by providing candidates that are more selective than 
ligands targeting the orthosteric site (Conn et al., 2014).  The conserved nature of the orthosteric 
binding site between GPCRs makes it challenging to obtain ligands with high selectivity 





binding site may lead to side effects and drug tolerance in treatment. Targeting allosteric 
modulation is an alternative approach to inhibit or potentiate the effect of the receptor upon 
binding of endogenous ligands. However, development of allosteric modulators is also 
challenging. The measurable effect of a modulator can differ depending of the orthosteric ligand 
used, and thereby complicating screening. In addition, the allosteric binding site is not as highly 
conserved between species as the orthosteric site and specie specific differences may affect 
testing of potential drug candidates in animal models (Conn et al., 2014).  The concept of biased 
agonism has also contributed to an increased understanding of receptor activation (Hauser et 
al., 2017) and possibilities for more selective drug candidates (Hauser et al., 2017).  
 
1.4 Class C of G-protein coupled receptors 
 
Class C members are distinguished from other GPCR classes by the large extracellular domain 
that contains the orthosteric binding site. This domain is called Venus flytrap (VFT) domain 
due to the resemblance to the carnivorous plant. The extracellular domain is connected to the 
7TM by a cysteine rich domain (CRD), which is absent in the GABAB-R (Chun et al., 2012) 
(Fig. 6). Class C GPCRs are obligate dimers, heterodimers as the GABAB-R, or homodimers 
as mGluRs (which can also form heterodimers) and the CaSR (Fig. 6) (Chun et al., 2012; 
Kaupmann et al., 1998). The transmembrane heptahelical domain hosts an allosteric binding 
site, and different studies have indicated that the allosteric site is located at a site corresponding 
to the orthosteric site in class A GPCRs (Harpsøe et al., 2016; Pin et al., 2003). The mGluRs 
are the most studied class C receptors, and the only subclass with a full 3D structure, the cryo-
EM structure of mGlu5 (Fig. 7) (Koehl et al., 2019). The mGluRs are therefore the main source 
for structural knowledge about class C GPCRs and frequently used as references in molecular 








































Figure 6 – A schematic illustration of the structural organization of the GABAB-R (above) and of the 
subclass mGluR (below). GABAB-R is an obligatory heterodimer, whereas mGluR forms a homodimer. 
Red spheres - orthosteric binding site, yellow sphere - allosteric binding site. 
 
Agonist binding in the VFT induces conformational changes in all domains leading to 
transduction of signals from the extracellular part to the intracellular site and activation of G-
proteins (Chun et al., 2012; Rondard et al., 2011). Full activation of mGluRs requires agonist 
binding in the orthosteric binding site of both VFTs in the dimer, while for the GABAB-R only 








Single-molecule Förster resonance energy transfer (smFRET) studies of mGluR2 and mGluR3 
have shown that the VFTs oscillate between the open/inactive and the closed/active 
conformations without ligand present, and that ligand binding shifts the conformational 
equilibrium depending on the function of the ligand (Grushevskyi et al., 2019; Olofsson et al., 
2014). The same mechanism is thought to apply to all class C members, but has still not been 
confirmed for the GABAB-R. X-ray structures of GABAB-R VFTs, FRET and 
Bioluminescence resonance energy transfer (BRET) studies have described the open/inactive 
conformation associated with antagonist binding and closed/active conformation associated 
with agonist binding, while conformational details about intermediate states are not known 
(Geng et al., 2013; Lecat-Guillet et al., 2017). These studies have also shown that the 
extracellular domains of mGluRs are associated with larger conformational changes and VFT 
rotations than the extracellular domains of the GABAB-R (Geng et al., 2013; Lecat-Guillet et 
al., 2017).  
 
The VFTs of most class C members are connected to the heptahelical domain through a linker 
region consisting of approximately 80 residues with 9 completely conserved cysteines, the 
CRD. The exception is the GABAB-R with a shorter linker region without the conserved 
cysteines (Chun et al., 2012). The crystal structure of the extracellular region of the mGluR3 
receptor showed that the CRD has a length of 40 Å, and thereby physically separates the VFT 
from the 7TM domain (Muto et al., 2007). 
 
Structural studies of mGluR5 show that activation of the receptor causes a substantial 
compaction of the dimer, causing the two complementary receptor subunits of the dimer to form 
interactions (Fig. 7) (Koehl et al., 2019). In the inactive state, only lobe 1 of the dimers are in 
contact, as for GABAB-R (Geng et al., 2013; Koehl et al., 2019). Activation of the receptor 
causes reorganization of the VFT dimer interface and closure of the VFTs, leading to 
conformational changes bringing the two dimer subunits closer together (Koehl et al., 2019). 
The average atomic distance between Glu527 located centrally in the two CRD domains of the 
homodimer decreased from 43 Å in the inactive state to 10 Å in the active state (Fig. 7). The 
distance between the two 7TM domains also decreased, and a rotation of approximately 20° of 
each of the 7TM domains was observed (Koehl et al., 2019). Activation of the 7TM heterodimer 
of GABAB-R also causes a rearrangement of the dimer interface where the TM6 of each 
monomer forms the new interface between GABAB1a/b and GABAB2, as opposed to the inactive 





GABAB–R 7TM dimer during activation are proposed to be smaller than for mGluRs (Xue et 
al., 2019).  
 
Figure 7 – The structural re-organization of mGluR5 upon receptor activation can be seen when 
comparing the Cryo-EM crystal structure of the mGluR5 in the active state (left) (PDB ID: 6N51) and 
the inactive state (right) (PDB ID: 5N52) (seen in the same view). The average atomic distance between 
Glu527 in the CRD of the heterodimer decreased 33 Å from the inactive (right) to the active state (left) 
(Koehl et al., 2019). 
 
These results are in consistency to the smaller conformational changes observed in GABAB-R 
VFT compared to mGluR and indicate that the structural changes of the entire receptor upon 
activation are more comprehensive in mGluRs than in the GABAB-R (Geng et al., 2013; Koehl 
et al., 2019; Lecat-Guillet et al., 2017; Xue et al., 2019). The changes upon activation of mGlu5 
are likely to enable two previously unexplored dimer interaction interfaces between ECL2 in 
the 7TM domains and between the CRD domains, giving two rigid attachment points. 
Mutational studies of residues within these interfaces suggested that these interactions are 
necessary for a stable transmission of agonist-induced conformational changes from the VFT 






The intracellular C-terminal domains of class C GPCRs are large, with approximately 250 
residues in the CaSR and between 250 and 500 for mGluRs depending on the subtype, while 
GABAB1b contains 94 and GABAB2 contains 190 residues (Calver et al., 2001; Riccardi and 
Brown, 2010; Willard and Koochekpour, 2013). The C-terminal region has high sequence 
variations between the receptors, and is thought to play a role in coupling to signaling proteins 
and scaffolding (Chun et al., 2012). In the case of GABAB-R, the GABAB2 is responsible for 
intracellular trafficking of GABAB1a/b from the endoplasmic reticulum (ER) to the membrane, 
because GABAB2 masks a retention signal by coiled-coil interaction with the C-terminal 
domain of GABAB1a/b  (Burmakina et al., 2014; Gassmann and Bettler, 2012).  
 
1.4.1 Structure and mechanism of the GABAB VFTs  
 
The GABAB-R is an obligate heterodimer comprised of the GABAB1a/b and GABAB2 subunits 
(Calver et al., 2000; Geng et al., 2013) where each subunit contains an extracellular domain 
connected to a heptahelical transmembrane domain by a linker region (Fig. 6). GABAB1a and 
GABAB1b are isoforms encoded by the same gene GABBR1, and structurally they only differ in 
the N-terminal region with the presence of a sushi domain on the GABAB1a subunit (Biermann 
et al., 2010). The sushi domain is reported to function as an intracellular sorting signal 
responsible for trafficking this isoform into axons (Biermann et al., 2010) and has not been 
implicated to affect the pharmacology or kinetics in heterologous cells (Benke, 2012; Gassmann 
and Bettler, 2012).  
 
Radiolabeled ligand- and site-directed mutagenesis studies, and later X-ray crystal structures 
have shown that in contrast to the mGluRs, only the VFT of the GABAB1a/b subunit and not the 
VFT of GABAB2 contains a binding site for the endogenous agonist GABA (Geng et al., 2013; 
Jones et al., 1998; Kniazeff et al., 2002; Urwyler et al., 2005). In addition, sequence analysis 
show that none of the residues implicated in ligand binding in GABAB1a/b are conserved in 
GABAB2 VFT (Geng et al., 2012). In the active closed state of the GABAB1a VFT, the GABAB2 
VFT remains in an open inactive state (Geng et al., 2013). Also, binding studies with 
recombinant receptor mutants showed that the VFT of GABAB1a/b is functional in the absence 
of the GABAB2 VFT, but with reduced agonist affinities (Liu et al., 2004; Nomura et al., 2008). 
In addition to increasing agonist affinity, the GABAB2 VFT is suggested to impact receptor 





contributing to increased agonist efficacy  (Liu et al., 2004; Nomura et al., 2008). The sequence 
identity between GABAB1a/b and GABAB2 VFTs is 33% (Frangaj and Fan, 2017).  
 
There are in total nine available X-ray crystal structures of the GABAB-R VFT dimer in the 
PDB (Geng et al., 2013), but the complete 3D structure that includes all receptor domains has 
not been solved. The structures show that the VFT heterodimer is formed by non-covalent 
interactions between the GABAB1a/b and GABAB2 (Fig. 8) and each VFT contains two distinct 
domains, the N-terminal Lobe 1 (LB1) and the C-terminal Lobe 2 (LB2) (Figs. 6 and 8). The 
GABAB1a/b and GABAB2 VFTs are similar in sequence length (approximately 400 residues), 
and the LB1 and LB2 of  GABAB1a/b are structurally similar to the corresponding lobes of 
GABAB2 (Fig. 8) (Geng et al., 2013). The X-ray structures show that the LB1 of 
GABAB1a/b VFT interacts with the LB1 of GABAB2 VFT both in the active and inactive VFT 
states. The interactions between LB1-LB1 in the VFTs are fully facilitated by non-covalent 
interactions which involves patches of hydrophobic interactions, hydrogen bonds and a salt 
bridge (Geng et al., 2013). The hydrophobic interactions are mainly facilitated by three 
conserved tyrosine residues that form stacking interactions at the LB1-LB1 interface (Fig. 8). 
Upon receptor activation, large conformational changes causes the LB2 domains of 
GABAB1a/b and GABAB2 to form an additional large non-covalent heterodimer interface (Geng 
et al., 2013) (Fig. 8). The LB2-LB2 interface is facilitated by a rich hydrogen bond network 
including the key residues Thr198, Glu201 and Ser225 of GABAB1a/b LB2 and Asp204, 
Gln206, Asn213 and Ser233 of GABAB2 VFT LB2 (Fig. 8). A site-directed mutagenesis study 
of the interfacial residues observed in the activated VFT dimer, showed that the conserved 
tyrosine residues were important for agonist dependent Gi-protein activity and GABA-induced 
GIRK currents (Geng et al., 2012; Rondard et al., 2008). The mutations also decreased the 
GABA induced stimulation of [35S]GTP-γS binding, but had no effect on the GABA affinity 



















































Figure 8 – The heterodimeric extracellular GABAB-R VFTs in the active state with amino acids 
important for Lobe1-Lobe1 and Lobe2-Lobe2 interactions displayed. Blue – GABAB1a/b VFT, green – 
GABAB2 VFT, gray – illustration of the approximate position of the orthosteric binding site (PDB ID: 






The linker region between the VFT and 7TM in both of GABAB-R subunits is composed of 
approximately 40 residues and is not cysteine rich as in other class C GPCRs (Margeta-Mitrovic 
et al., 2001). The linker has not been shown to be critical for the activation and signal 
transduction from the VFT to the 7TM domain (Margeta-Mitrovic et al., 2001; Rondard et al., 
2011). However, the distance between the C-terminus of the two LB2 subunits decreases from 
45 Å to 32 Å upon activation and is thereby likely to contribute to changes in the orientation of 
the two 7TM domains relative to each other (Geng et al., 2013; Lecat-Guillet et al., 2017). The 
transmembrane part of GABAB2 hosts an allosteric binding site as shown by binding studies of 
the isolated  GABAB2 subunits (Binet et al., 2004). It is also well demonstrated by studies 
manipulating the receptor composition that the GABAB2 subunit is responsible for G-protein 
binding (Galvez, 2001).  
 
1.4.2 GABAB1 orthosteric binding site and ligand recognition 
  
Agonists bind in a pocket located in the crevice of LB1 and LB2 of GABAB1a/b (Fig. 6 and Fig. 
9), and induce large conformational change into the GABAB1a/b VFT such that the LB1 and 
LB2 interact and form a stable closed conformation in timescales necessary for full receptor 
activation (Geng et al., 2013; Møller et al., 2017).  
 
Residues located in LB1 are responsible for anchoring both agonists and antagonists in the 
binding pocket (Geng et al., 2013). The LB1 residues Trp65, Ser130, Gly151, Ser153, His170, 
and Glu349 interact with both agonists and antagonists (Fig. 9). Mutational studies followed by 
radioligand - and [35S]GTPgS - binding assays showed that the mutation of Trp65 to Ala 
abolished the effects of ligand binding and function of the receptor (Geng et al., 2013). Mutating 
His170 to Ala prevented antagonist binding, but had less effect on agonist binding (Geng et al., 
2013).  
 
Interactions with Tyr250 in LB2 seem to be unique for agonists (Evenseth et al., 2019; Geng et 
al., 2013), while Trp278 located in the same domain interacts with high affinity but not low 
affinity antagonists, in addition to agonists (Fig. 9) (Froestl, 2010; Geng et al., 2013). 
Interactions with residues both in LB1 and LB2 are likely to be a requirement for agonist 
activation, and causes the agonists to become buried within the closed receptor. This is 
supported by mutational studies showing that Trp278 and Tyr250 were critical for agonist 





Figure 9 – Superposition of GABAB1 VFT in the active state (PDB-ID: 4MS4 - dark blue) and the 
inactive state (PDB ID: 4MR7 – light blue) with the binding pocket displayed as a mesh (black -active 
state, gray -inactive state) (left). The agonist baclofen (A) and the antagonist CGP54626 (B) in the 
active- and inactive orthosteric binding pocket. Ligands are surrounded by the residues important for 
ligand binding where Tyr250 and Trp278 is located in GABAB1 VFT LB2, while the other residues are 
located in LB1. 
All of the GABAB1a/b VFT co-crystalized ligands are GABA derivatives with an a-acid group 
and an g-amino group (Geng et al., 2013). These groups participate in hydrogen bonding with 
the receptor independent of intrinsic activity, where the a-acid group commonly are stabilized 
by Ser130 and Ser153, while Glu349 and His170 are stabilizing the g-amino groups orthosteric 
binding site (Fig. 9). Linking interaction pattern to ligand activity and affinity has though 
proven to be a difficult task as highly similar compounds show similar receptor interaction 
patterns despite opposite activities, e.g. baclofen and 2-hydroxysaclofen (Geng et al., 2013). 
Larger and more bulky antagonists, like CGP54626 and CGP62349, are thought to prohibit 
formation of a stable closed conformation by forming few and variable interactions with the 





antagonist binding favors the open conformation that corresponds to the resting or inactive state 
of the receptor, the antagonist remains accessible to the surrounding solvent (Geng et al., 2013) 
 
1.4.3 GABAB receptor signaling  
 
Activation of both pre- and postsynaptic GABAB-Rs by agonists results in inhibition of 
adenylyl cyclase (AC) through the Gαi/o pathway (Fig. 10) (Gassmann and Bettler, 2012). In 
the presynaptic terminal, binding of Gα to AC causes decreased levels of cAMP, which prevents 
vesicle fusion and thereby neurotransmitter release (Gassmann and Bettler, 2012). In addition, 
the Gβγ subunit of the G protein binds directly to voltage-gated Ca2+ channels (VGCC), 
resulting in inhibition of inward rectifying Ca2+ channels necessary for vesicle fusion 
(Gassmann and Bettler, 2012). The Gβγ subunit can also directly attach to SNAP receptors 
(SNARE) that are responsible for anchoring vesicles to the synaptic membrane and thereby 
inhibit presynaptic membrane vesicle fusion (Gassmann and Bettler, 2012). In the postsynaptic 
membrane, the Gβγ subunit also binds and inhibits the VGCC, but in this case it contributes to 
a hyperpolarization and inhibits the release of many neurotransmitters including noradrenaline, 
serotonin and dopamine (Gassmann and Bettler, 2012). Postsynaptic, the cAMP-dependent 
PKA signaling pathway is affected by the inhibition of AC (Gassmann and Bettler, 2012). This 
results in inhibition or reduced permeability of ion channels such as the ionotropic glutamate 
receptor NMDA receptor-mediated Ca2+ influx (Skeberdis et al., 2006). In addition, the Gβγ 
subunit stimulates the G-protein coupled inwardly rectifying K+ channels (GIRK), resulting in 
inhibition of postsynaptic potential and decreased long-term potentiation (LTP)  (Bettler et al., 
2004; Misgeld et al., 1995). 
 
The receptors function as auto- or heteroreceptors on both inhibitory and excitatory terminals. 
When GABA is released from a GABAergic neuron, it is likely that it can inhibit further release 
by binding to presynaptic autoinhibitory receptors that serve as a negative feedback loop 
(Kobayashi et al., 2012). These autoreceptors can also be activated by GABA released by a 
single action potential (Biermann et al., 2010). GABAB-Rs are also found on non-GABAergic 
neurons where they act as heteroreceptors and inhibit the release of other neurotransmitters 
such as glutamate from glutamatergic neurons (Biermann et al., 2010). Glutamatergic neurons 
have GABAB-Rs located both on the axon (GABAB1a isoform) and dendrites (both GABAB1a 
and GABAB1b isoforms) (Biermann et al., 2010).  
 
 
Figure 10 – Activation of the 
GABAB-R and signaling 
pathways in A) presynaptic 
neuron and B) postsynaptic 
neuron. (figure modified from 
(Gassmann and Bettler, 2012). 
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Cyclic Adenosine 
Monophosphate, ATP – 
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– Voltage-gated Ca2+ Channel, 
GIRK –  G-protein Coupled 
Inwardly Rectifying K+ channel, 
TREK2 – Twik-related K+ 
channels, NMDA – N-methyl-D-
aspartate, PKA – Protein Kinase 
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1.4.4 GABAB receptor desensitization  
 
Prolonged activation of the GABAB-Rs can lead to receptor desensitization (Gassmann and 
Bettler, 2012). GABAB-R does not necessarily follow classical desensitization mechanisms 
established for other GPCRs where phosphorylation-dependent uncoupling of G-proteins from 
the receptor by GRKs causes recruitment of arrestins and receptor internalization (Benke, 2012; 
Terunuma et al., 2010). There are evidences for that the GABAB-R subunits may not be 
substrates of GRKs and that the receptor becomes internalized by other mechanisms (Terunuma 
et al., 2010). Different mechanisms for GABAB-Rs desensitization have been proposed and the 
specific mechanisms may dependent on the neuronal population (Benke, 2012). A suggested 
phosphorylation-dependent pathway involves C-terminal association of N-ethylmaleimide 
(NEM) sensitive fusion proteins that causes recruitment of protein kinase C (PKC) which 
ensures phosphorylation followed by desensitization (Benke, 2012). An alternative suggested 
phosphorylation-independent pathway involves direct association between the C-terminal and 
GRK4 (a member of the G-protein coupled receptor kinase family), where GRK4 plays a central 
role in agonist-induced desensitization without phosphorylation (Benke, 2012; Terunuma et al., 
2010). Phosphorylation of Ser867 in GABAB1a/b by calmodulin-dependent protein kinase II 
(CaMKII) induces endocytosis and thereby impairments of the receptor function (Gassmann 
and Bettler, 2012). Phosphorylation of Ser783 in the C-terminal of the GABAB2 by AMP-
dependent protein kinase (AMPK) is coupled to receptor recycling, whereas dephosphorylation 
of this residue has been associated with lysosomal degradation (Gassmann and Bettler, 2012). 
Phosphorylation of other serine residues in the C-terminal part of GABAB2, and activity of 
potassium channel tetramerization domain-containing (KCTD) protein family have also been 
linked to the processes of surface stability, desensitization, recycling and degradation of the 
GABAB-R (Benke, 2012; Gassmann and Bettler, 2012).  
 
1.4.5 GABAB receptor-related pathophysiology  
 
Disruption of GABAB-R signaling pathways are connected to a variety of diseases and 
neuropsychiatric disorders such as depression, anxiety, schizophrenia, drug abuse and 
addiction, and gastroesophageal reflux disorder (GERD) (Calver et al., 2000; Fatemi et al., 
2017; Heaney and Kinney, 2016; Pilc and Nowak, 2005; Tyacke et al., 2010; Varani et al., 
2018). The effectors activated upon pre- and post-synaptic GABAB-R activation are known to 





associated with learning and memory (Gassmann and Bettler, 2012). The endogenous precursor 
of GABA, g-hydroxybutyrate (GHB) is also a weak GABA-R agonist marketed as a therapeutic 
drug for treatment of narcolepsy, but as the compound also binds other receptors, the connection 
between the GABAB-R binding and the pharmacological effects is uncertain (Carter et al., 2009; 
Gassmann and Bettler, 2012).  
 
Recent studies have linked stimulation by baclofen to the reduction of addiction-related 
behavior towards nicotine, cocaine and alcohol in preclinical animal models (Augier et al., 
2017; Varani et al., 2018). Drugs of abuse stimulate the reward system in the brain, called the 
mesolimbic system, which controls the release of the reward-associated neurotransmitter 
dopamine (Varani et al., 2018). In 2018, Varani et. al. published a comprehensive study on the 
involvement of the GABAB-Rs on rewarding effects of nicotine by neurochemical, 
biochemical, molecular alterations and behavioral studies (Varani et al., 2018). Nicotine 
stimulates nAchRs located on GABAergic, glutamatergic and dopaminergic neurons, causing 
release of dopamine and rewarding properties (Varani et al., 2018).When the animals were pre-
treated with baclofen, the drug activated GABAB-Rs in dopaminergic and GABAergic neurons 
which significantly reduced the dopamine release by inhibition of the dopaminergic neurons 
(Varani et al., 2018, 2014). 
 
The GABAB-R agonist baclofen has also been shown to have anxiolytic effects in animal 
cognition models and has been implied to reverse anxiogenic responses from addiction-related 
withdrawal (Cryan and Kaupmann, 2005; File, S.E, 1993; Pilc and Nowak, 2005; Pizzo et al., 
2017). Antagonists on the other hand have shown to exhibit antidepressant effects in a variety 
of animal models (Cryan and Kaupmann, 2005; Cryan and Slattery, 2010; Pilc and Nowak, 
2005). Abnormal peripheral serum concentrations of GABA and glutamate, in addition to 
reduced levels of the enzyme GAD in the brain causing reduced levels of GABA, have been 
found in young adults diagnosed with depression and schizophrenia (Fatemi et al., 2017). 
Clinical and post-mortem examination of patients with clinical depression has also revealed 
changes in GABAergic neurons and regional changes in the concentration of the GABAB-R 
isoforms in CNS (GABAB1a/b / GABAB2), which may support the theory of involvement of the 
GABAergic system in depression (Fatemi et al., 2017; Ghose et al., 2011; Lissemore et al., 
2018).  
 
The activation and regulation mechanisms of the receptor can also be affected by binding of 





marketed for therapeutic use, though a PAM, ADX771441, is in phase I clinical trial towards 
alcohol-related behavior (Augier et al., 2017). Another concept that complicates and stresses 
the need for discovery of new orthosteric ligands to increase the knowledge about physiology 
and pathophysiology, is the fact that ligands may show functional selectivity by being an 
agonist for one signaling pathway and an antagonist for other pathways. Biased agonism 
(functional selectivity) is well described for class A GPCRs and class C mGluRs, but was 
recently suggested for PAMs of GABAB-R (Emery et al., 2012; Sengmany and Gregory, 2016; 
Sturchler et al., 2017). The GABAB-R PAMs GS39783 and BHF177 were found to have 
functional selectivity for intracellular signaling pathways in a various functional assays such as 
ERK1/2 phosphorylation (Sturchler et al., 2017).  
 
1.4.6 Characteristics of ligands targeting the orthosteric binding site of 
GABAB  
 
Today, the majority of the approximately 55 known GABAB-R agonists and antagonists are 
GABA analogues (Evenseth et al., 2019; Froestl et al., 1996, 1995a, 1995b). The only FDA 
approved drug targeting the GABAB-R is the agonist baclofen, which is used as a muscle 
relaxant and antispastic agent (Herman et al., 1992; Pilc and Nowak, 2005a). Baclofen has 
multiple pharmacokinetic limitations such as low penetration through the blood-brain barrier 
(BBB), a short duration of action and patients develop rapid tolerance (Deguchi et al., 1995; 
Lal et al., 2009). A large effort on development of drugs targeting the GABAB-R has resulted 
in many structural analogues of GABA, but surprisingly many of these have shown to not bind 
to the receptor despite the high structural similarity to GABA (Brown et al., 2015). This 
emphasizes the need and benefit of discovering new GABAB-R ligands and chemotypes 
different from GABA to study functional selectivity that promote beneficial and block 
deleterious pathways, in addition to being able to substitute baclofen in clinical applications. 
This knowledge can enhance our understanding on mechanism of activation, clarification of the 
role of different signaling pathways and potentially benefit in understanding of therapeutic 
effects. 
 
The first  known GABA derivative was baclofen, which was obtained by adding an halogenated 
phenyl ring to the b-carbon (Fig. 11) (Enna, 1997). Further, new series of potent GABAB-R 
agonists was discovered by replacement of the carboxylic acid of GABA for unsubstituted 
phosphinic- and methylphosphinic acids (Froestl et al., 1995a). A series of antagonists was also 






and  sulfonic acid groups (Froestl, 2010; Froestl et al., 1996, 1995b). The baclofen analogues 
were found to be low affinity antagonists, such as 2-hydroxysaclofen (Fig. 11) that is one of the 
compounds available in X-ray crystal complexes (PBD ID: 4mqf). Despite that this compound 
show antagonistic properties, the interaction pattern is more similar with the interaction patterns 
of agonists including the VFT residues His170, Glu349, Ser130 and Ser 153 (Geng et al., 2013). 
The GABA phosphinic acids analogues were found to be high affinity antagonists in the lower 
nanomolar range when benzyl substituents were added (Fig. 11) (Blackburn and Bowery, 2010; 
Froestl et al., 1995b).   
 
 
Figure 11 – Structure of the agonists baclofen, the baclofen analogue 2-hydroxysaclofen which is a weak 

























1.5 Computer-based methods in structural biology and drug 
discovery 
1.5.1 Conventional drug discovery 
 
Drug discovery is the process of identifying new pharmaceutical ligands for a target. 
Identification of novel ligands with the ability to modulate the activity of biomolecular targets 
can contribute to the understanding of pathological and physiological mechanisms and to the 
development of new drugs (Coudrat et al., 2017; Sliwoski et al., 2014). Taken into consideration 
the high number of potential drug candidates, high-throughput screening (HTS) is essential for 
effective identification of novel ligands binding specific targets. HTS is often the first step in 
the process of identifying potentially new drug candidates, called hits, before the hits are 
optimized, and the efficacy and selectivity towards the target in vitro are determined. The next 
step in preclinical testing is animals studies to establish pharmacokinetics and toxicological 
profiling (Mohs and Greig, 2017). The next step is clinical trials, where drug candidates are 
tested on an increasing number of humans during the course of three phases to establish efficacy 
in humans and identify putative toxic effects among other properties (Mohs and Greig, 2017). 
The drug development process from identification of drug targets and potential candidates to 
marketing normally takes 12-15 years and the costs are estimated to reach billions of dollars 
(Mohs and Greig, 2017; Rang and Dale, 2012).  
 
Conventional approaches in the field of drug discovery rely mainly on stepwise synthesis and 
assays for screening large number of compounds to identify potential drug candidates (Sliwoski 
et al., 2014). During the last decades, efforts have been put into computational molecular 
modelling strategies for drug design and screening. The use of molecular modelling methods 
to identify drug candidates towards a target of interest is cost- and time effective compared to 
sole in vitro screening, and combined with in vitro methods, computational methods may speed 
up the screening process (Sliwoski et al., 2014).  
 
1.5.2  Molecular mechanics and force fields 
 
Molecular modelling includes all computer aided approaches that aspires to study 
characteristics such as chemical and physical properties of molecules and molecular systems, 
and mimic their behavior (Sansom and Smith, 1998). The first step in molecular modelling 





models in different types of calculations of molecular properties. The basis for most of the 
calculations is a molecular mechanical (MM) description of the molecules. In MM, the potential 
energy of a molecular system is approximated by treating each atom including the atomic 
particles as a point, or sphere, which are assigned charges (Leach, 2001). The points are 
connected by springs (bonds) and the energy within the system is calculated from terms such 
as bond stretching, angle bending, bond rotations (torsional energy associated with relative 
orientation of atoms in a dihedral or torsion angle) and non-bonded interactions (Patrick, 2017). 
Treating each atom with all its particles as a point is based on the Born-Oppenheimer 
approximation, which expresses that the movements of electrons will follow the movements of 
the nuclei (Leach, 2001). This assumption makes it possible to calculate the energy of the 
system as a function of the sphere coordinates (Leach, 2001). A contrast to this approach is 
quantum mechanics (QM), where the energy of the system is calculated by explicitly following 
the movement of all atomic particles in the system (Höltje et al., 2008).  
 
In MM, the potential energy of a system is calculated as a function of conformations reflecting 
the atom coordinates in space with 6N degrees of freedom and force constants (empirical 
parameters) by using a force field (FF) (Höltje et al., 2008; Leach, 2001). Most FF first assign 
an atom type to each atom in the system that contains information about the hybridization state 
(number of single, double or triple bonds a specific atom forms) and in some cases additional 
information about the local environment (Leach, 2001). The potential energy of a system is 
calculated as a function of intra- and inter molecular forces between these points with energetic 
penalties associated with deviation of bond lengths, angels and torsions from reference (i.e. X-
ray/NMR structures) or equilibrium values derived experimentally or by ab initio QM 
calculations (Leach, 2001). Assigning atom types is therefore also important because variables 
such as angle and bond length change depending on the type of bond between the atoms (Leach, 
2001). Calculation of the potential energy as a sum of the steric energy in terms of deviations 
from unrestrained ideal values, and non-bonded terms such as the van der Waals potential and 
the electrostatic coulomb potential together with force constants make up the FF (Höltje et al., 
2008). The total energy of the system is in fact a calculation of the intramolecular strain in 
relation to the ideal molecule, where all deviations from the “natural” unstrained molecule leads 
to an increase in the energy (Höltje et al., 2008). The general equation of a force field can be 
written as equation 1: 
 






where the total energy is a function of the covalent and non-covalent bonding terms (Höltje et 
al., 2008).  
 
More sophisticated force fields such as the MM2, MM3 and MM4 have additional terms, 
including improper torsions and out-of-plane bending motions (González, 2011; Leach, 2001). 
These types of force fields are more appropriate for calculations involving “small” molecules 
as they also have a comprehensive atom typing schemes e.g. differentiate types of carbon atom 
like those present in a cyclopropane, cyclopropene or a carbonyl (Leach, 2001). In addition, 
some force fields provide parameters for every single atom within the system (all-atom FFs, 
e.g. the Schrödinger OPLS3 FF (Harder et al., 2016)), while others exclude the non-polar 
hydrogens (united-atom FFs, e.g. the GROMOS96 FF (Hu and Jiang, 2009)) or represent 
molecules as “super atoms” (coarse-grained potential e.g. the Martini FF (Periole and Marrink, 
2013)). Hybrid force fields also exists, using both MM and QM to calculate the potential energy 
where the parts under investigation often are represented by QM, while the less relevant parts 
are represented by MM (González, 2011; Höltje et al., 2008; Vanommeslaeghe et al., 2014).   
 
A suitable FF describes as many different molecules as possible with a certain accuracy. Several 
FFs have been developed and the selection of an appropriate FF is dependent on the target under 
investigation and the goal of the study. The number of terms and the quality of the parameters 
will affect the potential energy function and thereby the reliability of the function (Höltje et al., 
2008). Calculations where high accuracy is necessary, like investigation of ligand interaction 
with a binding site, would require all atoms of the binding site and the ligand to be explicitly 
described in order to not loose essential information on interaction.  
 
1.5.3 Structural representation of molecules and energy minimization  
 
In order to perform molecular calculations on proteins or other molecules, a 3D structural 
representation of the target is necessary. The 3D structure of proteins and other macromolecules 
can be determined by experimental methods such as X-ray crystallography, nuclear magnetic 
resonance (NMR) spectroscopy or cryo-EM. If the target does not have a solved experimental 
structure, theoretical 3D homology models can be constructed if an appropriate template is 
available (Vyas et al., 2012). This approach takes advantage of the observation that tertiary 





(Chothia and Lesk, 1986), and uses the resolved structure of a homologous protein as a template 
for constructing the theoretical model of the protein target of interest.  
 
The atomic coordinates of experimentally determined 3D structures or homology models must 
be geometry/energy optimized using MM computational methods as unfavorable bond lengths 
and angels, and torsions may be present in the structure (Patrick, 2017). Optimization is 
performed by an energy minimization where the aim is to identify a stable and low-energy 
conformation of the protein and/or the ligand. There may be a large number of low energy 
conformations, and on an energy surface the conformation with the lowest energy is called the 
global energy minimum (Fig. 12) (Leach, 2001). There are multiple available energy 
minimization algorithms and the choice of algorithm is dependent of various factors such as 
size of the molecular system in consideration, computational requirements and robustness of 
the methods. Two of most popular minimization algorithms are the conjugated gradient and 
steepest decent methods. Sometimes a combination of these two methods is also used. These 
methods locate a minimum point on an energy surface by gradually changing the coordinates 
of the system as they move closer to this point based on previous iterations (Leach, 2001). 
 
 
Figure 12 – An illustration of an energy landscape of the folding states of a protein with the reaction 
coordinates along the x and z axis and the free energy along the y axis. The landscape shows multiple 
hills (saddle points) indicated with arrows that leads to local minimums (green and yellow colors) and 






1.5.4 Conformational dynamics 
 
Structural motions and dynamics are necessary for the interplay between biological molecules. 
During the process of drug recognition and binding, the drug and the target are adopting to the 
structure of each other, and the drug binding target conformation is not necessary the lowest 
energy conformation obtained from experimental studies. Computer simulations can be used to 
study conformational dynamics and may give insight into dynamic processes that are 
impossible to study by traditional experimental methods. Several theoretical methods are 
available for studying conformational dynamics. 
 
1.5.4.1 Molecular dynamics  
 
In a biomolecular system, every single atom has a specific mass, position in space and 
movement of certain velocity. The time-line of atomic movements has been experimentally 
studied indicating that the position of an atom change within 1-2 femtoseconds (fs), and this 
information has been utilized in numerical models for mimicking molecular behavior (Leach, 
2001).  
 
Molecular dynamics (MD) is one of the commonly used methods that can be applied for 
conformational analysis and studies on time-dependent structural motions. MD uses Newton’s 
laws of motion to mimic the evolution of a collection of interacting atoms as a function of time 
(Höltje et al., 2008). The simulation time is divided into time steps in the fs range in order to 
include the fastest motions of the system (Leach, 2001). At the beginning of the simulation, the 
gradient of the potential energy function is used to calculate the forces acting on each atom in 
the system, while the acceleration and velocities are generated randomly (Leach, 2001). Based 
on the initial position, new positions and velocities are updated at time t using Newton’s laws 
of motion (Leach, 2001; Patrick, 2017). The results are successively collected in a trajectory 
that specifies how the position and velocity of particles vary with time. 
 
Newton’s second law of motion states that the acceleration of a system is dependent on its mass 
and the forces acting upon the object and is calculated as:     
 
Fi (t) = mi ai (t)     (2) 
 
where Fi is the net force on atom i at time t, mi equals the mass of atom i and a is the acceleration 





As atoms are constantly moving, molecular systems can obtain a broad variety of 
conformations, where some are high in energy states (saddle points), while other are low energy 
states (local or global minimums) (Fig. 12). In an MD simulation, there is always a risk that the 
simulations are not long enough to reach all energetically favorable conformations (Henzler-
Wildman and Kern, 2007). This means that the system can be trapped in a local energy 
minimum without having explored the conformational space to access other local energy 
minimum or even the global minimum (Fig. 12). In nature, conformational changes of the 
protein main chain and protein folding occur in microsecond (µs) to second scales (Henzler-
Wildman and Kern, 2007), and with timesteps in the fs range, millions to trillions of timesteps 
are required to simulate in the nano- to millisecond (ns to ms) events. The required amount of 
computational power and storage space needed to perform such MD simulations on a system 
of a certain size is the limiting factor even with the current generation of computers where 
multiple processors can be used in parallel to perform the calculation (parallel computing) 
(Lindahl, 2015). However, tremendous progress has taken place in the field since the 
publication of the first MD simulation, the in vacuo 9.2 picoseconds (ps) simulation of the 58 
amino acid protein bovine pancreatic trypsin inhibitor, in 1977 (McCammon et al., 1977). For 
instance, the activation mechanism of the b2-adrenergic receptor (a class A GPCR) has been 
studied by performing 50 µs MD simulations of the receptor-agonist complex embedded a lipid 
bilayer and explicit water molecules (Dror et al., 2011). MD simulations have also been 
successfully applied to other studies like ligand binding/unbinding and protein folding (Zhu et 
al., 2017).   
 
1.5.4.2 Metadynamics and Path Collective Variables 
 
Sampling of rare events, exploration of reaction coordinates and reconstructing free energy 
surfaces associated with certain events can be calculated by using biased sampling algorithms 
like metadynamics (MetaD) (Branduardi et al., 2007). The method rely on a physical pathway 
describing a movement of interest as a function of a few reaction coordinates (Barducci et al., 
2011). These movements of a system are biased by adding a history-dependent bias potential 
in the form of Gaussians to the appropriately chosen reaction coordinates, called collective 
variables (CV) (Laio and Gervasio, 2008). These variables must be carefully chosen as they 
should represent the slow degrees of freedom and represent the states of the system under 






Selecting appropriate CVs is highly challenging as macromolecules have large degrees of 
freedom and topological complexity. The bias potential is deposited as a sum of Gaussian 
functions along points visited in space and thereby encouraging the system to explore new 
regions (Barducci et al., 2011). The sum of Gaussians added to the system is then used to 
reconstruct an estimator of the free energy and at the same time, providing the system with 
energy to escape local minima and explore higher energy conformations in the phase space that 
unbiased MD cannot access (Laio and Gervasio, 2008). The principle of the algorithm is often 
explained by using the example of a person out walking at night who falls into a pool (Laio and 
Gervasio, 2008). The pool edges are too steep for climbing out, and the darkness makes it 
difficult to detect the shallowest point. If the person has access to sand, she could deposit this 
sand in her current position (Gaussians) and by some point she would be able to climb out. By 
the time she climbs out, larger regions of the pool have been explored and she is likely to climb 
out from the shallowest point (Laio and Gervasio, 2008). The positions of the deposits could 
afterwards be used to reconstruct the negative image of the pool (free energy).  
 
Deciding when to terminate a MetaD simulation can be difficult because the energy does not 
converge to a definite value, but the molecular system rather fluctuates around or starts 
revisiting previous visited conformational space, and in the worst case is pushed into irrelevant 
conformational space (Barducci et al., 2008). Well-Tempered MetaD (WT-MetaD) has been 
developed in the effort to overcome this problem, where the Gaussian height is rescaled and 
decreased during the course of the simulation (Barducci et al., 2008). 
 
There are multiple CVs that can be applied, including dihedrals, angles, and atomic distances, 
and in addition a path may also be used as a CV (PCV) (Laio and Gervasio, 2008). PCVs 
provide an optimal description of the process under investigation, given that the endpoints of 
the transition are known and an educated guess of the underlying mechanism is made. 
Specifically, with PCVs, the path joining the endpoints is described by an ensemble of 
intermediate structures in conformational space (x) which represent the so-called frameset (i = 
1, 2, …, N). The frameset is used as a reference when running a simulation of the target of 
interest, and the simulation is evaluated by following the progression along the path and the 
distance from the path through the following variables (“CV Documentation,” n.d.): 
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where i is the index of the frameset ranging from 1 to N (number of frames in the path), the S 
and X are distance functions from each of the high-dimensional frames R[x-xi], and l is a 
smoothening parameter (Branduardi et al., 2007).  
In essence, if the description of the path from endpoints A to B is incorrect, large values of Z 
representing the distance from the path (often measured in mean square deviation from an 
optimal alignment) can be observed and the reaction under investigation might be incomplete 
(“Adaptive variables I,” n.d.). A simple visualization of the S(X) and Z(X) variables are showed 
in figure 13.   
 
Figure 13 – A schematic illustration of variables calculating the progression along the path (S(X)) 
between the endpoints and the distance (Z(X)) from the path. The endpoints are illustrated as the inactive 
(open) and active (closed) VFT conformations.  
 
1.5.4.3 Monte Carlo 
  
Monte Carlo simulation is a stochastic method that generates conformations of a system by 
random particle sampling (Höltje et al., 2008). After performing a random move, an energy 
minimization is performed and the new configuration is compared to the previous one. If the 
new conformation is in a lower stable energy state, the conformation is accepted and used as a 
starting point for the next iteration (Leach, 2001; Patrick, 2017). The method provides an 
ensemble of conformations, but does not provide any information about time evolution (Paquet 
and Viktor, 2015). If the method is run for sufficient amount of time, the whole conformational 
space should in theory be covered, but with a high risk of resampling already visited 
conformations (Höltje et al., 2008). The method is not restricted by the size of the system; 
however, very flexible systems may not converge due to the large conformational space (Höltje 





1.5.5 Water models  
 
Water molecules are the most important and active biomolecules in nature as they are essential 
in processes such as stabilization of macromolecular structures, dynamics, function and 
interactions. Ligand binding induces a conformational change in the receptor and displacement 
of water molecules can increase the binding affinity (Höltje et al., 2008). The water molecules 
might also bridge protein and ligand interactions (Lemmon and Meiler, 2013). In molecular 
modelling, water molecules are important components that can be included in a macromolecular 
system implicitly or explicitly (Leach, 2001).  
 
In implicit water models, there is no actual water molecules present in the system, but a 
dielectric model is added to the electrostatic interaction term calculated by the FF as the effect 
of a solvent will dampen theses intermolecular forces (Leach, 2001). In contrast, explicit 
solvation models specifically encounter solvent interactions with the solute (Leach, 2001). In 
simple water models such as transferable intermolecular potential 3P (TIP3P) and simple point 
charge (SPC) model (Mark and Nilsson, 2001), three interaction sites for electrostatic 
interactions are included in which the two hydrogen atoms are given a slightly positive charge 
which is balanced by a negative charge on the oxygen atom and only oxygen atoms in 
interacting water molecules are participating in van der Waals interactions (Leach, 2001).   
 
In exhaustive sampling methods such as MD and MC, explicit water molecules are preferably 
used in order to make the systems as realistic as possible to increase the accuracy of the 
calculations. When docking a large database during virtual screening (VS), the inclusion of 
water molecules becomes much more difficult (Höltje et al., 2008). The ligand binding mode 
may not be known and the positions of water molecules might not be known, and both position 
and numbers of water molecules for binding may vary between ligands. If resolved 3D 
structures of the target are available, this could provide information about the presence of water 
molecules, but incorporating them into a VS process might be inaccurate and is computationally 
demanding. The included water molecules are often treated as a part of the protein in a fixed 
position and ligands should therefore be docked with and without the presence of water to 
evaluate the effect (Höltje et al., 2008). The consequences of not considering the presence of 
water molecules might include incorrect binding mode, and studies investigating the accuracy 
of predicting correct ligand pose by re-docking ligands into their respective 3D structures were 





2005). However, in such cases compared to using a water model, the results only affect the 
sampling of ligands and not the scoring (Lemmon and Meiler, 2013). 
 
1.5.6 Virtual Screening 
 
In silico (computer-aided) methods applied in a process that aims to identify active molecules 
from chemical databases, is called virtual screening (Shoichet, 2004). A VS protocol can be 
seen as a complementary approach to experimental HTS (Coudrat et al., 2017). There are a 
wide variety of computational techniques and algorithms that can be used in a VS, and the 
methods are divided into two major categories; active compounds retrieved based on 
knowledge of excising ligands (ligand-based methods) or available structure information 
(structure-based methods) (Aparoy et al., 2012). In 2010, Ripphausen et al. reported, after a 
comprehensive study on published VS procedures, that structure-based methods were much 
more commonly used than ligand-based methods (322 published studies using structure-based 
methods as the last step in the VS protocol against 107 studies using ligand-based methods), 
despite the fact that ligand-based methods on average identified ligands with higher potency 
(Ripphausen et al., 2010). 
 
Screening libraries containing millions of compounds can be time-consuming and 
computational exhausting. This is one of the reasons for that a typical work-flow often 
combines both ligand- and structure based methods, in addition to filtering methods (Sliwoski 
et al., 2014). Starting a VS campaign with the less time consuming methods such as filtering 
procedures is beneficial to reduce the large number of compounds to a more manageable size 
where more comprehensive methods can be applied like docking or extensive energy 
calculations such as Linear Interaction approximation (LIA) or MD (Sliwoski et al., 2014). The 
result of the work-flow is a library of ligands theoretically predicted to bind the target, that must 
be further tested/evaluated experimentally (Fig. 14) (Sliwoski et al., 2014).  
 
There are multiple methods that can be applied for in vitro testing and the choice of method 
depends on factors such as the amount of ligands to test and the target protein in the study. 
High-throughput methods such as radioligand binding studies are often used as a first step in 
the screening procedure to remove unlikely binders effectively (Zhang and Xie, 2012). Other 
high-throughput methods such as cAMP- or calcium assays can be applied for investigation of 





Xie, 2012). In later stages of the in vitro evaluation, more accurate and time-consuming 

























Figure 14 – An illustration of a classical VS work-flow starting from filtering followed by ligand-based 





1.5.6.1 Ligand databases for Virtual Screening 
 
There are multiple commercially available databases of compounds that can be used for in silico 
screening. Typically, these databases contain up to millions of compounds, from natural 
products to synthetic compounds. The ZINC database is a curated collection of commercially 
available chemical compounds that in 2016 contained more than 100 million compounds (Irwin 
and Shoichet, 2016), and will continue to grow as it has been estimated that the number of drug-
like molecules that could be synthesized are approximately 1033 (Polishchuk et al., 
2013). Databases often provide options of different subsets of compounds from unfiltered 
collections to lead-like collections. 
 
1.5.6.2 Filtering of ligand databases 
 
A compound can be labeled as drug- or lead-like compound based on a set of rules (filters) 
determined from analysis of approved pharmaceuticals and compounds reaching phase II of 
clinical trials (Lipinski et al., 2001; Yusof and Segall, 2013). The most commonly applied 
filters for determining drug-likeness is the Lipinski’s “rule of five” (Lipinski et al., 2001) and 
the Veber’s rules (Veber et al., 2002). The “rule of five” describes a set of characteristics that 
drugs with good bioavailability (high proportions reaching systemic circulation) share, after 
oral administration (Battista et al., 2015; Lipinski et al., 2001). Lipinski’s “rule of five” states 
that compounds with molecular weight < 500 Da, octanol-water partition coefficient (log P) < 
5, the number hydrogen bond acceptors < 10 and the number of hydrogen bond donors < 5, 
have good oral bioavailability (Lipinski et al., 2001). Lipinski suggested that if a compound 
breaks two of the rules it is less likely to be absorbed (Lipinski et al., 2001). After testing more 
than 1100 drugs in rat, Veber et al. suggested two additional rules for ensuring bioavailability 
after oral administration (Veber et al., 2002). They found that ligands with an oral 
bioavailability of ³ 20% after oral administration have a polar surface area (PSA) of £ 140 Å2, 
and a number of rotatable bonds of £ 12, and suggested that both molecular flexibility and PSA 
influence drug absorption (Veber et al., 2002). 
 
Drugs that act in the CNS, e.g. antidepressant and anxiolytic drugs, are required to have more 
strict characteristics than previously described due to the presence of the BBB. The blood 
vessels transporting nutrition and waste products in and out of the CNS, have a unique property 
allowing them to tightly regulate the flow of molecules and serves multiple functions including 





vessels elsewhere, the endothelial cells of these vessels are connected by tight junctions, 
surrounded by a special cell type called astrocytes (a non-neuronal cell in the CNS) in addition 
to other supportive cell types and together they comprise the blood-brain-barrier (BBB) 
(Daneman and Prat, 2015). It has been estimated that more than 98 % of the approved drugs do 
not cross the BBB (Geldenhuys et al., 2015) and multiple studies have investigated the 
necessary properties of a drug to penetrate the BBB by passive diffusion (Geldenhuys et al., 
2015; Konovalov et al., 2007; Yan et al., 2013).  Ghose et al. (2012) did a comprehensive study 
that included 943 approved drugs, and suggested following BBB penetrating criterions: PSA < 
76 Å2, > one nitrogen atom, < 7 linear chains outside a ring structure, < 3 polar hydrogens, 
solvent-accessible surface area of 460-580Å2, a volume of 740-970 Å3, and the Schrödinger 
QikProp CNS value > 0 (Ghose et al., 2012).  
 
The Lipinski, Veber and “BBB” rules have many strengths and weaknesses, and exceptions of 
the rules exist. A study, investigating the 82 best-selling drugs reported by the American 
Information Medical Statistics in 2007, found that 11.7 % of the drugs did not follow two or 
more of the Lipinski rules (Gimenez et al., 2010). Another analysis of data retrieved from the 
US FDA on small-molecule drugs showed that out of 1204 unique drugs, 885 passed the rule 
of five but only 70 % of the 885 compounds were administered orally (Overington et al., 2006). 
Compounds produced by living organisms, called natural products, such as the macrolide class 
antibiotics (Benet et al., 2016), are also excluded from the “rule of five” because they are 
substrates for transporters in the body (Lipinski et al., 2001). This show that the rules should be 
encountered more as guidelines than strict rules. Filtering large databases of millions of 
compounds is necessary to decrease and remove a substantial amount of unlikely drug 
candidates. Rejecting potential good candidates is always a risk, especially if rules are too 
strictly emphasized, and the filtration criteria should therefore be carefully selected. Both 
Lipinski´s and Veber´s rules are related to oral administration, which is the most preferred route 
of administrations and other routs of administration such as topical or parenteral have other 
rules (Yusof and Segall, 2013).  
 
There are also filters that more extensively calculates the physicochemical properties than the 
The Lipinski, Veber and “BBB” rules. Pharmacokinetic properties such as absorption, 
distribution, metabolism, elimination and toxicity (ADMET) can be included in the screening 
process (Ntie-Kang, 2013). ADMET properties are commonly applied in the process where hits 





optimization and for further optimizing leads (Sliwoski et al., 2014). Calculations of some 
ADMET-based properties can also be applied earlier in the screening process, to eliminate 
unlikely candidates (Sliwoski et al., 2014). An ADMET profile can include descriptors such as 
solvent-accessible surface area including the size of the hydrophobic area, number of likely 
metabolic interactions, polarizability, binding to serum albumin, number of reactive groups just 
to mention a few properties (Ntie-Kang, 2013). The Schrödinger (Schrödinger Release  2019-
3, 2019) software offers calculation of ADMET profiles, where a total of 52 properties are 
encountered including the previous motioned filters for oral absorption and gives an estimate 
of the likelihood that a compound will have undesirable properties (Schrödinger, 2019).  
 
1.5.6.3  Ligand-based drug discovery methods  
 
In general, Ligand-based Drug Discovery (LBDD) is a term used for methods that are based on 
utilizing information about the structure of known active- and inactive ligands and constructing 
a predicative relationship between their structure and the activity (Höltje et al., 2008). LBDD 
is based on the very basic assumption that similar ligands have similar biological 
activity (Martínez-Archundia et al., 2018). The most common and important methods within 
this category are pharmacophore models, fingerprint methods and quantitative structure activity 




Binary 2D fingerprinting is a widely used ligand-based method applied in drug discovery with 
the purpose of characterizing and comparing molecules to find structural similarities. 
Characteristics of molecules are described by using a set of bits (numbers) representing 
the presence or absence of chemical moieties within ligands and together these bits form a 
binary fingerprint (Duan et al., 2010). The ligands are fragmented into different sized fragments 
before the presence or absence of features are displayed as “on” bits by flipping the integer 
from 0 to 1 in the bit string (Cereto-Massagué et al., 2015). There are multiple different 
fingerprinting methods that differ in the way they perform molecular fragmenting, atom typing 
schemes and hashing, but the main objective for all methods is to transform a molecular 
representation into a bit string (Cereto-Massagué et al., 2015; Duan et al., 2010). Some 
fingerprinting methods also compare the absence or presence of features in a molecule to pre-
defined schemes of substructures before turning on bits if the substructure is found, called 












Figure 15 – Representation of a hypothetical 10-bit substructure keys-based fingerprint. Three bits are 
set (integer 1) because the substructure they represent is present in the molecule.  
 
 
2D fingerprinting methods are commonly used to screen databases to identify new ligands with 
similar characteristics using a similarity index (Duan et al., 2010). Tanimoto similarity index is 
one of the most commonly used similarity metrics methods and computes the similarity 
between two molecules by calculating the relationship between “on” bits shared by the ligands 
in relation to “on” bits in the individual molecules according to equation 3 (Cereto-Massagué 
et al., 2015; Duan et al., 2010). 
Tanimoto similarity = c / (a + b - c)     (5)  
where a is the number of activated bits in molecule A, b is the number of activated bits in 
molecule B and c is the number of active bits shared between molecule A and B (Duan et al., 
2010).  
 
1.5.6.3.2  Ligand-based pharmacophore modelling 
 
A pharmacophore model is a representation of the 3D arrangement of chemical- and steric 
features that are in common for active molecules targeting a specific protein (Horvath, 2010). 
Pharmacophore models should represent the 3D features necessary for activity, and in theory 
represent the complementarity of the target binding pocket (Höltje et al., 2008). When multiple 
active ligands are available they can be clustered based on their structures in order to develop 





The typical workflow for generating pharmacophore models starts with identification and 
collection of active ligands before conformational sampling of the ligands. The next step is 
assigning atom types or classification of atoms according to their chemical environment and 
potential interaction behavior based on their chemical characteristics (Horvath, 2010). The 
ligands are then aligned or superimposed in such a way that a maximum numbers of common 
features overlap in the geometrical space (Fig. 16) (Sliwoski et al., 2014). A common feature 
map is then generated with features such as aromatic rings, hydrogen bond donors and 
acceptors, cations and anions and hydrophobic areas (Fig. 16) (Sliwoski et al., 2014). The 
models are commonly implemented as spheres with a matching-tolerance radius (Sliwoski et 
al., 2014). After common pharmacophores models are constructed, they are often ranked based 
on the “matching-rate” with the ligands in the dataset (Güner, 2000). A last evaluation step is 
often performed to test the selectivity of the models, where the models are testes against inactive 
ligands (Sliwoski et al., 2014).  
 
The pharmacophore models can be applied for screening a compound database to identify new 
potential active ligands that can be mapped to the 3D hypothesis (Salam et al., 2009).  
 
 
Figure 16 – Ligand-based pharmacophore model with features shown as spheres. Left) Multiple ligands 
are superimposed to find common pharmacophore features. Right) A pharmacophore model with 4 
pharmacophore features and the intersite distance (Å) between the features. Red (N) - Negatively 







1.5.6.4 Structure-based drug discovery methods 
 
Structure-based Drug Discovery (SBDD) methods elucidate the structural information of the 
drug target from either experimentally resolved 3D structures and/or homology models, or 
implicitly by using pharmacophore models that in theory consists of features complementary 
to the binding pocket (Höltje et al., 2008). The most common and important method within 
SBDD is docking and scoring, where ligands are sampled in the binding pocket and scored 
according to energies associated with specific poses in order to select the best pose and rank 
the different ligands (Huang and Zou, 2010).   
 
1.5.6.4.1  Docking and scoring  
 
The process of ligand binding to a target was initially described in 1894 by Emil Fischer as 
“key in a lock” concept where complementary geometric shapes are required for the substrate 
(key) to fit in the enzyme (lock) (Koshland, 1995). This principle was later modified by 
Koshland who described the binding of a substrate to an enzyme as a dynamic process where  
the enzyme underwent conformational changes, a process named induced fit (Koshland, 1995). 
In molecular modelling, one approach of molecular docking is the process where a ligand is 
placed within the binding site of a target with the main goal to predict the ligand conformation, 
orientation and binding affinity (Kitchen et al., 2004; Morris and Lim-Wilby, 2008). A 
sampling algorithm is used for searching ligand conformations and orientations, and a scoring 
function is used to estimate the “match”, in terms of relative binding affinity, between the ligand 
and the binding pocket (Kitchen et al., 2004). Ideally, sampling algorithms should reproduce 
the experimental binding mode and the scoring function should also rank that binding mode 
highest among all generated conformations. 
 
Both ligands and their macromolecular targets are flexible in nature, but including flexibility in 
docking is computationally very costly and, hence, different docking procedures have been 
developed. In a rigid docking process, the ligands only have some degrees of freedom by only 
allowing rotation and translation while the target is kept rigid, while in a semi-flexible approach 
the target is kept rigid and the ligand fully flexible by prior generation of multiple 
conformations (Höltje et al., 2008). There are also methods for including structural flexibility 
into the amino acids of the receptor binding pocket. The Schrödinger suite of program has a 
solution called Induced fit docking (IFD) (Sherman et al., 2006). The protocol can be divided 





4) Final scoring (Sherman et al., 2006). The first step is to generate a diverse ensemble of poses 
of the docked ligand without generating unlikely poses. To reduce steric clash between the 
ligands and the unmodified binding pocket, side chains that are predicted to be highly flexible 
are mutated to alanine and the van der Waals radii is scaled (Sherman et al., 2006). The next 
step includes sampling of the protein structure with considerations to the previous sampled 
ligand pose, resulting in receptor conformations optimized for the ligand poses. The residues 
previously replaced with alanine are restored and an energy minimization is performed on 
residues with at least one atom within 5Å of the ligand, after the conformations of the residues 
have been predicted (Sherman et al., 2006). This step also includes energy minimization of the 
generated ligand poses from step 1, before each complex are ranked according to the energy. 
The ligands are further resampled in the previously optimized receptor structures and the 
previous softened potentials are set to the original values (Sherman et al., 2006). The final step 
is ranking the complexes according to score accounting for both estimated the docking score 
and strain- and solvation terms (Sherman et al., 2006).  
 
Protein flexibility can also be ensured by using a slightly different approach called ensemble 
docking. The Internal coordinate mechanics (ICM) software offers this methodology where 
docking into a stack of pre-generated target conformations is performed, called 4D docking 
(Bottegoni et al., 2009). Ideally, the descriptions used for representing binding pocket 
conformations are obtained from multiple crystal structures of the target, but this is not always 
possible due to unavailability or too similar conformation of the crystal structures. A stack or 
ensemble of conformations can in that case be generated by optimizing side-chains within the 
ligand binding pocket (Gabrielsen et al., 2012; Kitchen et al., 2004).  
 
The structure of the target and the selected ligands must be structurally prepared before docking 
by defining features such as ionization, chirality, adding hydrogens, assigning bond orders and 
energy minimization among other properties. 3D space and characteristics of the binding pocket 
can be pre-defined and described by a grid energy map that stores the energy information of the 
binding site and simplify interaction energy calculations (Höltje et al., 2008). Grid maps are 
used by most docking programs, and usually take into account features such as shape, 
electrostatic-, van der Waals- and steric properties of the binding pocket (Patrick, 2017). 
Various fragments or atoms are often used as probes to measure these interactions with residues 





et al., 2014). When ligands are docked, the binding strength can quickly be calculated by 
identification of ligand atoms interacting with pre-calculated grid points (Patrick, 2017).   
 
It is always a challenge to balance accuracy and efficiency during docking and scoring. The 
Schrödinger suite contains the Glide package which offers an array of options for accuracy and 
speed by providing docking and scoring algorithms that can be applied for different purposes, 
like screening of databases with high throughput virtual screening (HTVS) or docking by 
standard precision (SP) or extra precision (XP). HTVS and SP docking functions use series of 
hierarchical filters to search for the optimal ligand pose within the target structure (Friesner et 
al., 2004; Halgren et al., 2004). This process includes steps such as exhaustive enumeration of 
ligand torsions, torsional space refinement of the ligand in the grid using a FF in conjugation 
with a distance-dependent dielectric model, and finally a post-docking minimization with full 
flexibility of the ligand (Friesner et al., 2004; Halgren et al., 2004). These algorithms are less 
strict in the way that they identify ligands with reasonable propensities to bind, without strict 
rejection of poses that may diverge from the ideal complex complementarity in terms of energy, 
but are fast in terms of time by using on average only 2 second/compound for HTVS and 10 
seconds/compound for SP (Friesner et al., 2004). The Glide XP methodology is much more 
comprehensive than the previously explained HTVS and SP and the procedure is reported to 
use 2 minutes/compound (Friesner et al., 2006). Various rigid fragments of the ligands are 
“anchored” within the binding pocket based on complementarity between the ligand and the 
grid map, before the software “grows” the flexible parts of the ligand step-by-step to achieve 
better ligand poses (Friesner et al., 2006). Various positions of the anchors are clustered before 
a representative from each cluster is selected and the side chain is grown from relevant points 
on the anchor. Candidate poses are selected based on the score of each conformation eliminating 
structures with steric clash between side chains. In the last step the selected candidate poses are 
minimized using Glide’s energy function and ranked according to MM energy and empirical 
scoring terms (Friesner et al., 2006). If selected poses have penalties of various types, such as 
insufficient hydrogen bonding between ligand and target compared to the solvated protein in 
the unbound state, they are re-grown as an attempt to escape these penalties. The final single 
pose is selected based on an empirical scoring function composed of ligand–protein energy 






A large number of scoring algorithms have been developed to evaluate protein-ligand 
complementarity and predict the binding free energy. The free energy of a binding process is 
given by the Gibbs-Helmholtz equation: 
 
DG = DH – TDS     (6) 
where DG is the free energy, DH the enthalpy, T temperature in Kelvin and DS the entropy 
(Höltje et al., 2008).  
 
The binding free energy can further be related to the binding constant Ki by the following 
equation: 
 
DG = - RT ln Ki     (7) 
where R is the gas constant (Höltje et al., 2008).  
 
The scoring methods vary considerably in accuracy and speed. Methods such as Linear 
Interaction Energy (LIE) (Åqvist et al., 1994) or Free Energy Perturbations (FEP) (Cournia et 
al., 2017) can be used for quite accurate predictions, but they are computational expensive 
because they include features such as larger degrees of conformational freedom and sometimes 
explicit water models (Höltje et al., 2008). Such methods therefore have limitations in a VS 
approach. In high-throughput screening, quick methods are preferred to roughly estimate the 
energy with the aim to optimize the placement of ligands and the rank them (Höltje et al., 2008).  
 
Scoring functions can be categorized into three main groups (1) MM force-field-based scoring 
functions, (2) Empirical scoring functions, (3) Knowledge-based scoring functions, and in 
addition consensus scoring is also used for ranking  (Huang and Zou, 2010). Force-field-based 
based scoring functions calculate the ligand binding energy based on the individual interaction 
terms described in the FF which includes van der Waals- and electrostatic energies, in addition 
to the torsions, angles and bond stretching (Huang and Zou, 2010). Empirical scoring functions 
such as Glide score (Friesner et al., 2004), combine energies calculated for the individual 
components from the FF with experimental binding affinities to calculate a final energy score 
(Huang and Zou, 2010). Knowledge-based scoring functions use structural information 
extracted from experimentally determined ligand-protein complexes based on potential of mean 
force (Höltje et al., 2008). Consensus scoring is not a scoring function, but a technique where 






1.5.6.4.2  MM-GBSA 
The Molecular Mechanics Generalized-Born and Surface Area (MM-GBSA) tool is commonly 
used as a post-processing step in a VS workflow. The method approximates the binding free 
energy by encountering the MM energies, the surface area energy and differences in solvation 
energy by encountering the ligand and protein both in the unbound and bound states using an 
solvation model (Eq. 6) (Knight et al., 2014). The method can provide a more accurate 
estimation of binding energies compared to methods such as docking where only the bound 
state is considered, and more efficiently than expensive sampling methods such as free energy 
perturbation (Knight et al., 2014). The ligands and the poses are ranked according to the 
estimated MM-GBSA score that is estimated based on the following calculation: 
 
Gbind=  DEMM + DEsolv + DESA  (6) 
 
DEMM is sum of the differences in force field energy (bonded and non-bonded terms) between 
the bound and unbound states. The DEsolv is the difference in solvation energy between the 
bound and unbound states of the ligand and the protein by using an implicit or explicit solvent 
model, and the DESA is the difference in the surface energy between the two states (Knight et 
al., 2014).  
 
Sampling of the protein and ligand can be achieved by MD simulations, MC sampling or by 
minimization. Using MD or MC is more computational demanding than performing a simple 
minimization, but provides dynamic effects whereas minimization heavily depends on the 
starting structures (Genheden and Ryde, 2015). 
 
1.5.6.4.3 Structure-based pharmacophore modelling 
 
Structure-based information can be utilized to develop pharmacophore hypotheses from the 
protein binding pocket. A docking program such as Glide with the XP scoring function 
(Friesner et al., 2004) can be used to energetically describe ligand-receptor structures as it is 
a comprehensive algorithm describing energy terms of a complex by encountering hydrophobic 
sites, p-p and p-cation interactions as previously described. The ligand-receptor energies can 
be calculated by either docking known active ligands, fragment libraries from vendors or purely 
based on the structure of the target binding pocket alone, before the pharmacophore sites are 
generated using the same six chemical features as used for ligand-based pharmacophores: 





and hydrophobic groups (Sliwoski et al., 2014). The ligand-receptor energies calculated from 
the scoring function after refinement of a ligand pose are energetically mapped onto atoms of 
the binding pocket, before pharmacophore sites are generated (Salam et al., 2009). The energies 
of atoms contributing to each pharmacophore site are summarized, ranked and the most 
favorable sites are selected for the final hypothesis with the possibility to modify the desired 
number of features in the hypothesis composition (Salam et al., 2009). The 
pharmacophore hypothesis can then be applied in VS approach to identify ligands 
complementary to the structure-based pharmacophore features. 
 
1.5.6.5 Linear interaction energy and linear interaction approximation 
 
LIA is a simplification of the linear interaction energy (LIE) method (Åqvist et al., 1994). Both 
methods are used for prediction of binding affinities of unknown ligands based on the 
experimental affinity values of known active ligands used as a training set. In LIE, the 
conformations of ligands in the training set and the target are sampled during MD simulations 
or Monte Carlo minimizations both in the bound and unbound states (Åqvist et al., 1994; Åqvist 
and Marelius, 2001). In the LIA, energy minimizations are used for conformational sampling 
(Liaison Manual 5.8, 2015). The simulation data are analyzed and in combination with the 
empirically derived affinity data, three scaling factors for the energy terms van der Waals 
energy (α), electrostatic energy (β) and a cavity term (γ) are generated (Liaison Manual 5.8, 
2015). These scaling factors can subsequently be used to predict binding energies for other 
unknown ligands for the same target using the following equation: 
 
∆G = α ( Ubvdw – Ufvdw ) + β ( Ubelec – Ufelec ) + γ ( Ubcav – Ufcav ) (7) 
 
where b = bound form of the ligand, f = free form of the ligand, Uvdw = van der Waals energy, 
Uelec = electrostatic energy, Ucav = cavity energy term in a Surface Generalized Born (SGB) 
continuum solvent model where the cavity term is proportional to the exposed surface area of 






































2 Aim of the study 
 
The involvement of the GABAB-R in the pathophysiology of different diseases and disorders 
makes it an interesting target for drug intervention. At present, there are few known ligands 
targeting the orthosteric binding site of GABAB-R and the majority are GABA analogues. The 
low structural diversity of known GABAB-R ligands may indicate that the conformational space 
of the orthosteric GABAB-R binding site and of GABAB-R agonists and antagonists are not 
fully explored. Ligand recognition and binding, activation and signal transduction are dynamic 
processes requiring conformational changes of both receptor and ligand. Other structurally 
stable VFT conformations than the closed/active and opened/inactive structures from X-ray 
crystallography may exist and be favorable for binding of yet unexplored chemical scaffolds of 
ligands. Understanding the conformational dynamics, and identifying intermediate VFT 
conformations associated with the oscillation between the open/inactive and the closed/active 
conformations may therefore be valuable for the identification of new orthosteric GABAB-R 
ligands. 
 
The aims of this study was to enhance our knowledge about the structural dynamics of the 
GABAB-R VFT and utilize available structural information about the receptor and known 
agonists and antagonists to identifying novel orthosteric ligands. First, we aimed to establish a 
VS workflow as an effort to identify new ligands targeting the orthosteric binding site. 
Secondly, we aimed study the movement of the VFT to explore conformational energies 
associated with the transition from active closed VFT state to inactive open VFT state to 
understand if the receptor oscillates between these states independently of the presence of an 
agonist.  
 
The goals of the work described in the thesis can be divided into three specific tasks: 
• Evaluation of the applicability of commonly used ligand- and structure-based VS 
methods when the available structural information about ligands is limited to a small 
selection of structural analogs (paper 1).  
• Application of selected ligand- and structure-based methods in a VS workflow to 
identify new ligands binding to orthosteric binding site (paper 2). 
• Study the transitions between active and inactive conformations of the GABAB1 VFT 





structural dynamics of receptor and the mechanism associated with receptor activation, 

























3 Methods  
3.1 Paper 1 and 2 
3.1.1 Software 
 
The Schrödinger software package (Small-Molecule Drug Discovery Suite 2018-4) was used 
for all molecular modelling calculations in paper 1 and 2. The available crystal structures of 
GABAB-R VFT were downloaded from the protein data bank (PDB ID: 4MR7, 4MR8, 4MR9, 
4MQE, 4MQF, 4MRM, 4MS1, 4MS3 and 4MS4) and pre-processed in Schrödinger Protein 
Preparation wizard with default settings (Protein Preparation Wizard, 2017).  
 
Known GABAB-R agonists, antagonists and assumed non-binding ligands (decoys) were 
prepared using Schrödinger LigPrep with default settings (LigPrep, 2017). Molprint2D (M2D) 
fingerprints were generated before hierarchical clustering of agonists and antagonists  based on 
Tanimoto similarity with the average cluster linkage method using Schrödinger’s Canvas 
software (Canvas, 2017), as a first step in the ligand-based approach. Schrödinger’s Qikprop 
was used for ADMET filtering of selected databases used for VS. Pharmacophore models for 
each cluster of agonist, antagonists and outliers were generated using the Phase software which 
is included in the Schrödinger Small-Molecular Drug Discovery suit (Phase, 2017). The 
structure-based pharmacophore models were generated based on all available X-ray crystal 
structure complexes of the GABAB-R VFT by mapping a library of fragments in the binding 
pockets using the Schrodinger’s Phase software (Phase, 2017).   
 
Docking of fragments, GABAB-R agonists and antagonists, decoys and the virtual database was 
performed by Schrödinger Glide software (Glide, 2017, 2015). SP docking was used for decoys 
and known agonists and antagonists, while a virtual screen workflow (VSW) tool combining 
HTVS, SP and XP docking were used for the VS of compound databases. Only 10% of the top 
scored compounds from HTVS and SP docking were kept, and 100% of the output was kept 
after XP docking. The false positive decoys identified based on docking score (scoring better 
than the threshold selected by docking of agonists and antagonists), were applied in a LIA 
model generated using Schrodinger Liaison software in combination with the strike software 
(Liaison, 2015; Strike version 2.2, 2015). The output from VSW was post-processed with Prime 






3.1.2 Traditional computer-aided drug discovery methods 
 
A total of 55 ligands were collected from the literature and considered active towards the 
GABAB-R. M2D fingerprints were calculated for each of the compounds, before they were 
used to cluster the compounds based on similarity using Tanimoto similarity using the average 
linkage method, which resulted in six clusters after manual adjustments. As the clustering was 
able to separated agonists from antagonists, and X-ray crystal structures were available of both 
active and inactive receptor conformations, we intended to develop screening methods that 
theoretically also should split between antagonists and agonists. Cluster 1 was generated by 
merging singletons and doubletons, containing both agonists and antagonists, and considered 
as a cluster of outliners. An average fingerprint (modal fingerprint) of each cluster was 
calculated, and the selectivity tested by applying them to screen GABAB-R ligands and decoys 
from other clusters. 
 
In paper 1, pharmacophore models were generated for each cluster and evaluated by mapping 
against decoys and known agonists and antagonists in order to identify the numbers of false and 
true positives and true and false negatives that were used to calculate the Matthews correlation 
coefficient (MCC) and “Goodness of Hits” (GH) (Matthews, 1975; Seal et al., 2013). One 
pharmacophore model was selected to represent each cluster, resulting in 4 models for agonists 
and 1 model for antagonist. An additional model representing agonists and antagonist from 
cluster 1 was also included to potentially retrieve both agonist and antagonists during VS. These 
models were applied as the first step in the VS, keeping compounds retrieved from agonist-
based and antagonist-based pharmacophore models separate.  
 
The compounds retrieved from ligand-based pharmacophore step were docked into selected X-
ray crystal structures. For evaluation of methods in paper 1, one presumed active (from a  
complex with agonist) and one presumed inactive (from a complex with antagonist) GABAB-
R conformation were selected (PDB ID: 4MR7 for antagonist and 4MS4 for agonist) for 
docking. In paper 2, all available GABAB-R X-ray crystal structures with an agonist or 
antagonist were used for docking the compounds retrieved form the ligand based 
pharmacophore VS. The compounds retrieved from the agonist specific pharmacophore models 
were docked into agonist induced active receptor conformations (PDB IDs: 4MS3 and 4MS4), 
while potential antagonists were docked into the six antagonist induced receptor conformations 
(PDB IDs: 4MR7, 4MR8, 4MR9, 4MQF, 4MRM and 4MS1). The compounds retrieved using 





representing both the active and inactive receptor conformations. In both papers, the binding 
pockets described by grid maps were defined using the centroid of the co-crystalized ligand. 
The map size was increased from the default box size of 10 Å3 to 15 Å3, to ensure docking of 
ligands with a larger size that the co-crystalized ligands. Only Glide SP docking was applied 
for the method validation in paper 1. However, in paper 2, we applied all Glide docking 
algorithms, keeping 10 % of the best scored ligands after HTVS and SP, but 100 % after the 
XP docking. In addition we generated 3 poses per ligand as required for MM-GBSA 
postprocessing.  
 
LIA models are linear regression models generated by combining experimental activity data 
with theoretically calculated descriptors such as van der Waal and electrostatic forces to create 
a model for predicting or correlate binding energy. In paper 1, the LIA method was evaluated 
for its applicability in VS.  The method not only encounters forces in the complex, but also the 
ligand and the receptor in an unbound state solvated in an implicit water model. The methods 
is a simplification of the LIE method originally proposed by Åqvist et al. (Åqvist et al., 1994). 
We generated one LIA model for affinity prediction of agonists and one for antagonists. The 
models were generated by selecting approximately 50 % of the agonists and antagonists with 
known experimental pIC50 values as training sets, before evaluating the models on the 
remaining known agonists and antagonists. After docking known active ligands and false 
positive decoys from the ligand based approach, ligands scoring better than threshold values, 
defined by redocking agonists and antagonists, were applied in the LIA models to evaluate their 
ability to identify ligands as false positive. 
 
After docking of the compounds from the pharmacophore screening in paper 2, an inhouse 
script was used to select one pose of each compound based on docking score, remove duplicates 
(ligands present from more than one vendors), predicted affinity and identify the number of 
grid maps the ligands were docked into. The compound after removal of duplicates were 
clustered by Tanimoto similarity matrix based on M2D fingerprints before candidates from the 
different clusters were selected, visually inspected in the binding pocket, purchased and 








3.1.3 Experimental verification of ligands 
 
A total of 37 hits were purchased and tested in a cAMP assay using Chinese Hamster Ovarian 
cells stably overexpressing the human GABAB-R receptor and on WT CHO-K1 cells without 
the receptor. The HitHunter cAMP assay from DiscoverX was applied to investigate the cellular 
effects of the hits on the receptor activation. The assay uses two b-galactosidase fragments that 
works as enzyme donors conjugated with cAMP and an enzyme acceptors, in addition to anti-
cAMP antibodies and a substrate (DiscoverX, n.d.). When the levels of endogenous cAMP is 
high, it binds and saturates the cAMP antibody causing the excess levels of donor cAMP to 
complement with the enzyme acceptor. Combination of these two fragments forms an active 
enzyme that hydrolyzes the substrate, resulting in a detectable chemiluminescent signal 






Figure 17 – A simplified illustration of principle behind the HitHunter cAMP assay from DiscoverX. 
The EA enzyme becomes activated upon ED-cAMP binding which causes hydrolyzation of a substrate 
causing a detectable light signal. ED – enzyme donor, EA – enzyme acceptor and AB – antibody. (Figure 











The compounds were dissolved in 100 % Dimethyl sulfoxide (DMSO), before the solubility 
was tested in the assay buffer. Three compounds showed low solubility. The 34 remaining 
compounds were tested in a single concentration (10 µM) together with forskolin (50 µM), a 
compound that stimulates adenylyl cyclase resulting in cAMP production (Seamon et al., 1981), 
in the WT cells to evaluate the off-target effects. Testing on the CHO-K1 GABAB-R cells were 
performed using a single concentration (10 µM) of the test compound, together with forskolin 
(30 µM) and GABA (EC20 and EC80 concentration, respectively). The selected concentrations 
of GABA, EC20 and EC80, were used to investigate the possibility of the compounds to also 
functioning as PAMs or NAMs (Klein et al., 2013). The cells were harvested washed and 
resuspended in Hank´s Balanced Salt Solution (HBSS), followed by 2 hour pre-incubation at 
25°C. After adding compound mixture, the reaction proceeded for 24 minutes at 25°C before 
the cAMP reagents were added and incubated without light in additional 14-16 hours at room 
temperature. The cAMP signals were measured on a ClarioStar® plate reader (BMG 




















3.2 Paper 3 
3.2.1 Molecular dynamics simulation and metadynamics 
 
The MD simulations were performed with GROMACS using the AMBER99SB-ILDN force 
field, before the conformations of the resulting trajectories were clustered using a GROMACS 
clustering tool (Berendsen et al., 1995). The freely available climber tool was used to connect 
the trajectory clusters (Weiss and Levitt, 2009), before the PLUMED driver utility (Tribello et 
al., 2014) was used to calculate the progress of the morphed path along the reaction coordinates 
of the unbiased MD using the path as a PATHMSD collective variable. The visual molecular 
dynamics (VMD) program was used for visualization and RMSD calculation to analyze the 
obtain path (Humphrey et al., 1996). GROMACS patched with Plumed was used to perform a 
Well-Tempered Metadynamics (WT-MetaD) using the path as a CV. 
Six 1 µs MD simulations without ligand present were performed. One simulation was started 
from the X-ray crystal structure of the GABAB-R apo form (PDB id: 4MQE), two were started 
from an open agonist induced conformation (PDB IDs: 4MS3 and 4MS4) after removal of 
agonist, while three were started from an antagonist induced (PDB IDs: 4MQF, 4MR7 and 
4MR8 ) after removal of the antagonist. The six molecular systems were equilibrated by a 100 
ps simulations using the NVT ensemble (constant number of atoms (N), volume (V) and 
temperature (T)) followed by a 5 ns NPT (constant number of atoms (N), pressure (P) and 
temperature (T)) equilibration. Production runs of 1 µs were performed as an extension of the 
previously NPT ensemble with coordinate sampling every 10 ps. RMSD analysis showed 
overlapping conformational space indicating that the reaction coordinates for the transition 
between closed/active conformation to the open inactive conformation were explored during 
the simulation. The trajectories were merged before performing a cluster analysis on the 
aggregated trajectory. Cluster centroids were selected and connected using by the climber tool. 
An in-house script was used to extract equispaced frames that were applied as a path collective 










4 Summary of results 
4.1 Paper 1 
 
In Silico Methods for the Discovery of Orthosteric GABAB Receptor Compounds, 
Linn M. Evenseth, Dawid Warszycki, Andrzej J. Bojarski, Mari Gabrielsen and Ingebrigt 
Sylte, Molecules, 2019, DOI 10.3390/molecules24050934 
 
The relative low number of known agonists and antagonists for the GABAB-R complicates the 
use of computer aided drug-discovery methods for identifying new orthosteric ligands. At the 
moment 13 antagonists and 42 agonists are known, and the majority are of them are GABA 
analogues. The low number of ligands that cover a relatively small conformational space 
reduces the quality of ligand-guided studies and complicates the validation of structure-based 
methods. Classical ligand-based methods such as fingerprinting and pharmacophore mapping 
and structure based-methods like structure-based pharmacophores, docking and LIA were 
tested for their applicability to identify new orthosteric GABAB-R. All methods were evaluated 
by their ability to separate 55 known agonist and antagonists from decoys, generated in a ratio 
1:50 per active compound. The results showed that modal fingerprints generated from 
fingerprints of clustered ligands and structure-based pharmacophores could not discriminate 
between active ligands and decoys. However, the results from the structure-based 
pharmacophores based on docking of fragments gave a good insight into the properties of the 
binding pocket. Based on the result, we could conclude that that combining ligand-based 
methods with different structure-based methods, despite low accuracy on individual methods, 
can identify active ligands in front of assumed inactive ligands and confirmed inactive ligands 













4.2 Paper 2 
 
Identification of orthosteric GABAB receptor compounds by virtual screening,   
Linn S. M. Evenseth, Imin Wushur, Dawid Warszycki, Andrzej J. Bojarski, Mari 
Gabrielsen and Ingebrigt Sylte, Manuscript, 2019 
 
A VS workflow was employed to screen a collection of databases including Vitas M, 
Chembridge, Chemdiv, Maybridge, UORSY, Specs and Enamine. The methods used in the 
workflow was selected based on the results from paper 1 in order to identify new ligands 
targeting the orthosteric binding site of the GABAB-R. A combination of ligand-based and 
structure-based approaches optimized to be selective for agonists or antagonists was applied to 
screen a library of 8.2 million compounds. The library was filtered with to a small selection of 
ADMET properties, reducing the number of compounds to approximately 5.3 million. The 6 
cluster-based pharmacophore models generated in paper 1 were applied for screening of the 
remaining library, reducing the number of compounds to ~ 686.000. There are in total 8 
available X-ray crystal structures of the GABAB-R VFT co-crystalized with agonists or 
antagonist and they represent small differences of the binding pocket. In the structure-based 
part of the VS protocol, compounds retained by agonist based pharmacophore models were 
docked into two X-ray crystal structures representing closed/active conformations, while 
compounds retained by antagonist based pharmacophore models were docked into 6 X-ray 
crystal structures representing open/inactive conformations. A Glide docking workflow was 
used for the docking, consisting of HTVS, SP and XP docking. The retained compounds were 
post-processed by MM-GBSA calculation, which resulted in 2761 potential agonists and 71960 
antagonists. The compounds were structurally clustered and compounds from each cluster were 
selected for in vitro testing based on visual inspection of complexes, XP gscore, relative binding 
affinity from the MM-GBSA calculation and the number of grid maps the compound could 
dock into. Based on the VS screening, 37 ligands were ordered, but only 34 were soluble and 
thereby tested in a functional cAMP assay using Chinese hamster ovary cells stably 
overexpressing the human GABAB-R (CHO-K1 cells) and on WT CHO-K1 cells. The results 








4.3 Paper 3 
 
Exploring the conformational dynamics of the extracellular Venus flytrap domain of the 
GABAB receptor: a path-metadynamics study,  
Linn S. M. Evenseth, Riccardo Ocello, Mari Gabrielsen, Matteo Masetti, Ingebrigt Sylte, 
and Andrea Cavalli, Manuscript, 2019 
 
In this study, we aimed to investigate the structural dynamics of the GABAB1 VFT and describe 
the natural behavior of this domain in absence of ligands. A total of six molecular dynamic 
(MD) simulations of one microsecond were run, from both the inactive/open and closed/active 
states, to possibly explore the conformational transitions state of the GABAB1b VFT. The six 
trajectories were merged and based on cluster analysis of the trajectory, centroids were 
extracted and linked in order to describe the structural movements between the two states in an 
optimized path. The optimized path further used as a path-CV in a WT-MetaD to fully 
characterize the transition between the two states and reconstruct the Free Energy Surface (FES) 
associated with the transition. The results show that the pool of trajectories could be used to 
derive a suitable reaction coordinate for describing the full transition between the open and 
closed states. However, the individual six simulations did not show a full transition. The results 
from the metadynamics showed two local minimum on the FES corresponding to the 
closed/active and the open/inactive conformations. The two local minimums were iso-
energetic, but the energy barriers separating these conformations was of 20 kcal/mol. This 
results indicate that the transition is not likely to occur in the absence of an agonist. Other 
metastable intermediate states were also observed, and these states might play an important role 
in the receptor transition. Analysis of selected metastable states showed that most of the 
investigated residues located in the binding pocket where stable during the simulation. 










































The GABAB-R plays an important role in neurotransmission by binding the main inhibitory 
neurotransmitter GABA and is involved in the regulation of cellular inhibition and excitation 
(Bettler et al., 2004). Dysregulation of the receptor has not surprisingly been linked to a broad 
variety of diseases and disorders (Bittiger et al., 1996; Tyacke et al., 2010). The receptor was 
linked to major depressive disorder already in the beginning of the 1980´s and since then the 
receptor has frequently been targeted in different drug discovery efforts against affective 
disorders (Lloyd et al., 1985; Lloyd and Pilc, 1984; Pilc and Nowak, 2005). Despite all the 
efforts to develop GABAB-R drugs, there is currently only one drug on the market targeting the 
GABAB-R, the agonist baclofen (Froestl et al., 1995b, 1995a). New orthosteric ligands are 
important for elucidating the structure and activity of the receptor and increase the 
understanding of signaling and pathophysiology.  
 
5.1 Application and evaluation of computer-aided methods in a 
virtual screening workflow  
 
Combining ligand-based and structure-based methods in VS workflows can be more effective 
and accurate than applying either of the approaches alone. The choice of methods often depends 
on the available information about the target of interest. For ligand-based approaches it is 
necessary with available data about active- and preferably inactive ligands, while structure-
based methods requires one or multiple 3D models of the target (Sliwoski et al., 2014). The 
size and chemical diversity of the ligand dataset affects the accuracy and thereby the 
functionality of a method. This was demonstrated in paper 1 when evaluating ligand-based 
methods for their application in a screening protocol against GABAB-R (Evenseth et al., 2019). 
The dataset of active orthosteric ligands was quite small, containing only 55 highly similar 
ligands as most of them are GABA analogues. After hierarchical clustering of the ligands based 
on similarity between the M2D fingerprints with mol2 atom-typing scheme, modal fingerprints 
were generated for each cluster. The modal fingerprints were evaluated by their ability to 
retrieve actives and decoys. The results showed that the method was not selective for active 
ligands within the cluster from which the modal FPs were generated and retrieved multiple 
decoys. Decoys are assumed non-binders generated from the active ligands to match the 





actual binders (Mysinger et al., 2012). However, as long as the decoys are not verified 
experimentally, it is impossible to rule out that they are actual inactive compounds.  
The pharmacophore models also suffered from the structurally narrow selection of ligands and 
the default inter-site distance had to be modified from 2 Å to 1.5 Å for two of the clusters, 
creating stricter hypothesis. Changing this constraint allows pharmacophore features to be in a 
closer proximity and thereby increased the number features and diversity between the generated 
models. In addition, only one pharmacophore model for each of the 6 clusters of agonists and 
antagonists was evaluated to have an acceptable quality for further application. Larger datasets 
comprised of chemical diverse ligands generates more diverse pharmacophore models as seen 
in comprehensive pharmacophore studies on targets such as the serotonin 5-HT1A receptor with 
> 3.500 known active ligands (Warszycki et al., 2013). Application of the selected 
pharmacophore models from paper 1 in the VS protocol (paper 2), showed that the less accurate 
models retrieved up to approximately 75.000 compounds compared to approximately 11.000 
compounds in one of the better performing models (Fig. 18). We also included a nonspecific 
pharmacophore model generated based on mapping compounds from a cluster consisting of a 
mixture of agonists and antagonists in the VS, and this model retrieved approximately 500.000 
compounds. The aim of applying this pharmacophore model in the VS was to potentially 
identify new structural chemotypes. We did not consider the high number of theoretically false 
positive hits as negative, since we had the option to apply more robust methods in the following 
steps. If that was not an option, the process of selecting candidates for experimental verification 


















Figure 18  – A summary of the workflow from VS screening to experimental testing with corresponding 
results (presented in paper 1 and 2). HTVS: high throughput virtual screening, SP: standard precision, 
XP: extra precision, MM-GBSA: Molecular Mechanics-Generalized Born Surface Area. 
Structure-based methods are in general preferred when structural data of high quality are 
available because the ligands can be customized according to the properties of the binding 
pocket. However, Ripphausen et al. reported in 2010 that despite higher success rates of 
structure-based screening, hits from ligand-based approaches have a considerably higher 
potency (Ripphausen et al., 2010). A balance between accuracy and computational costs is 
important when planning a VS approach, but essentially the choice depends on the available 
data.  
 
Only two out of the nine available GABAB-R VFT X-ray crystal structures were used in paper 
1 to save calculation time. The choice supported by the low RMSD between the structures 
showing that they were highly similar. Also, in this paper we did not aim to evaluate the 
selectivity of the available X-ray structures. The two X-ray crystal structures with the highest 
resolutions were selected to represent the agonist-bound active conformation, and the 
antagonist-bound inactive conformation. Fragments were docked into the selected structures 
before e-Pharmacophores were generated using the default maximum numbers of features. A 
quantitative evaluation of these models was impossible as the required matching level was set 





ranked higher than any of the active ligands. As pointed out in paper 1, generating e-
Pharmacophores by docking fragment libraries can in our case be expedient for the purpose of 
describing binding pocket properties in lead-optimization purposes.  
 
Receptors and ligands are structurally flexible molecules and ligand recognition and binding 
induces conformational changes in the ligand binding site. The changes can be a movement of 
a simple side chain to backbone movement or larger rearrangement of a domain (B-Rao et al., 
2009). Incorporating structural flexibility in docking studies is very important for prediction of 
the ability of a ligand to bind, and for predicting the correct pose. However, incorporating 
structural flexibility in a docking algorithm is difficult due to the large number of degrees of 
freedom in a macromolecular complex, and the complex interactions between the target and the 
ligands, which both increase the calculation time considerably (B-Rao et al., 2009). Despite 
that the available X-ray structures were similar as calculated by RMSD in paper 1, there were 
small variations in the binding pocket such as a flip of approximately 170° of the Trp278 located 
in lobe 2 of agonist-bound receptor conformations. We applied all the nine available crystal 
structures in the actual VS campaign presented in paper 2, and performed multiple docking 
studies. Incorporation of ligand flexibility was handled by using the full Glide VSW docking 
protocol, that uses three different docking algorithms; HTVS, SP and XP (Friesner et al., 2004).  
 
The extensive VSW protocol was only applied in the actual screening protocol (Paper 2) and 
not when evaluating the methods (Paper 1). The main goal of using the VSW protocol was to 
remove unlikely drug candidates from the library, and due to the large amount of hits from the 
pharmacophore screening we had to apply a stricter docking protocol than initially thought.  
 
5.2 Linear Interaction Approximation 
 
The LIA methodology is a simplified version of the original LIE method where sampling is 
performed by minimization, MD or Monte Carlo using an implicit water model (Åqvist et al., 
1994). The results from evaluation of this method was acceptable, despite that the coefficients 
α and β made non intuitive sense. The value of both α and β should be positive when the bound 
state is favored over the free unbound ligand. Other studies have also reported similar 
observations, where the α and β coefficients favor the unbounded state (Alam and Naik, 2009). 
As discussed in paper 1, there might be various reasons for this results including insufficient 
sampling and handling of water molecules. This method was removed from the Schrödinger 





flow. The MM-GBSA methodology was instead applied as this method also calculates the 
ligand binding energy considering the ligand and the receptor in a bound and unbound states 
solvated in an implicit water model.  
 
5.3 In vitro evaluation of hits from VS 
  
Hits from the VS protocol were evaluated based on the Glide XP score (gscore) and MM-GBSA 
score, before the compounds were clustered. Cluster centroids were selected and visually 
investigated, before 37 candidates were purchased (paper 2).  
 
Functional cAMP assay is a high-throughput method that can easily be applied to investigate 
ligands effect on production of cAMP upon GPCR activation. The assay requires pre-
knowledge of the coupling mechanism of the GPCR since cAMP levels most commonly are 
affected through activation of Gas and Gai/o pathways. Our candidates are currently being 
evaluated by their ability to effect the cAMP levels in a CHO-K1 cell line stably expressing the 
human GABAB(1b,2)-R that couples to Gai/o.  
 
Before applying the candidates to the recombinant cells, they were tested in WT CHO-K1 cells 
to evaluate if the compounds bound to other targets than the GABAB-R. In total, 20 of them 
showed activity in WT cells and were therefore not be further evaluated in the cells 
overexpressing the GABAB-R. Out of the remaining 14, only 8 have been tested in the cAMP 
assay using CHO cells expressing the GABAB-R. 
 
The obtained results show that a single concentration of the test compounds in the assay without 
GABA, did not reduce the levels of cAMP and thereby ruled out that the compounds could be 
agonists. Applying the EC20 concentration of GABA without results also ruled out that the 
compounds could be PAMs, as a PAM theoretically should have increased the potency and 
reduce the cAMP formation. Two of the compounds was able to increase the cAMP formation 
indicating antagonist or NAM activity. These two compounds were further evaluated in a 
GABA dose-response studies with fixed concentration of each compound (30 µM). Compound 
23 showed an increase in cAMP formation at high GABA concentrations, while compound 28 
increased the cAMP concentration at low GABA concentrations in addition. These results 
indicate that compound 23 and 28 might have weak antagonistic properties. However, we 
cannot confirm that the compounds actually bound to the orthosteric binding pocket as they 





of a radioligand binding assay would determine more certain the site of binding and binding 
affinity.  
 
As the cAMP assay is based on detecting activation of a specific pathway, compounds that 
might exhibit functional selectivity are likely to be reject. In the case of our studies, we cannot 
rule out that 6 of the tested compounds might have functional selectivity for other G-protein 
independent or independent pathways. b-arrestin recruitment assay is a high-throughput method 
that could be applied to investigate functional selectivity towards a G-protein independent 
pathway (Zhang and Xie, 2012). Also, performing additional G-protein dependent assays for 
potentially detecting other cellular effects of ligand activation should be considered because of 
the ability for the compounds to act as an agonist (or PAM) for one pathway and antagonist (or 
NAM) for others. The GABAB-R can also affects the intracellular calcium levels by different 
mechanisms such as regulating the NMDA receptor or by activating PLC in a synergy with 
mGluRs coupled to Gaq, causing increased calcium levels  (Gassmann and Bettler, 2012). A 
calcium mobilization assay using a chimeric G-protein could therefore be considered to 
investigate alternative functions or pathways. Sturchler et al. recently published a study 
highlighting the benefit of using multiple assays to investigate and characterize the function of 
ligands by performing multiple experiments including cAMP assay, calcium mobilization assay 
and measuring ERK activation (Sturchler et al., 2017). The study investigated 3 GABAB-R 
allosteric modulators with similar pharmacokinetic properties. The results showed that all 
compounds increased the GABA potency in the cAMP assay, indicating that they were PAMs. 
Two of the compounds had no effect on calcium mobilization, while one of the compounds 
decreased the GABA potency and thereby executed NAM activity. Only one of the compounds 
showed increased ERK activation, while the others had no effects (Sturchler et al., 2017). The 
results of this study clearly highlights the complexity of intracellular signaling and emphasizes 
the importance of combining multiple experimental procedures if possible. 
 
The two compounds were retrieved by pharmacophore models originally generated based on 
agonists and they were therefore docked into the closed/active receptor conformation. This 
result, together with the results from docking of the known antagonists (Paper 1) show that 
antagonists can also fit in the closed receptor conformation as described for mGluRs (Muto et 
al., 2007). However, the docking score was poorer than of the agonist, and we still believe that 
in a natural environment with full flexibility of the protein and the ligand, the antagonist would 





matrix showed that compound 23 was similar to some of the antagonists. Compound 28 
represents a completely new chemotype that is highly similar to already approved drugs 
targeting other receptors (results not disclosed).  
 
5.4 Molecular dynamics and metadynamics to study Venus 
flytrap dynamics 
 
Molecular dynamics simulations can provide a great understanding of the atomic motions as 
function of time. In order to properly include the fastest motions of a system such as bond 
bending and stretching and correctly integrate the equation of motion, sampling in the fs range 
is necessary (Leach, 2001). Sampling of the movement of every atom in a system at such a 
timescale, makes this an accurate method that fully describes protein dynamics (Henzler-
Wildman and Kern, 2007). However, many interesting biological events such as large domain 
changes upon ligand binding or protein-protein interaction occurs in µs to second timescales, 
which would result in the need of 109 to 1015 MD steps to explore the motions (Barducci et al., 
2011). In addition, solvent and maybe the cellular membrane need to be added, resulting in 
extremely expensive calculations in terms of memory and time consumption, where only 100 
ns can take multiple days to run depending on the hardware and the number of atoms in the 
system  (Henzler-Wildman and Kern, 2007; Laio and Gervasio, 2008). This implies that MD 
are used to study local flexibility or so called “fast motions” rather than larger domain motions 
which is slower and requires crossing energy barriers, thereby referred to as rare events in terms 







Figure 19 – A simplified illustration of protein dynamics and energy barriers in a one-dimensional free 
energy landscape. The DG+ illustrates the energy required for the protein to cross the barrier and 
transition from state A to state B. Such large domain motions often occur in the µs to ms scale, while 
smaller motions such as side chain rotations often follow in the ps to ns scale due to smaller energy 
barriers. (Illustration modified from (Henzler-Wildman and Kern, 2007).  
 
Metadynamics is one of several enhanced sampling methods that is capable of overcoming the 
timescale problem, cross high energy barriers and explore rare events inaccessible through 
unbiased MD (Henzler-Wildman and Kern, 2007). The method may also discover new reaction 
pathways because it naturally passes the lowest saddle point of a FES into a new minimum 
(Barducci et al., 2011). Metadynamics facilitate sampling by adding a force (bias potential) to 
selected degrees of freedom that represent the process under investigation (Barducci et al., 
2011). In paper 3, we used a path representing the transition from the closed state to a wide 
open state. To our knowledge, there is only very limited number of studies applying path-
metadynamics to study conformational transition in molecules of this size. The reaction 
coordinates for this transition were observed during the unbiased MD when the separate 
simulations were merged, and was used to construct this path. The wide-open state of the VFT 





of the missing stabilization forces from the GABAB2 VFT or it can be a conformation that is 
seldom explored.  
 
The obtained path was used as a CV in a 2 µs metadynamics run. The result from our study 
showed that progression along the path proceeded with low Z values, indicating that our path 
was a good prediction and no alternative transition pathways was discovered. Also, multiple 
metastable states were detected along the transition, but they were separated by high energy 
barriers. Only important residues of the binding pocket were analyzed and we found that the 
majority remained stable during the simulation. The GABAB2 VFT has been shown to increase 
the agonist affinity and stabilize the closed conformation of GABAB1 VFT during activation 
(Geng et al., 2013; Liu et al., 2004; Nomura et al., 2008). However, as the GABAB2 VFT is 
believed to be stably present in an inactive/open state, it might not affect the transitions in other 
ways than stabilizing the endpoint of GABAB1 VFT activation (closed VFT). Our results 
suggest that the GABAB1 VFT requires a ligand to cross these barriers and is capable of closing 
in the absence of GABAB2 VFT.   
 
There are multiple challenges and considerations that need to be accounted for successfully 
running Metadynamics. The biggest challenge is selection of CVs to describe the process 
under investigation. There are multiple criteria for selection of an appropriate CV such as it 
must be able to describe all slow modes of the system and completely distinguish between 
the initial and final state (Barducci et al., 2011). Another challenge in a standard 
metadynamics is to decide when the system has converged. The point of convergence can be 
hard to detect because the free energy fluctuates around the filled FES in addition to the risk 
of overfilling the FES. This problem can be solved by using a WT-MetaD, where a bias 
factor is used to rescale the Gaussian height in such a way that when the system is in a local 
minimum the Gaussians accumulate and the height is reduced. When the system crosses the 
lowest saddle point and starts exploring a new local minimum, the height becomes restored 
(Barducci et al., 2011, 2008). As the Gaussians become smaller during the simulation, the 
convergence becomes smoother on the FES (Barducci et al., 2008). Thus, decreasing 
Gaussian height should be accompanied by observation of the system revisiting regions in 
the CV space to ensure convergence. However, deciding the correct value of both the bias 
factor and the Gaussian height without knowing anything about the energy barriers between 





low, the Gaussian height decreases faster and may not provide the system enough potential 
to escape the local minimum. 
 
5.5 Structural dynamics of the Venus flytrap  
 
The extracellular part of GABAB-R has major structural differences from the mGluRs, which 
suggest that the receptor mechanisms might be different. The mGluRs can form both homo-
and heterodimers, where binding of ligands in both the VFT orthosteric sites is necessary for 
full receptor activation (Møller et al., 2017). The VFTs of mGluRs is in an equilibrium 
between the open/active and closed/inactive states and interactions is stabilized by disulfide 
bonds between the VFTs (Møller et al., 2017). A cysteine rich domain is responsible for 
linking the VFTs to the 7TM domain, and mutational studies of this region showed 
impairment of activation (Huang et al., 2011). The GABAB-R is a obligate heterodimer, and 
only the VFT of GABAB1 is capable of binding ligands and GABAB2 is necessary for G-
protein coupling  (Geng et al., 2012; Møller et al., 2017). The GABAB-R linker connecting 
the VFT to the 7TM, does not possess the conserved cysteine residues. Also, mutational 
studies of the linker have implicated that changing the sequence has no impact on the 
activation of the receptor (Margeta-Mitrovic et al., 2001). The structural rearrangement of 
GABAB-R and mGluRs VFT(s) upon activation is transmitted to the 7TM domains causing 
a rearrangement of these domains as well, which is necessary for full receptor activation 
(Møller et al., 2017). The presented studies only focus on the orthosteric binding site in the 
VFT, and structural mechanisms of the 7TM domain or signal transduction will therefore 
not be discussed in great detail.         
 
Investigation of the conformational dynamics of mGluR1 by FRET studies using saturating 
concentrations of agonist show that closure of the VFT occurs in the sub-millisecond velocity 
(Grushevskyi et al., 2019; Olofsson et al., 2014). The closure of the VFT is directly linked to 
the repositioning of the 7TM, where the conformational changes occur significantly slower (~ 
20 ms) (Grushevskyi et al., 2019). The VFT of mGluR2 was suggested to shift between inactive 
open and active closed states independent of the ligand, while agonist binding was suggested 
to shift the equilibrium from a rapid transition between open and closed conformation towards 
an active closed conformational state (Olofsson et al., 2014). However, Vafabakhsh et al., 
studied group 2 mGluRs using FRET and found that the VFT interconverts, not only between 





R VFT dynamics, could not show the same behavior of the GABAB-R VFT. In fact, it was 
not found any FRET modulation upon receptor stimulation when labeling the N-terminal 
domains of the dimer (Lecat-Guillet et al., 2017). Lecat-Guillet et al. suggested that the 
reason for this discrepancy with the suggested VFT mechanism of mGluR, was due to lower 
structural reorganization upon activation or formation of stable oligomers (Lecat-Guillet et 
al., 2017). Koehl et al. recently showed that activation of the mGluR5 VFTs caused a 
substantial rearrangement of the extracellular domains causing a compaction propagated to 
the 7TMs (Koehl et al., 2019). This rearrangement caused the 7TMs to move closer together, 
in addition to creating a  reorientation by a 20° rotation (Koehl et al., 2019).  Structural 
analysis of available resolved X-ray structures of the GABAB-R supports that the 
conformational rearrangement upon VFT activation is smaller for GABAB-R than for 
mGluRs (Geng et al., 2013; Koehl et al., 2019). These results together with our results 
presented in paper 3, strengthens the suggestion that the activation mechanism of mGluRs is 
not directly transferable to GABAB-R. We have suggested that the open/inactive and 
closed/active conformations GABAB-R VFT do not alternate naturally between the two states 
like the mGluRs. Rather, they represent two energetically equal and low energy 
conformations, separated by sizeable energy barriers of about 20 kcal/mol.  
 
Mutational studies show the importance of specific ligand-protein interactions, where 
removal of residues can change the activity for ligands. As for the GABAB-R VFT, Trp65 
and Ser131 among other residues, were found to disrupt ligand binding and receptor activity 
(Galvez et al., 1999; Geng et al., 2013). The interaction pattern in a protein-ligand complex 
may affect the receptor conformation as studies initially investigating allosteric modulation 
and biased signaling of mGluRs and GABAB-R suggested that the receptor conformation is 
dependent on the ligand and thereby causing conformational specific pathway activation 
(Lecat-Guillet et al., 2017; Olofsson et al., 2014).  Emery et al., studied ligand bias of 
mGluR1a and discovered that pathway-activation could be linked to the ligand interaction 
pattern in the orthosteric binding pocket (Emery et al., 2012). Further, mutational studies of 
mGluR1a showed that agonists initially capable of activating both the G-protein dependent 
pathway and arrestins, became pathway biased when certain interactions were eliminated 
(Emery et al., 2012). These discoveries suggest that ligands can induce different receptor 
conformations based on interactions with the binding pocket and that even small differences 






In the case of GABAB-R, this could explain why the low affinity antagonists used in paper 
1, phaclofen and saclofen (GABA analogues) execute the opposite extracellular function of 
GABA and baclofen (Froestl et al., 1996, 1995a). The presented study (paper 1) and previous 
X-ray crystal structures show that the binding of these ligands are mainly facilitated by LB1 
and that there are fewer stabilizing interactions for phaclofen and saclofen than for GABA 
(Geng et al., 2013). This results in less stabilization of these antagonists in the binding pocket 
and distort VFT closing, causing the receptor to arrange into another conformation 








































6. Conclusion and future perspectives 
 
The GABAB-R is an important drug target as it binds to the main inhibitory neurotransmitter in 
the CNS and is associated with a broad variety of diseases. Almost 40 years have passed since 
the GABA was associated with affective disorders for the first time, and despite all efforts, only 
a small number of ligands are found to target the receptor. GABAB-R is a very special target, 
different from other class C GPCRs members by being an obligate heterodimer, missing the 
cysteine rich domain and by not following the classical desensitization mechanism involving 
GRKs. Understanding the concept of receptor dynamics, how ligands effect receptor 
conformation and the coupling to intracellular signaling pathways, is important for the 
understanding of drug mechanisms and for identification of conformational states that can 
be targeted by new drugs. The results presented in this study is an effort to enhance the 
understanding concerning the mechanism and identify new ligand scaffolds.  
 
Ligand-based and structure-based methods were evaluated and applied in a VS protocol to 
identify, so far, two potential new GABAB-R ligands targeting the orthosteric binding (paper 
2). The compounds will be further evaluated in a radioligand binding assay using a tritium-
labeled potent antagonist. The successful candidates will be further used to create scaffolds 
representing structural distinct compound from those already known. The generated e-
Pharmacophore models turned out to be useless in a screening procedure due to low selectivity 
(paper 1), but we will use them to facilitate this work by indicating where the compounds can 
be modified by adding specific chemical groups to optimize ligand-receptor interactions. In the 
next round of selecting and purchasing hits, we will use the obtained trajectories (paper 3) to 
analyze conformational movements and select conformations to be used in a docking procedure 
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Abstract: The GABAB receptor (GABAB-R) is a heterodimeric class C G protein-coupled receptor
comprised of the GABAB1a/b and GABAB2 subunits. The endogenous orthosteric agonist
 -amino-butyric acid (GABA) binds within the extracellular Venus flytrap (VFT) domain of the
GABAB1a/b subunit. The receptor is associated with numerous neurological and neuropsychiatric
disorders including learning and memory deficits, depression and anxiety, addiction and epilepsy, and
is an interesting target for new drug development. Ligand- and structure-based virtual screening (VS)
are used to identify hits in preclinical drug discovery. In the present study, we have evaluated classical
ligand-based in silico methods, fingerprinting and pharmacophore mapping and structure-based
in silico methods, structure-based pharmacophores, docking and scoring, and linear interaction
approximation (LIA) for their aptitude to identify orthosteric GABAB-R compounds. Our results
show that the limited number of active compounds and their high structural similarity complicate
the use of ligand-based methods. However, by combining ligand-based methods with different
structure-based methods active compounds were identified in front of DUDE-E decoys and the
number of false positives was reduced, indicating that novel orthosteric GABAB-R compounds may
be identified by a combination of ligand-based and structure-based in silico methods.
Keywords: GABAB receptor; orthosteric binding site; virtual screening; ligand-based screening;
structure-based screening
1. Introduction
Virtual screening (VS) is the application of knowledge-based computational methods to identify
novel compounds [1]. VS methods are divided into two major categories: ligand-based drug discovery
(LBDD) methods and structure-based drug discovery (SBDD) methods [2]. The LBDD methods
use information about known ligands (e.g., structure, target affinity/activity and physico-chemical
properties) to search for new compounds, while the SBDD methods use structural information about
the drug target and ligand-target complexes. LBDD and SBDD are time- and cost-effective methods
that either alone or in combination have led to the discovery of novel compounds towards assorted
targets, including the ↵1a adrenergic receptor, the serotonin transporter and the 5-HT7 receptor [3–6].
 -Aminobutyric acid (GABA) is the main inhibitory neurotransmitter in the mammalian central
nervous system (CNS). GABA exerts its physiological effects by binding to the ionotropic GABAA
and GABAC receptors and the metabotropic GABAB receptor (GABAB-R) [7]. The GABAB-R is an
obligate heterodimeric assembly, comprised of the GABAB1a/b and GABAB2 subunits, that belongs to
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class C of G-protein coupled receptors (GPCRs) [8,9]. Each subunit contains an extracellular domain
called the “Venus flytrap” (VFT) domain, and a heptahelical transmembrane (7TM) domain. The VFTs
have a bi-lobular architecture with two distinct domains, Lobe 1 (LB1) and Lobe 2 (LB2), which come
into close contact upon agonist binding, hence the name VFT [9]. The GABAB1a/b is responsible for
the ligand binding through the orthosteric site located in the VFT. The GABAB2 VFT does not bind
to any known ligands, as shown by radiolabelled ligand binding and mutagenesis studies, but is
important for the activation as the ectodomain interacts with the GABAB1a/b ectodomain to enhance
agonist affinity [10,11]. The transmembrane part of the GABAB2 subunit hosts an allosteric binding
site and is responsible for G-protein coupling [12–14]. The three-dimensional (3D) structure of the
entire GABAB-R is not known, however, eight X-ray crystal structures of the VFTs co-crystalized with
different agonists or antagonists and one of the VFT apo-form have been published [9].
The GABAB-R is linked to a variety of neurological and neuropsychiatric disorders including
memory and learning deficits, addiction, epilepsy, anxiety and depression, and is an interesting target
for drug intervention [15–18]. However, at present, the agonist baclofen ( -(4-chloro-phenyl)GABA) is
the only marketed drug targeting the GABAB-R. Baclofen is used as a muscle relaxant and antispastic
agent to treat muscle spasticity and other muscle symptoms caused by e.g., multiple sclerosis [19,20].
A major drawback with baclofen is the side effects which include dizziness, nausea, insomnia, and
hallucinations caused by abrupt withdrawal [21]. Animal models have also linked baclofen and
other GABAB-R agonists to anti-addictive effects towards nicotine, cocaine and alcohol, however,
clinical studies of baclofen in alcohol abuse have shown conflicting results [22–25]. Animal cognition
models such as the swim-test and plus-maze test, have indicated that baclofen also has anxiolytic
effects [18,26,27]. GABAB-R antagonists show antidepressant effects in different variants of the swim
test [18,28], while baclofen show worsening of depression symptoms [29,30]. The newly discovered
concept of ligand bias (ligand functional selectivity) emphasises the benefit of discovering new
compounds that promote beneficial signalling pathways, while at the same time blocking potential
deleterious GABAB-R pathways. New orthosteric compounds may expand the knowledge about the
physiological importance and the activation mechanism of the receptor [31,32], and be interesting as
drug or probe candidates, either alone or in combination with allosteric modulators.
At present, fewer than 15 antagonists and approximately 40 agonists are classified as active
GABAB-R compounds [33]. Most of them are analogues of GABA or baclofen. Their low structural
diversity may indicate that the conformational space of orthosteric GABAB-R compounds is not fully
explored. In the present study, we have evaluated the classical LBDD methods, chemical fingerprinting
and pharmacophore modelling, and the SBDD methods docking and scoring, structure-based
pharmacophores (e-Pharmacophores) and linear interaction approximation (LIA) models for their
predicative ability in VS. The aim was to identify a practical VS workflow for identification of
orthosteric GABAB-R compounds. Our results suggested that large structural similarities between
known compounds limits the feasibility of ligand-based in silico methods, but by combining
ligand-based methods with structure-based in silico methods, novel orthosteric GABAB-R compounds
may be identified, and the number of false positives may be reduced.
2. Results
2.1. Compound Datasets
All ChEMBL (version 24_1, EMBL-EBI, Hinxton, Cambridgeshire, United Kingdom) compounds
tested for GABAB-R activity were downloaded and used to generate two datasets, one with high
affinity/activity compounds hereafter called active compounds, and one with low affinity/activity and
inactive compounds, hereafter called inactive compounds. Threshold values for being including in the
set of active compounds were: IC50 < 4100 nM, Ki < 1500 nM, EC50 < 25 µM, or fold changes/inhibition
indicating higher activity than GABA, and that the compound has been tested in assays of cloned or
native human or rat GABAB-R. The IC50 value is defined as the half maximum inhibitory concentration,
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while the EC50 value is the concentration of a compound needed to produce half maximal response [34].
In total, 217 entities were downloaded, but after removal of duplicates the dataset of active compounds
contained 55 compounds (13 antagonists and 42 agonists) (Supplementary Material, Table S1), while
the inactive contained 97 compounds (Supplementary Material, Table S2).
The active compounds were structurally clustered into four clusters of agonists (cluster 2:
12 compounds, cluster 4: nine compounds, cluster 5: four compounds and cluster 6: 13 compounds),
and one of antagonists (cluster 3: 11 compounds). In addition, two antagonists and four agonists not
fitting into other clusters were grouped together in cluster 1. In the following, these compounds are
termed outliers. A dataset of DUD-E decoys (assumed non-binders) were generated from the structure
of the active compounds. Fifty DUD-E decoys were generated per compound, giving a total of 300
DUD-E decoys for the cluster of outliers (cluster 1), 1900 DUD-E decoys for agonists (cluster 2: 600,
cluster 4: 450, cluster 5: 200 and cluster 6: 650) and 550 DUD-E decoys for antagonists (cluster 3).
2.2. Fingerprinting
For each cluster of active, molprint2D (M2D) chemical fingerprints were used to generate modal
(average) fingerprints that were used to search the active/DUD-E decoy datasets. The Tanimoto similarity
metric method was used to evaluate the results. The evaluation showed that the fingerprinting
approach was not able to rank active compounds in front of DUD-E decoys (results not shown).
2.3. Development and Evaluation of Ligand-Based Pharmacophore Models
Pharmacophore models were evaluated by mapping the compound datasets of active, inactive
and DUD-E decoys to the hypotheses. One pharmacophore model per cluster was selected based on
the Matthews correlation coefficient (MCC) and the “Goodness of Hits” score (GH). All pharmacophore
hypotheses contained three to five features (Table 1, Figure 1). The statistical evaluation displayed
variation in the quality of the generated pharmacophores with a range of the MCC and GH values
from 0.20 to 0.95 (Table 1). The model giving lowest GH and MCC scores was generated from the
structural cluster containing outliers. In total, 23 of 650 DUD-E decoys generated for GABAB-R
antagonists and 115 of 2100 DUD-E decoys generated for agonists were found to be false positives
by the pharmacophore mapping. Mapping all 55 actives to the agonist-based models showed that
the models not only recognized agonists, but also some of the antagonists. In addition, all agonist
based models identified agonists in other clusters. The more general models with few features, like
those of cluster 4 and 6, identified most compounds (Table 1). The antagonist-based model identified
only antagonists. Mapping of the 97 inactive compounds showed that the pharmacophore models
recognized 61 of the compounds in the inactive dataset.
Table 1. The pharmacophore hypotheses with the number of active compounds (#Actives) in the cluster,
the number of true positives (TP), false negatives (FN), false positives (FP) and true negatives (TN)
obtained after mapping actives and DUD-E decoys to the pharmacophore model. These values were
used to calculate the Matthews correlation coefficient (MC) and Goodness of Hit (GH). AR: number of
actives retrieved after mapping all active compounds to the models. Abbreviations; Ant: antagonists,
Ago: agonists. Feature abbreviations; hydrophobic feature: H, hydrogen bond acceptor feature: A,
hydrogen bond donor feature: D, aromatic feature: R, positively charged feature: P, and negatively
charged feature: N.
Cluster Hypothesis #Actives Actives Decoys MCC GH AR
TP FN FP TN Ant Ago
1 AHHHR * 6 3 3 21 279 0.22 0.20 1 2
2 ADN 12 7 5 30 270 0.31 0.27 11 11
3 ANPR 11 9 2 2 548 0.82 0.82 9 0
4 NPR 9 9 0 2 448 0.90 0.95 12 13
5 DDDHR 4 4 0 55 145 0.22 0.22 3 11
6 DDDN 13 13 0 9 641 0.76 0.68 7 40
*: Outliers (both agonists and antagonists).
Molecules 2019, 24, 935 4 of 20




  H1 H2 H3 R 
A 3.26 3.36 4.68 3.98 
H1  2.14 5.3 4.1 
H2   5.13 5.13 




 D N 
A 3.9 3.12 




 N P R 
A 4.38 2.92 4.68 
N  4.53 5.3 
P   3.83 
Cluster 4 
 
  P6 R7 
N5 5.12 4.47 
P6  4.04 
Cluster 5 
 
  D2 D3 H R 
D1 1.64 1.64 7.34 4.80 
D2  1.64 5.80 3.32 
D3   7.14 4.42 




 D2 D3 N 
D1 3.26 3.36 4.68 
D2  1.64 5.88 
D3   6.04 
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baclofen, 27 and CHEMBL112203, respectively, are displayed. Feature abbreviations; hydrophobic 
feature: H, hydrogen bond acceptor feature: A, hydrogen bond donor feature: D, aromatic feature: R, 
positively charged feature; P, and negatively charged feature: N. 
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Figure 1. Pharmacophore models obtained from each cluster with the matrix of distances (Å) between
features. The best mapped compound for cluster 1–6, CHEMBL2322934, CHEMBL113348, CGP54626,
baclofen, 27 and CHEMBL112203, respectively, are displayed. Feature abbreviations; hydrophobic
feature: H, hydrogen bond acceptor feature: A, hydrogen bond donor feature: D, aromatic feature: R,
positively charged feature; P, and negatively charge feat re: .
2.4. Development and Evaluation of Structure-Based e-Pharmacophore Models
Structure-based pharmacophore models (e-Pharmacophores) for an agonist-induced VFT
conformation (Figure 2A) and antagonist-induced VFT conformation (Figure 2B) were generated
using the Phase program [35]. A library of 441 unique frag e ts ere a e to t e binding pocket of
the antago ist-i duce (inactive) VFT conformation (PDB I : 4MR7) and the agonist-i duce (active)
VFT onformati (PDB ID: 4MS4).
Mapping the fragment library in the inactive VFT conformation identified an aromatic feature
in LB2 close to hydrophobic- and aromatic residues (Tyr250 and Trp278), together with a hydrogen
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bond donor and a hydrogen bond acceptor feature (Figures 2B and 3). In LB1, one hydrogen bond
donor, one hydrogen bond acceptor and one negative charged feature were identified. These features
were connected to Cys129 and the serine residues located in position 130, 131, 152, 153 and 154.
Some of these serine residues were involved in both agonist and antagonist binding (Figures 2 and 3)
as described by Geng et al. [9].
The e-Pharmacophore features in the agonist-induced VFT were clustered closer together than
those of the antagonist-induced, with shorter distances between features (Figure 2). An aromatic group
was located close to the Tyr279 and Trp278 in LB2 and Tyr250 in LB2. A hydrophobic feature was
located in LB2 in close proximity to the hydrophobic part with aromatic residues almost buried inside
the VFT. A hydrogen bond donor was also located in the cleft between LB1 and LB2, almost at the
opening of the VFT. Another aromatic ring was located between LB1 and LB2 in close proximity to
Trp278, Trp65 and His170. One hydrogen bond donor and one acceptor were in LB1 close to the Ser152
and Ser153 as for the inactive VFT conformation (Figures 2 and 3).
Mapping the datasets of active compounds and DUD-E decoys to the e-Pharmacophore models
showed that the e-Pharmacophore features were not selective for active compounds. In the antagonist-
induced conformation four of total 13 unique antagonists and 602 DUD-E decoys were mapped, while
in the agonist-induced conformation only nine out 42 agonists and 1000 DUD-E decoys (the maximum
number) were mapped.
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2.5. Analysis of the Docking Results
2.5.1. Docking of Active GABAB-R Compounds
The dataset of 55 GABAB-R active compounds were docked in both agonist (PDB ID: 4MS4) and
antagonist (PDB ID: 4MR7) induced VFT conformation. The C↵ Root Mean Square deviation (RMSD)
between these conformations was 7.0 Å, with largest differences in loop regions. The overall RMSD of
residues within 5 Å of the co-crystalized ligands was 2.1 Å. Superimposition showed that the active
conformation had a more closed VFT than the inactive conformation (Figure 2).
The average docking score of the 42 agonists in the agonist-induced conformation was
 8.3 kcal/mol. The best score was  11.2 kcal/mol, while the poorest was  5.7 kcal/mol. Docking
antagonists into the agonist-induced VFT gave an average docking score of  5.9 kcal/mol, and with
poses inconsistent with X-ray structure complexes. The average docking score for the 13 antagonists
in the antagonist-induced VFT was  7.1 kcal/mol, where the best score was  8 kcal/mol and the
poorest  5.6 kcal/mol. Docking of the agonists into the antagonist-induced VFT gave an average
docking score of  6.4 kcal/mol.
Ser130 and Ser153 interacted with all 55 active compounds, independent of intrinsic activity.
The agonists were fully buried within the receptor interior, inaccessible to solvent, thereby increasing
the number of interactions between the agonists and the receptor and stabilizing the closed VFT
conformation. As known agonists and most antagonists are analogues of GABA or baclofen, all ligands
selected as cluster representatives showed similar ligand-interaction patterns (Figure 3). The LB1
residues Ser130 and Ser153 formed hydrogen bonds with a carboxylic acid moiety present in all agonists
and antagonists. The LB1 residue Tyr65 and the LB2 residue Tyr250 stabilized the agonists by forming
⇡-stacks or ⇡-cation interactions, while Glu349 formed a salt bridge or ionic interaction with the
amine moiety present in the agonists (Figure 3). The LB2 residue Trp278 formed a ⇡-cation interaction
with the ligands selected from three of four agonist clusters. Interactions between antagonists and
hydrophobic residues in LB2 such as Trp278 and Tyr250 were observed for the highest affinity
antagonists. The GABAB-R antagonists are bigger and more bulky than agonists and will most
likely prohibit the VFT closing as previously described by Geng et al. [9].
The average docking scores of known agonists and antagonists (dataset of active compounds)
were used as threshold values for evaluating the docking of inactive compounds and false positive
DUD-E decoys from the pharmacophore mapping.
2.5.2. Docking of Inactive GABAB-R Compounds
Docking the dataset of 97 inactive GABAR-R compounds (Supplementary, Table S2) showed
that 79 of 97 compounds docked into the agonist-induced VFT, while all of them could dock into the
inactive antagonist-induced conformation. In total, 13 compounds scored better than the threshold
for agonists (average score of the 42 agonists) in the agonist-induced conformation. The compounds
scoring higher than threshold are baclofen analogues containing an aromatic ring with a halogen and
an alkyl chain with amino and carboxylic end groups. In total, 10 from the set of inactive compounds
scored better than the threshold for antagonists (average score of the 13 antagonists) in the open
inactive antagonist-induced VFT conformation.
2.5.3. Docking of False Positive Compounds from the Ligand-Based Pharmacophore Mapping
The false positive DUD-E decoys from the pharmacophore mapping were docked into the X-ray
crystal structures in order to reveal if a succeeding docking procedure could reduce the number of
false positives in a VS campaign. Twenty-three of the 650 DUD-E decoys generated from antagonists
were identified as false positives by pharmacophore mapping. All of them scored worse than the
threshold value for known antagonists ( 7.1 kcal/mol), and 11 scored better than the poorest scored
known antagonist ( 5.6 kcal/mol). As the average docking score was used as the threshold, none was
applied for further investigation by LIA models.
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In total 116 DUD-E decoys generated from agonists were found to be false positive after
pharmacophore mapping. Of these, five had a docking score better than the agonist threshold
( 8.0 kcal/mol) and 72 out of the 116 gave a better score than the poorest scored agonist
( 5.7 kcal/mol). The five compounds with docking score better than threshold were studied in
the agonist LIA model to evaluate if the LIA method could identify the compounds as theoretically
inactive DUD-E decoys.
2.6. Generation and Evaluation of LIA Models
The Liaison software in combination with Strike included in the Schrödinger package [36,37]
were used for generating linear interaction approximation (LIA) models of agonists and antagonists
and predicting ligand-receptor affinities using the LIA models. A training set of 11 agonists were used
to construct the agonist LIA model, while a training set of eight antagonists were used to generate
the antagonist LIA model. The models were evaluated by true positives from the pharmacophore
mapping, but excluding those included in the training sets.
The LIA model generated for antagonists gave a R2 value of 0.98 indicating that the predicted
pIC50 values highly correlate to the fitted regression line of the experimental pIC50 values. The standard
deviation was 0.41 with a P-value of 0.0044 (Table 2 and Figure 4). The LIA model generated for
agonists gave a R2 value of 0.61, which indicates that the predicted pIC50 values correlate to the fitted
regression line of the experimental pIC50 values. The standard deviation was calculated to be 0.32
with a p-value of 0.074 (Table 2), and applying the LIA model to predict the pIC50 values of the true
positive from the pharmacophore screening, gave less accurate results for agonists then for antagonists
(Figure 4).
The agonist LIA model was applied to the five false positive DUD-E decoys from docking.
Only one out of the false positives had a predicted pIC50 value < 5. Five is normally considered as the
threshold pIC50 value for activity, and the agonist LIA model could therefore identify only one of the
five compounds as a false positive.
Table 2. The statistical values and LIA parameters (↵,   and  ) of the LIA models for agonists
and antagonists.
LIA Model R2 Standard Deviation p ↵    
Agonist 0.61 0.322 0.074  0.015  0.0012 0.34
Antagonist 0.98 0.41 0.00445  0.1707 0.0073  0.842
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3. Discussion
The GABAB-R has a large potential as a target for new drugs. The number of known compounds
is limited and most of them re analogu s of the endogenou compound GABA nd the therapeutically
used agonist b clofen. Known compou ds repr sent a quite mall conformational space that
complicates the understanding of molecular descriptors contributing to differences in affinity and
intrinsic activity, and it is a challenge to identify new and improved orthosteric GABAB-R compounds.
Our dataset of active compounds consists of compounds from experimental studies using different
assay conditions (Suppleme tary Material, Table S1), which is a challenge for the robustness of the
dataset since binding data from different assays are n t ecessary directly comparable. However,
in order to get an acceptable number of compounds for the ligand-based approaches it was necessary
to include compounds that had been evaluated using different experimental procedures. We used
threshold values for experimental activity to discriminate between active and inactive compound
datasets in order to reduce the influence of low affinity compounds on our in silico models. The dataset
of inactive omp unds therefore contained not only inactive compounds, but also compounds with
low GABAB-R activity. The compounds with highest affinity in the set of inactive c mpoun s were
four antagonists also used to generate LIA models (Supplementary Material, Table S1). Other low
affinity/activity compounds in the set of inactive compounds had activity values far below these
antagonists. The low affinity compounds are also structural analogues of GABA and baclofen, which
complicates the present study since the datasets of active and inactive compounds both contains GABA
and baclofen analogues. Discriminating between the active and inactive datasets by the LBDD and
SBDD in silico methods in the present study is therefore challenging.
3.1. Ligand-Based Screening
3.1.1. Fingerprinting, Clustering and Modal Fingerprints
Average fingerprints for each cluster failed to recognise the compounds from which the
fingerprints were generated in front of active compounds from other clusters, and in addition, they
did not discriminate between actives and DUD-E decoys. This was not a surprise due to the structural
similarities between clusters. Selecting more structurally divergent compounds was not possible.
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Using fingerprinting alone in a VS campaign for new orthosteric compounds would therefore most
likely not identify novel GABAB-R compounds.
3.1.2. Ligand-Based Pharmacophore Modelling
One pharmacophore hypothesis per cluster was selected after statistical evaluation (Table 1).
Ideally, a higher number of pharmacophores would be preferable for screening to account for
structural diversity, but this was not possible due to structural similarities between the clusters.
The pharmacophores for cluster 1, 2 and 5 gave poor discrimination between actives and DUD-E decoys,
and identified many false positive compounds. In these models, the hypothesis composition was very
general with repetitive features able to align with multiple compound structures. Low discrimination
and retrieval of many false positives is not necessarily negative in a VS workflow, as also these models
could contribute to discovery of new structural scaffolds.
A pharmacophore model of only three features can be problematic as several compounds may fit to
the model, and the models may select many false positives during VS. The GABAB-R agonists are small
with few functional groups, which gives few pharmacophore features in the hypothesis. Changing the
intersection distance constraints from 2 Å to 1.5 Å (for cluster 5 and 6) gave demanding hypotheses,
i.e., an amine group with two hydrogen bond donating features, whereas the default intersection
distance (2 Å) would generate only one hydrogen bond donor or preferably a positive charged site,
as seen for two of the clusters. A main purpose of generating cluster-based pharmacophore models
was to increase the possibility of retrieving new chemotypes. Decreasing the intersection distance to
avoid repetitive feature composition as most of the actives contains a positive- and a negative charged
group in the same positions, could also contribute to new chemotypes.
Known antagonists are larger than agonists, and may give a higher number of features in
pharmacophores than agonists. However, there are only 13 known high affinity antagonists for
the GABAB-R. Of these, 11 were grouped into the same structural cluster (cluster 3) when applying the
similarity metric and thereby only one pharmacophore model was generated. In a VS approach this
hypothesis would be considered as accurate due to selectivity towards active ligands, and it is not too
strict in terms of feature composition.
Mapping the inactive set of compounds to the pharmacophores also confirms the high structural
similarity between the active and inactive compound datasets (Supplementary, Tables S1 and S2) as 61
out of the 97 could be mapped to the models.
3.2. Structure-Based Screening
3.2.1. Structure-Based e-Pharmacophore Models
E-Pharmacophores can be applied for VS and compound optimization (e.g., hit-to-lead and lead
optimization). Using fragments that cover a wide range of functional groups to map the binding
pocket gives new insight into the properties of the binding pocket. This knowledge can be used to
guide ligand growing into areas of the pocket where specific ligand features are beneficial, as suggested
for the areas discovered in the inactive VFT structure. This possibility can be more restricted when
applying active ligands for e-Pharmacophore development, especially if the information about active
ligands is limited, as for the GABAB-R.
The antagonist-based e-Pharmacophore identified an aromatic feature in the LB2 moiety close to
Tyr250 and Tyr278. In both the X-ray complexes and our docking studies, interactions are seen only
for high affinity antagonists at this site [9], indicating that this feature is important for high affinity
antagonist binding. In addition, both a hydrogen bond donor and a hydrogen bond acceptor feature
located in this area were unexplored in our docking studies, despite being within the generated grid
map (Figure 2). These sites could be further explored by growing antagonists anchored in LB1 towards
these points using fragments complementary to the discovered features. As described, amino acids
in LB1 are essential anchoring points for antagonists and the features located in this site were not
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unexpected. In the LB1, a negatively charged feature, a hydrogen donor and one hydrogen bonding
accepting feature were identified which represents serine residues that are necessary for both agonist
and antagonist binding. None of the identified features in the agonist-induced active VFT conformation
revealed any areas not already identified in our docking studies.
3.2.2. Docking
Visual inspection of the GABAB-R VFT co-crystalized with agonists or antagonists showed that
most of the ↵-acid groups formed interactions with residues in LB1 such as His170, Trp65, Ser130
and Glu349. Amino acid located in LB2 such as Tyr250 and Trp278 interact with the agonists in all
complexes. Trp65 forms van der Waals interactions with all antagonists. An interesting observation
was a ~180  flip of Trp278 in the structure co-crystalized with baclofen compared with the other
agonist bound VFT 3D structures [9]. This flip is probably necessary for stabilizing the aromatic ring
of baclofen. Visual inspection of selected inactive and low affinity compounds that scored better than
threshold in both receptor conformations showed similar binding patterns as the active compounds,
which also was expected due to structural similarities.
None of the 23 false positive antagonist-like DUD-E decoys from the pharmacophore mapping
scored better than the average score of active antagonists when docking into the antagonist-induced
conformation. In the agonist-induced VFT, the number of false positive agonist-like DUD-E decoys was
reduced from 116 to five when using the average score of active agonists as threshold. This indicates
that using average docking scores of active compounds as a threshold in combined ligand- and
structure-based VS for orthosteric GABAB-R compounds may have filtered out most of the false
positives from the pharmacophore mapping. Identification of ligands with high affinity is desirable
and to ensure fulfilling this criterion, the threshold for evaluating docking pose should be set to the
average value instead of the value of the poorest scored active ligand in a VS campaign. By using
the average value as threshold, it is of course a possibility of overlooking putative compounds, but
most probably high affinity compounds would be identified. Using average docking scores may also
account for the inaccuracy obtained by assuming similar activity of all generated enantiomers of a
compound when the active form(s) is/are not known (Section 4.1).
Only two of nine available VFT structures were used in our docking. Ideally, the ligands should
have been docked into multiple VFT conformations in order to account for the structural flexibility
of the binding process [38]. However, the available X-ray crystal structures of the VFT are very
similar. The RMSD between the binding site residues of the agonist bound VFTs is 0.26 Å, while the
corresponding average value between six antagonists’ bound is 0.27 Å. The overall C↵-RMSD between
agonist-induced VFTs was 2 Å, while corresponding RMSDs between antagonist-induced VFTs were
in the range of 0.75 to 2 Å. Visual investigation showed that the main differences were in regions other
than the binding pocket, and available VFT X-ray crystal structures were therefore not encountered as
conformational distinct.
The necessity of docking as a step in a VS protocol for identifying GABAB-R compounds is clearly
shown by the present study, but also the difficulty to differentiate between very similar compounds
as shown by the docking of the false positives from the ligand-based pharmacophore screening.
Ligand-based methods are more time- and cost-effective than docking and scoring, and in VS for
new GABAB-R compounds, ligand-based methods may remove some compounds in the library that
definitely do not bind, before a docking step reduces the number of remaining false positives.
3.3. Generation and Evaluation of LIA Models
The methodology for predicting ligand-protein free energies by comparing the bound complex to
the free ligand-receptor state using an explicit-solvent for building a model to predict/correlate binding
free energies, was first suggested by Åqvist [39,40]. Their approach is computationally demanding
as it uses molecular dynamic simulations with an explicit water model for sampling conformations.
Using this approach for screening of a large number of compounds is therefore problematic. In the
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present study, we have therefore evaluated the LIA method, which generates thermodynamic averages
by using minimization as sampling method for the different molecular systems instead of MD.
In contrast to the original Linear Interaction Energy (LIE) method by Åqvist et al., we have also
used an implicit water model to speed up the calculations.
Åqvist found that the coefficients ↵ = 0.18 and   = 0.5 (given a charged ligand) were sufficient to
give results in agreement with experimental values for several protein systems. Later others reported
that the values could be changed and still make intuitively sense [41]. However, our simplifications
may affect the accuracy of the method, and may create coefficients different from the Åqvist LIE
method. When a full simulation is not performed, the displacement of the water molecules from the
receptor and placement of ligand in the pocket that is partly hydrophobic, is not necessarily satisfying
in terms of calculating the energy and/or entropy.
Some coefficients obtained in the present study have negative values (Table 2). When using the
OPLS2005 force field it is considered as acceptable if the   value is negative due to changes in the
cavity term [42]. Negative ↵ and   coefficients, indicates that the van der Waals (vdW) and electrostatic
forces favours the unbound state, but as previously discussed, the background of the LIE theory
does not correspond completely with the methodology applied for calculating the Liaison parameters.
Alman et al. applied the method for calculating the binding affinity of podophyllotoxin analogous
for tubulin using MD for sampling, and got negative ↵,   and   coefficients, but a significant squared
correlation coefficient (R2 = 0.73) [43].
The p-value of the LIA model for agonists was slightly higher than the normally accepted p-value
(<0.05), but was tolerated due to the correlation coefficient and low standard deviation. The LIA
model for predicting pIC50 values for antagonists, performed well with a correlation coefficient of
0.98. The agonists have in general a lower pIC50 value than antagonists, and the threshold must be
set accordingly. Totally four DUD-E decoys generated from agonist structures were considered as
actives after pIC50 predictions by the agonist LIA model. DUD-E decoys generated from cluster 1 of
outliers were included in the decoy set of both agonists and antagonists, and may have contributed to
a lower accuracy.
The statistics of the agonist LIA model were significantly less specific than the model for
antagonists. The results for prediction of pIC50 value of false positives were therefore not unexpected,
but it cannot be ruled out that these compounds are actually binders as they are only assumed
non-binders with physicochemical properties resembling known binders. The assumption that
enantiomers have identical experimental values may significantly affect the accuracy of the agonist
LIA model. Stereochemistry plays a major role in target selectivity and pharmacokinetics. Chiral drugs
can behave very differently in a system, which points out the inaccuracy with assuming an identical
pIC50 for enantiomers [44,45].
4. Materials and Methods
4.1. Datasets
All ChEMBL (version 24_1) compounds tested for GABAB-R binding were downloaded and
used to generate compound sets of active and inactive compounds. The activity threshold values for
being including in the set of active compounds were: IC50 < 4100 nM, Ki < 1500 nM, EC50 < 25 µM,
or fold changes/inhibition indicating higher activity than GABA, and that they have been tested on
assays of cloned or native human or rat GABAB-R. The dataset of actives contained 13 antagonists
and 42 agonists, including enantiomers (assuming same activity measurement for enantiomers when
not specified) [33,46–50]. MOLPRINT 2D (M2D) chemical fingerprints of all 55 active compounds
were generated, before Hierarchical clustering using Tanimoto similarity matrix was performed in
Canvas [51]. The number of clusters was set to 10, but after manual modifications and merging of
singletons and doubletons, the total number of clusters was reduced to six (Supplementary, Table S1).
The clustering method separated agonists from the antagonists, giving 1 cluster with antagonists
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and 4 clusters with agonists, in addition a cluster of outliers that merged singletons and doubletons
from the initial clustering (4 agonists and 2 antagonists). The DUD-E methodology [52] was used
to generate DUD-E decoys, using the structure of active compounds (agonists and antagonists) as
input. Fifty DUD-E decoys per active ligand were generated. The compound structures were prepared
by LigPrep [53] at a pH of 7.4. Tautomers were generated and the specified chirality of compounds
was retained.
Phase Databases
Phase is an engine that is used in pharmacophore modelling [35]. The engine can also be used to
generate and modify databases. A Phase databases were generated for each cluster of agonists and
antagonist. In addition, a Phase database containing all 55 actives, and two DUD-E decoys databases
one containing agonist-like decoys and one containing antagonist-like decoys were also generated.
Default settings with generation of up to 50 conformers per ligand were used.
4.2. Ligand-Based Methods
4.2.1. Fingerprinting
Modal fingerprints for each cluster were generated by averaging the M2D fingerprints of ligands
in each cluster into cluster based modal fingerprints, representing each of the six clusters [54].
The fingerprints selectivity were evaluated by their ability to identify true actives from DUD-E decoys
by Tanimoto similarity metric.
4.2.2. Ligand-Based Pharmacophore Modelling
Pharmacophore models for each cluster of active compounds were generated in Schrödinger’s
Phase [55] using all compounds in each cluster as input. The pharmacophore models were generated
with default parameters: 10 conformers per rotatable bond, maximum 100 conformers per compound,
2 Å RMSD tolerance level for match [55,56]. As the compounds are very similar, the intersite distance for
cluster 5 and 6, i.e., the distances between pairs of potential features in the pharmacophore composition
were changed from default 2 Å to 1.5 Å to produce more variable hypotheses, including additional
features than by default (Table 2). Selection of pharmacophore features was conducted automatically.
Any manual selection of features (or constraints) [57] was not applied due to the limited number of
active compounds available. A pharmacophore model was considered valid when the model mapped
and matched at least 50% of the compounds used to generate that particular pharmacophore model.
Mapping and matching were performed by representing each feature of a pharmacophore composition
as a distance vector that must overlap with that of the mapped ligand in order to be considered as
a match. The pharmacophore hypothesis from each cluster were also evaluated by mapping their
respective database of DUD-E decoys generated by the DUD-E methodology [58].
After mapping the respective databases of DUD-E decoys and actives to the pharmacophore
models, the accuracy of the models was evaluated by calculating the Matthews correlation coefficient
(MCC) (Equation (1)) and “Goodness of Hits” score (GH) (Equation (2)). MCC and GH are calculated
from the number of true positives (TP), false positives (FP), true negatives (TN) and false negatives
(FN). The compound had to match all features specified for a model to be classified as active, with the
exception of the cluster with outliners where the threshold was set to match four out of five features:
MCC =
TP·TN   FP·FNp













where Ha = TN, Ht = TP + FP, A = TP + FN and D = DUD-E decoys.
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The last step in the evaluation, was mapping all active and inactive compounds across clusters to
all generated models. MCC gives a correlation between the observed and predicted classifications,
in this case actual active and false positive compounds. MCC can be used even if the number of
compounds in each class differ [59]. The value can range from  1 to 1, where 1 represents a perfect
prediction, 0 indicates a random prediction and  1 represents an inverse prediction [60]. GH scoring
function takes into account the sensitivity, specificity and enrichment. The GH scoring thereby gives a
good indication of model quality by compromising the yield and actives retrieved and by taking into
account the hit list size in comparison with the library size. The score ranges from 0 to 1, where a score
of 1 represents the ideal model that perfectly separates active and inactive compounds [61].
4.3. Structure-Based Methods
4.3.1. Protein Preparation
Two crystal structure complexes of GABAB-R VFT with agonists (PDB IDs: 4MS3, 4MS4) and six
with antagonists (PDB IDs: 4MR7, 4MR8, 4MR9, 4MS1, 4MRM, 4MQF) are present in the PDB-database.
The PBD ID 4MR7 in complex with the antagonist CGP54626 with a resolution of 2.15 Å, and the PDB ID
4MS4 in complex with the agonist baclofen with a resolution of 1.9 Å were used for the structure-based
studies. They were selected to represent the active agonist and inactive antagonist-induced VFT
structures due to the resolution. The structures were pre-processed in Schrödinger Protein Preparation
wizard with default settings; Hydrogen bonds were assigned with a PROPKA pH of 7. A restrained
minimization was performed with converging heavy atoms at RMSD of 0.3 Å [62].
4.3.2. Structure-Based e-Pharmacophore Model
The Phase program [35] was used to generate e-Pharmacophores. Receptor binding sites were
defined using the centroids of residues involved in ligand binding in all agonist-receptor complexes
and most of the antagonist-receptor complexes. For agonists the centroid of Tyr250, Ser130, Ser153,
Glu349 and Trp278 was used, while for antagonists the centroid of Ser130, Ser153, Tyr65, His170,
Gly151 and Tyr250 was used. The features of each pocket was then found by mapping a library of
441 unique fragments [35] to the binding pocket. The library consisted of 1–7 ionization/tautomer
variants of each fragment, and each fragment contained 6–37 atoms with molecular weight ranging
from 32 to 226 Da. In total, the set consisted of 667 low energy fragments with ionic and tautomeric
states and with metal state penalties for each fragment. The fragments were docked into both X-ray
crystal structures by using the Glide XP docking protocol, before the pose viewer file was used to
generate e-Pharmacophores. The maximum number of features was set to seven and the hydrogen
bond donors were projected as points instead of the default vectors.
The models were screened against the generated databases of active and DUD-E decoys in order
to evaluate the capability of the models to select the active from DUD-E decoys. The matching rate of
features was set such that at least four out of the seven features should match for the antagonists and
three out of seven for agonists. The maximum number of hits was kept at the default number of 1000.
The results were evaluated by calculating the Matthews correlation coefficient (MCC) and “Goodness
of Hits” score (GH) (Equations (1) and (2))).
4.3.3. Docking Studies
The docking was performed with the Glide program of the Schrödinger suit [63]. One grid map
was generated per selected crystal structures, 4MS4 and 4MR7, by selecting the co-crystalized ligand as
the centroid of the grid box. However, the grid size was increased by changing the inner box diameter
from 10 Å to 15 Å such that larger compounds than the co-crystallized ligands could be docked.
The remaining settings for the grid generation were kept at default values. A standard precision (SP)
docking protocol in Glide was set up with enhanced sampling and generation of maximum 10 poses
per ligand. Binding poses with Coulomb and van der Waals forces > 0 kcal/mol were by default
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filtered away, while ligand poses with RMSD < 0.5 Å were treated as duplicates and one of them was
removed. The scoring threshold for agonists and the antagonists were found by calculating the average
docking score of 42 agonists and the 13 antagonists, respectively. A cross-docking where agonists were
docked into in antagonist-induced VFT conformation and antagonists into the agonist-induced was
also performed.
After the docking, one representative compound from each cluster was selected for analysis and
description of the interaction patterns between known orthosteric GABAB-R compounds and the
VFT. The interactions between the selected ligands and the VFT were compared to identify potential
differences in binding modes between the clusters and between agonists and antagonists. Cluster 1
was not included since it contains outliers of both agonists and antagonists. Known inactive and low
activity compounds (compounds with IC50, Ki or EC50 values higher than those used in the selection
of actives) were also docked and scored in the VFT of both agonist and antagonist-induced VFT
conformation (Supplementary, Table S2).
The false positive compounds from the pharmacophore screening were also docked using the
standard precision (SP) docking protocol in Glide with the same settings as previously described, to
evaluate if the docking could correctly assign these compounds as TN in contrast to the pharmacophore
screening which predicted these compounds as active.
4.4. LIA Model Development and Evaluation
In LIA calculations, molecular mechanics (MM) simulations are used to calculate energy of ligand
both in a bound and unbound state, using a continuum solvation model. The Liaison program used
the following equation to predict the free energy of binding (DGbind):
DGbind = ↵(hUbvdwi   hUfvdwi) +  (hUbeleci   hUfeleci) +  (hUbcavi   hUfcavi) (3)
The brackets indicate that the calculation uses the average energy of conformations sampled
during MM simulations. Uf describes the molecule free in solution and Ub describes the target-ligand
complex. The energy terms are the van der Waals interactions (Uvdw), the electrostatic interactions
(Uelec) and the cavity parameter (Ucav). A training set of compounds with known affinity is
used to build an energy model by fitting three coefficients (↵,  , and  ,) to their experimental free
energy of binding. The models can then be used to predict affinities of ligands with unknown
experimental affinity.
In total, 42 compounds (including enantiomers) were considered as highly active GABAB-R
agonists. Their experimental values were converted to IC50 (assuming IC50 = Ki ⇥ 2) and then
to pIC50 [64]. Six agonists were excluded since their experimental values were incompatible with
conversion to pIC50 (Supplementary Material, Table S1). Without considering enantiomers, there were
then 20 unique agonists and due to the low diversity in pIC50 totally 11 out of the 20 compounds
were included in the training set for generating the agonist LIA model (Supplementary Material,
Table S1). The remaining nine compounds were used in the test set in addition to all true positives
identified by the pharmacophore mapping, however, agonists used in the training set were removed
but enantiomers of these were kept.
Based on the affinity values, 13 compounds were considered as highly active GABAB-R
antagonists. Three of these were selected for the training set, in addition 4 low affinity antagonists from
the set of inactive were included in the training set (Supplementary Material, Table S1), to increase the
structural diversity and the range of the pIC50 value to give more useful LIA models for identification
of antagonists in a VS approach. Two of the included low affinity antagonists were from the X-ray
complexes 4MQF and 4MRM of the GABAB-R VFTs. The test set consisted of true positives from
the pharmacophore mapping which included eight of 10 remaining high affinity antagonists. Two of
the high affinity antagonists were found to be false negatives as they were not retrieved by the
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pharmacophore mapping and therefor excluded from the test set, resulting in totally eight compounds
in the test set.
The training and test sets of agonists and antagonists were docked into their respective crystal
structures (PDB ID: 4MR7 for antagonists and 4MS4 for agonists) [65] before a Truncated Newton
minimization sampling was performed with the maximum number of sampling steps set to 1000
(default settings). The flexible region of the receptor included the amino acids in the binding pocket.
A similar sampling minimization procedure was also performed for the unbound ligand and receptor.
The sampling simulations were performed in an implicit water model (default settings) [36,37].
The three necessary energy descriptors (van der Waals, electrostatic and a cavity term energies of
bound and unbound states), were calculated from the simulations of the training sets. Together with
the experimentally obtained activity values these energy values were used to derive the coefficients
↵,  , and  , and for making linear regression models and statistical evaluation by comparing the
predicted pIC50 values of the test set to the provided experimental values. The models were also
applied to the false positive agonists retrieved by the docking protocol, to evaluate the predictability
of the models.
5. Conclusions
The low number of available active ligands towards the GABAB-R complicates and limits the
use of both ligand-based and structure-based approaches. The quality of ligand-based methods
and validation of the predictability of structure-based models are dependent on both the number
and diversity of active ligands. Fingerprinting methods were used and evaluated, but did not give
reliable results. The pharmacophore models combined with docking on the other hand, showed a
discrimination between actives and DUD-E decoys acceptable for a VS process. The pharmacophore
mapping gave false positives, but docking reduced this number. The present study indicates that
the use of LIA models only slightly will affect the outcome of a VS campaign as only one DUD-E
agonist decoy from docking was recognised as a false positive by the agonist LIA model. The structural
analysis of X-ray structure complexes and docking showed that certain LB1 interactions are necessary
for anchoring the ligands in the crevice of the VFT, and that the interactions with residues of LB2 will
impact the function of the ligand and the affinity. On the background of previously mentioned studies
and in light of the results in this study, there is a strong correlation with the specific ligand features
and the number of interactions with key residues in both LB1 and LB2. In circumstances where a low
number of actives is known, exhaustive structure-based methods in combination with pharmacophore
modelling may lead to identification of novel compounds.
Supplementary Materials: The following are available online, Table S1: Biological data. The structure and
activity of the 55 agonists and antagonist in the set of active GABAB-R compounds. Table S2: structure of
inactive compounds.
Author Contributions: L.M.E. and D.W. performed and analyzed all ligand-based methods; L.M.E. performed
and analyzed all structure-based methods; M.G., A.J.B., and I.S. supervised and administrated the studies; L.M.E.
wrote the first draft of the manuscript, L.M.E., M.G., D.W., A.J.B. and I.S. revised the manuscript; A.J.B., D.W. and
I.S. achieved funding.
Funding: The study was supported by the Polish-Norwegian Research Program operated by the Polish National
Centre for Research and Development under the Norwegian Financial Mechanism in the frame of the project
PLATFORMex (Pol-Nor/198887/73/2013) and by Northern Norway Health Authorities (HelseNord) project
number HNF1426-18. D.W. was supported by the Polish National Centre for Research and Development grant
LIDER/37/0137/L-9/17/NCBR/2018.
Conflicts of Interest: The authors declare no conflict of interest.
Molecules 2019, 24, 935 17 of 20
References
1. Coudrat, T.; Simms, J.; Christopoulos, A.; Wootten, D.; Sexton, P.M. Improving virtual screening of G
protein-coupled receptors via ligand-directed modeling. PLoS Comput. Biol. 2017, 13, e1005819. [CrossRef]
[PubMed]
2. Aparoy, P.; Kumar Reddy, K.; Reddanna, P. Structure and Ligand Based Drug Design Strategies in the
Development of Novel 5-LOX Inhibitors. Curr. Med. Chem. 2012, 19, 3763–3778. [CrossRef] [PubMed]
3. Evers, A.; Klabunde, T. Structure-based Drug Discovery Using GPCR Homology Modeling: Successful
Virtual Screening for Antagonists of the Alpha1A Adrenergic Receptor. J. Med. Chem. 2005, 48, 1088–1097.
[CrossRef] [PubMed]
4. Gabrielsen, M.; Kurczab, R.; Siwek, A.; Wolak, M.; Ravna, A.W.; Kristiansen, K.; Kufareva, I.; Abagyan, R.;
Nowak, G.; Chilmonczyk, Z.; et al. Identification of Novel Serotonin Transporter Compounds by Virtual
Screening. J. Chem. Inf. Model. 2014, 54, 933–943. [CrossRef] [PubMed]
5. Kurczab, R.; Nowak, M.; Chilmonczyk, Z.; Sylte, I.; Bojarski, A.J. The development and validation of a
novel virtual screening cascade protocol to identify potential serotonin 5-HT7R antagonists. Bioorg. Med.
Chem. Lett. 2010, 20, 2465–2468. [CrossRef] [PubMed]
6. Ripphausen, P.; Nisius, B.; Peltason, L.; Bajorath, J. Quo Vadis, Virtual Screening? A Comprehensive Survey
of Prospective Applications. J. Med. Chem. 2010, 53, 8461–8467. [CrossRef] [PubMed]
7. Pin, J.-P.; Prezeau, L. Allosteric Modulators of GABAB Receptors: Mechanism of Action and Therapeutic
Perspective. Curr. Neuropharmacol. 2007, 5, 195–201. [CrossRef] [PubMed]
8. Calver, A.R.; Medhurst, A.D.; Robbins, M.J.; Charles, K.J.; Evans, M.L.; Harrison, D.C.; Stammers, M.;
Hughes, S.A.; Hervieu, G.; Couve, A.; et al. The expression of GABAB1 and GABAB2 receptor subunits in
the cNS differs from that in peripheral tissues. Neuroscience 2000, 100, 155–170. [CrossRef]
9. Geng, Y.; Bush, M.; Mosyak, L.; Wang, F.; Fan, Q.R. Structural mechanism of ligand activation in human
GABAB receptor. Nature 2013, 504, 254–259. [CrossRef] [PubMed]
10. Jones, K.A.; Borowsky, B.; Tamm, J.A.; Craig, D.A.; Durkin, M.M.; Dai, M.; Yao, W.-J.; Johnson, M.;
Gunwaldsen, C.; Huang, L.-Y.; et al. GABAB receptors function as a heteromeric assembly of the subunits
GABABR1 and GABABR2. Nature 1998, 396, 674–679. [CrossRef] [PubMed]
11. Kniazeff, J.; Galvez, T.; Labesse, G.; Pin, J.-P. No Ligand Binding in the GB2 Subunit of the GABA B Receptor
Is Required for Activation and Allosteric Interaction between the Subunits. J. Neurosci. 2002, 22, 7352–7361.
[CrossRef] [PubMed]
12. Binet, V.; Brajon, C.; Le Corre, L.; Acher, F.; Pin, J.-P.; Prézeau, L. The Heptahelical Domain of GABA B2 Is
Activated Directly by CGP7930, a Positive Allosteric Modulator of the GABA B Receptor. J. Biol. Chem. 2004,
279, 29085–29091. [CrossRef] [PubMed]
13. Eswar, N.; Webb, B.; Marti-Renom, M.A.; Madhusudhan, M.S.; Eramian, D.; Shen, M.; Pieper, U.; Sali, A.
Comparative Protein Structure Modeling Using Modeller. In Current Protocols in Bioinformatics; Bateman, A.,
Pearson, W.R., Stein, L.D., Stormo, G.D., Yates, J.R., Eds.; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2006;
pp. 5.6.1–5.6.30. ISBN 978-0-471-25095-1.
14. Pin, J.-P.; Parmentier, M.-L.; Prézeau, L. Positive Allosteric Modulators for  -Aminobutyric Acid B Receptors
Open New Routes for the Development of Drugs Targeting Family 3 G-Protein-Coupled Receptors.
Mol. Pharmacol. 2001, 60, 881–884. [CrossRef] [PubMed]
15. Heaney, C.F.; Kinney, J.W. Role of GABAB receptors in learning and memory and neurological disorders.
Neurosci. Biobehav. Rev. 2016, 63, 1–28. [CrossRef] [PubMed]
16. Tyacke, R.J.; Lingford-Hughes, A.; Reed, L.J.; Nutt, D.J. GABAB Receptors in Addiction and Its Treatment.
In Advances in Pharmacology; Elsevier: Amsterdam, The Netherlands, 2010; Volume 58, pp. 373–396. ISBN
978-0-12-378647-0.
17. Varani, A.P.; Pedrón, V.T.; Aon, A.J.; Höcht, C.; Acosta, G.B.; Bettler, B.; Balerio, G.N. Nicotine-induced
molecular alterations are modulated by GABAB receptor activity: GABAB receptors and nicotine. Addict. Biol.
2018, 23, 230–246. [CrossRef] [PubMed]
18. Pilc, A.; Nowak, G. GABA-ergic hypotheses of anxiety and depression: Focus on GABA-B receptor.
Drugs Today 2005, 41, 755. [CrossRef] [PubMed]
19. Hedley, D.W.; Maroun, J.A.; Espir, M.L. Evaluation of baclofen (Lioresal) for spasticity in multiple sclerosis.
Postgrad. Med. J. 1975, 51, 615–618. [CrossRef] [PubMed]
Molecules 2019, 24, 935 18 of 20
20. McIntyre, A.; Mays, R.; Mehta, S.; Janzen, S.; Townson, A.; Hsieh, J.; Wolfe, D.; Teasell, R. Examining the
effectiveness of intrathecal baclofen on spasticity in individuals with chronic spinal cord injury: A systematic
review. J. Spinal Cord Med. 2014, 37, 11–18. [CrossRef] [PubMed]
21. D’Aleo, G.; Cammaroto, S.; Rifici, C.; Marra, G.; Sessa, E.; Bramanti, P.; Di Bella, P. Hallucinations after
abrupt withdrawal of oral and intrathecal baclofen. Funct. Neurol. 2007, 22, 81–88. [PubMed]
22. Farokhnia, M.; Schwandt, M.L.; Lee, M.R.; Bollinger, J.W.; Farinelli, L.A.; Amodio, J.P.; Sewell, L.;
Lionetti, T.A.; Spero, D.E.; Leggio, L. Biobehavioral effects of baclofen in anxious alcohol-dependent
individuals: A randomized, double-blind, placebo-controlled, laboratory study. Transl. Psychiatry 2017,
7, e1108. [CrossRef] [PubMed]
23. Reynaud, M.; Aubin, H.-J.; Trinquet, F.; Zakine, B.; Dano, C.; Dematteis, M.; Trojak, B.; Paille, F.; Detilleux, M.
A Randomized, Placebo-Controlled Study of High-Dose Baclofen in Alcohol-Dependent Patients—The
ALPADIR Study. Alcohol Alcohol. 2017, 52, 439–446. [CrossRef] [PubMed]
24. Varani, A.P.; Aso, E.; Moutinho, L.M.; Maldonado, R.; Balerio, G.N. Attenuation by baclofen of nicotine
rewarding properties and nicotine withdrawal manifestations. Psychopharmacology 2014, 231, 3031–3040.
[CrossRef] [PubMed]
25. Augier, E.; Dulman, R.S.; Damadzic, R.; Pilling, A.; Hamilton, J.P.; Heilig, M. The GABAB Positive Allosteric
Modulator ADX71441 Attenuates Alcohol Self-Administration and Relapse to Alcohol Seeking in Rats.
Neuropsychopharmacology 2017, 42, 1789–1799. [CrossRef] [PubMed]
26. Andrews, N.; File, S.E. Handling history of rats modifies behavioural effects of drugs in the elevated
plus-maze test of anxiety. Eur. J. Pharmacol. 1993, 235, 109–112. [CrossRef]
27. Pizzo, R.; O’Leary, O.F.; Cryan, J.F. Elucidation of the neural circuits activated by a GABA B receptor positive
modulator: Relevance to anxiety. Neuropharmacology 2018, 136, 129–145. [CrossRef] [PubMed]
28. Cryan, J.F.; Slattery, D.A. GABAB Receptors and Depression: Current Status. In Advances in Pharmacology;
Elsevier: Amsterdam, The Netherlands, 2010; Volume 58, pp. 427–451. ISBN 978-0-12-378647-0.
29. Ghose, S.; Winter, M.K.; McCarson, K.E.; Tamminga, C.A.; Enna, S.J. The GABAB receptor as a target for
antidepressant drug action: GABAB receptor expression and depression. Br. J. Pharmacol. 2011, 162, 1–17.
[CrossRef] [PubMed]
30. Nakagawa, Y.; Ishima, T.; Ishibashi, Y.; Tsuji, M.; Takashima, T. Involvement of GABAB receptor systems in
action of antidepressants. II: Baclofen attenuates the effect of desipramine whereas muscimol has no effect in
learned helplessness paradigm in rats. Brain Res. 1996, 728, 225–230. [CrossRef]
31. Bowery, N. GABAB receptor: A site of therapeutic benefit. Curr. Opin. Pharmacol. 2006, 6, 37–43. [CrossRef]
[PubMed]
32. Pin, J.-P.; Bettler, B. Organization and functions of mGlu and GABAB receptor complexes. Nature 2016,
540, 60–68. [CrossRef] [PubMed]
33. Hersey, A. CHEMBL Database Release 21; EMBL-EBI: Hinxton, Cambridgeshire, UK, 2016.
34. Cornish-Bowden, A. Fundamentals of Enzyme Kinetics, 4th ed.; Wiley-Blackwell: Weinheim, Germany, 2012;
ISBN 978-3-527-33074-4.
35. Phase Schrödinger Release 2017-4; Schrödinger, LLC: New York, NY, USA, 2017.
36. Liaison Schrödinger Release 2015-3; Schrödinger, LLC: New York, NY, USA, 2015.
37. Strike Version 2.2 Schrödinger Release 2015-3; Schrödinger, LLC: New York, NY, USA, 2015.
38. Totrov, M.; Abagyan, R. Flexible ligand docking to multiple receptor conformations: A practical alternative.
Curr. Opin. Struct. Biol. 2008, 18, 178–184. [CrossRef] [PubMed]
39. Aqvist, J.; Medina, C.; Samuelsson, J.E. A new method for predicting binding affinity in computer-aided
drug design. Protein Eng. 1994, 7, 385–391. [CrossRef] [PubMed]
40. Aqvist, J.; Marelius, J. The Linear Interaction Energy Method for Predicting Ligand Binding Free Energies.
Comb. Chem. High Throughput Screen. 2001, 4, 613–626. [CrossRef] [PubMed]
41. Gassmann, M.; Bettler, B. Regulation of neuronal GABAB receptor functions by subunit composition. Nat. Rev.
Neurosci. 2012, 13, 380–394. [CrossRef] [PubMed]
42. Liaison Manual 5.8 Schrödinger Release 2015-3; Schrödinger, LLC: New York, NY, USA, 2015.
Molecules 2019, 24, 935 19 of 20
43. Alam, M.A.; Naik, P.K. Applying linear interaction energy method for binding affinity calculations of
podophyllotoxin analogues with tubulin using continuum solvent model and prediction of cytotoxic activity.
J. Mol. Graph. Model. 2009, 27, 930–943. [CrossRef] [PubMed]
44. Caldwell, J. The importance of stereochemistry in drug action and disposition. J. Clin. Pharmacol. 1992,
32, 925–929. [PubMed]
45. McConathy, J.; Owens, M.J. Stereochemistry in Drug Action. Prim. Care Companion J. Clin. Psychiatry 2003,
5, 70–73. [CrossRef] [PubMed]
46. Froestl, W.; Mickel, S.J.; Hall, R.G.; von Sprecher, G.; Strub, D.; Baumann, P.A.; Brugger, F.; Gentsch, C.;
Jaekel, J. Phosphinic Acid Analogs of GABA. 1. New Potent and Selective GABAB Agonists. J. Med. Chem.
1995, 38, 3297–3312. [CrossRef] [PubMed]
47. Froestl, W.; Mickel, S.J.; von Sprecher, G.; Diel, P.J.; Hall, R.G.; Maier, L.; Strub, D.; Melillo, V.; Baumann, P.A.
Phosphinic Acid Analogs of GABA. 2. Selective, Orally Active GABAB Antagonists. J. Med. Chem. 1995,
38, 3313–3331. [CrossRef] [PubMed]
48. Kaupmann, K.; Huggel, K.; Heid, J.; Flor, P.J.; Bischoff, S.; Mickel, S.J.; McMaster, G.; Angst, C.; Bittiger, H.;
Froestl, W.; et al. Expression cloning of GABAB receptors uncovers similarity to metabotropic glutamate
receptors. Nature 1997, 386, 239–246. [CrossRef] [PubMed]
49. Locock, K.E.S.; Yamamoto, I.; Tran, P.; Hanrahan, J.R.; Chebib, M.; Johnston, G.A.R.; Allan, R.D.
 -Aminobutyric Acid(C) (GABA C) Selective Antagonists Derived from the Bioisosteric Modification of
4-Aminocyclopent-1-enecarboxylic Acid: Amides and Hydroxamates. J. Med. Chem. 2013, 56, 5626–5630.
[CrossRef] [PubMed]
50. Blackburn, T. GABAb Receptor Pharmacology: A Tribute to Norman Bowery, 1st ed.; Advances in Pharmacology
(Book 58); Academic Press: Cambridge, MA, USA, 2010; Volume 54, ISBN 978-0-12-378647-0.
51. Canvas Schrödinger Release 2017-4; Schrödinger, LLC: New York, NY, USA, 2017.
52. Mysinger, M.M.; Carchia, M.; Irwin, J.J.; Shoichet, B.K. Directory of Useful Decoys, Enhanced (DUD-E):
Better Ligands and Decoys for Better Benchmarking. J. Med. Chem. 2012, 55, 6582–6594. [CrossRef] [PubMed]
53. LigPrep; Schrödinger, LLC: New York, NY, USA, 2017.
54. Duan, J.; Dixon, S.L.; Lowrie, J.F.; Sherman, W. Analysis and comparison of 2D fingerprints: Insights into
database screening performance using eight fingerprint methods. J. Mol. Graph. Model. 2010, 29, 157–170.
[CrossRef] [PubMed]
55. Dixon, S.L.; Smondyrev, A.M.; Knoll, E.H.; Rao, S.N.; Shaw, D.E.; Friesner, R.A. PHASE: A new engine for
pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and
preliminary results. J. Comput. Aided Mol. Des. 2006, 20, 647–671. [CrossRef] [PubMed]
56. Khan, M.F.; Verma, G.; Akhtar, W.; Shaquiquzzaman, M.; Akhter, M.; Rizvi, M.A.; Alam, M.M.
Pharmacophore modeling, 3D-QSAR, docking study and ADME prediction of acyl 1,3,4-thiadiazole amides
and sulfonamides as antitubulin agents. Arab. J. Chem. 2016. [CrossRef]
57. Warszycki, D.; Mordalski, S.; Kristiansen, K.; Kafel, R.; Sylte, I.; Chilmonczyk, Z.; Bojarski, A.J. A linear
combination of pharmacophore hypotheses as a new tool in search of new active compounds—An application
for 5-HT1A receptor ligands. PLoS ONE 2013, 8, e84510. [CrossRef] [PubMed]
58. Huang, N.; Shoichet, B.K.; Irwin, J.J. Benchmarking Sets for Molecular Docking. J. Med. Chem. 2006,
49, 6789–6801. [CrossRef] [PubMed]
59. Matthews, B.W. Comparison of the predicted and observed secondary structure of T4 phage lysozyme.
Biochim. Biophys. Acta 1975, 405, 442–451. [CrossRef]
60. Shimizu, K.; Hirose, S.; Noguchi, T. POODLE-S: Web application for predicting protein disorder by using
physicochemical features and reduced amino acid set of a position-specific scoring matrix. Bioinformatics
2007, 23, 2337–2338. [CrossRef] [PubMed]
61. Seal, A.; Yogeeswari, P.; Sriram, D.; Consortium, O.; Wild, D.J. Enhanced ranking of PknB Inhibitors using
data fusion methods. J. Cheminform. 2013, 5, 2. [CrossRef] [PubMed]
62. Madhavi Sastry, G.; Adzhigirey, M.; Day, T.; Annabhimoju, R.; Sherman, W. Protein and ligand preparation:
Parameters, protocols, and influence on virtual screening enrichments. J. Comput. Aided Mol. Des. 2013, 27,
221–234. [CrossRef] [PubMed]
63. Glide Schrödinger Release 2017-4; Schrödinger, LLC: New York, NY, USA, 2017.
Molecules 2019, 24, 935 20 of 20
64. Haupt, L.J.; Kazmi, F.; Ogilvie, B.W.; Buckley, D.B.; Smith, B.D.; Leatherman, S.; Paris, B.; Parkinson, O.;
Parkinson, A. The Reliability of Estimating Ki Values for Direct, Reversible Inhibition of Cytochrome P450
Enzymes from Corresponding IC50 Values: A Retrospective Analysis of 343 Experiments. Drug Metab.
Dispos. 2015, 43, 1744–1750. [CrossRef] [PubMed]
65. Glide Schrödinger Release 2015-3; Schrödinger, LLC: New York, NY, USA, 2015.
Sample Availability: Not Available.
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
 
Molecules 2018, 23, x; doi: FOR PEER REVIEW  www.mdpi.com/journal/molecules 
Supplementary Material 
In Silico Methods for the Discovery of Orthosteric 
GABAB Receptor Compounds 
Linn M. Evenseth 1, Dawid Warszycki 2, Andrzej J. Bojarski 2, Mari Gabrielsen 1 and Ingebrigt 
Sylte 1,* 
1 Molecular Pharmacology and Toxicology, Department of Medical Biology, Faculty of Health Sciences, UiT 
—The Arctic University of Norway, NO-9037 Tromsø, Norway; linn.evenseth@uit.no (L.M.E.); 
mari.gabrielsen@uit.no (M.G.) 
2 Department of Medicinal Chemistry, Institute of Pharmacology, Polish Academy of Science, Smetna 12, 31-
343 Kraków, Poland; warszyc@if-pan.krakow.pl (D.W.); bojarski@if-pan.krakow.pl (A.J.B.)  
* Correspondence: ingebrigt.sylte@uit.no; Tel.: +47-77-64-4705 
Table S1 - Biological data. The table shows the dataset of active GABAB-R compounds. Threshold values for 
being including in the set of active compounds were: IC50 < 4100 nM, Ki < 1500 nM, EC50 < 25 µM, or fold 
changes/inhibition indicating higher activity than GABA. Compounds were structurally clustered into six 
clusters based on fingerprints. The compounds are shown with activity values and the source of the data 
(reference). Cluster 1: four agonists and two antagonists. Cluster 2: 12 agonists. Cluster 3: 11 antagonists. Cluster 
4: nine agonists. Cluster 5: four agonists. Cluster 6: 13 agonists.  
 
Compound  Activity  Source 
Structure Name Type Value  
Cluster 1 
CGP52432* IC50 0.055 µM [1] 
 










EC50 24.90 µM [3] 
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1.  GABA B receptor pharmacology: a tribute to Norman Bowery; Blackburn, T.P., Bowery, N., Eds.; 
Advances in Pharmacology; Elsevier, Acad. Press: Amsterdam, The Netherlands, 2010; ISBN 978-
0-12-378647-0. Inhibition of binding of [3H]CGP27492  
2.  Bolser, D.C.; Blythin, D.J.; Chapman, R.W.; Egan, R.W.; Hey, J.A.; Rizzo, C.; Kuo, S.C.; Kreutner, 
W. The pharmacology of SCH 50911: a novel, orally-active GABA-beta receptor antagonist. J. 
Pharmacol. Exp. Ther. 1995, 274, 1393–1398. Inhibition of the binding of 5 nM [3H]GABA.  
3.  Han, C.; Salyer, A.E.; Kim, E.H.; Jiang, X.; Jarrard, R.E.; Powers, M.S.; Kirchhoff, A.M.; Salvador, 
T.K.; Chester, J.A.; Hockerman, G.H.; et al. Evaluation of Difluoromethyl Ketones as Agonists of 
the γ-Aminobutyric Acid Type B (GABA B Receptor). J. Med. Chem. 2013, 56, 2456–2465. 
Inhibition of forskolin stimulated (10 μM) cAMP production.  
4.  Locock, K.E.S.; Yamamoto, I.; Tran, P.; Hanrahan, J.R.; Chebib, M.; Johnston, G.A.R.; Allan, R.D. 
γ-Aminobutyric Acid(C) (GABA C ) Selective Antagonists Derived from the Bioisosteric 
Modification of 4-Aminocyclopent-1-enecarboxylic Acid: Amides and Hydroxamates. J. Med. 
Chem. 2013, 56, 5626–5630. Percent of maximum GABA (300 μM) response at a concentration of 
300 μM of tested compound. 
Cluster 2 
 
56 (R)+ IC50 0.213 µM [5] 
56 (S) IC50 0.213 µM  [5] 
 
55 (R) IC50 0.077 µM  [5] 
 
55 (S) IC50 0.077 µM [5] 
 
52 (S) IC50 1.160 µM  [5] 
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52 (R) + IC50 1.160 µM  [5] 
 
45 (S) IC50 0.140 µM  [5] 
 
45 (R) IC50 0.140 µM  [5] 
 
44 IC50 1.050 µM  [5] 
 
43+ IC50 0.089 µM [5] 
 
ChEMBL325921 IC50 1.350 µM (*) [5] 
 
ChEMBL112710 IC50 0.0066 µM (*) [5] 
5.  Froestl, W.; Mickel, S.J.; Hall, R.G.; von Sprecher, G.; Strub, D.; Baumann, P.A.; Brugger, F.; 
Gentsch, C.; Jaekel, J. Phosphinic Acid Analogs of GABA. 1. New Potent and Selective GABAB 
Agonists. J. Med. Chem. 1995, 38, 3297–3312.: Inhibition of binding of 10nM [3H]Baclofen (*) or 2 
nM [3H]CGP 27492 to GABAB receptors from rat cortex. 
Cluster 3 
 
CGP63360 IC50 0.0390 µM [1] 
 
CGP71782 IC50 0.0024 µM [6] 
 
CGP64213* IC50 0.002 µM        [6] 
 
CGP56999 IC50 0.0004 µM [6] 
 
CGP56433 IC50 0.080 µM [1] 
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CGP61334 IC50 0.036 µM [1] 
 
CGP62349(S) IC50 0.002 µM [1] 
 
CGP62349(R) IC50 0.002 µM [1] 
 
CGP54626(S) IC50 0.002 µM [6] 
 
CGP54626(R) IC50 0.002 µM [6] 
 
CGP55845* IC50 0.006 µM [1] 
1.  GABA B receptor pharmacology: a tribute to Norman Bowery; Blackburn, T.P., Bowery, N., Eds.; 
Advances in pharmacology; Elsevier, Academic Press: Amsterdam, The Netherlands, 2010; ISBN 
978-0-12-378647-0. Inhibition of binding of  [3H]CGP27492  
6.  Kaupmann, K.; Huggel, K.; Heid, J.; Flor, P.J.; Bischoff, S.; Mickel, S.J.; McMaster, G.; Angst, C.; 
Bittiger, H.; Froestl, W.; et al. Expression cloning of GABA(B) receptors uncovers similarity to 




13(S) IC50 0.360 µM [5] 
 
13(R) + IC50 0.360 µM [5] 
 
14(S) IC50 0.880 µM [5] 
 
14(R) + IC50 0.880 µM [5] 
 
R-Baclofen IC50 0.015 µM [5] 
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S-Baclofen IC50 1.770 µM [5] 
 
12(S) IC50 0.039 µM [5] 
 
12(R) IC50 0.039 µM [5] 
 
ChEMBL312675 IC50 0.200 µM [7] 
5.  Froestl, W.; Mickel, S.J.; Hall, R.G.; von Sprecher, G.; Strub, D.; Baumann, P.A.; Brugger, F.; 
Gentsch, C.; Jaekel, J. Phosphinic Acid Analogs of GABA. 1. New Potent and Selective GABAB 
Agonists. J. Med. Chem. 1995, 38, 3297–3312. Inhibition of binding of the binding 10nM 
[3H]Baclofen to GABAB receptor from rat cortex. 
7.  Carruthers, N.I.; Spitler, J.M.; Shing-Chun Wong; Blythin, D.J.; Xiao Chen; Ho-Jane Shue; 
Mittelman, S. Synthesis and resolution of β-(aminomethyl)-4-chlorobenzeneethanesulfinic acid a 
potent gabaB receptor ligand. Bioorg. Med. Chem. Lett. 1995, 5, 237–240. Not specified 
Cluster 5 
 
27(S) IC50 0.065 µM [5] 
 








Inhibition 66% [5] 
5.  Froestl, W.; Mickel, S.J.; Hall, R.G.; von Sprecher, G.; Strub, D.; Baumann, P.A.; Brugger, F.; 
Gentsch, C.; Jaekel, J. Phosphinic Acid Analogs of GABA. 1. New Potent and Selective GABAB 
Agonists. J. Med. Chem. 1995, 38, 3297–3312. Inhibition of binding of 10nM [3H]Baclofen  
Cluster 6 
 
GABA IC50 0.025 µM [5] 
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Table S1. Cont. 
 
7(S) IC50 0.920 µM [5] 
 
7(R) + IC50 0.920 µM [5] 
 
8(S) IC50 0.780 µM [5] 
 
8(R) + IC50 0.780 µM [5] 
 
ChEMBL112203 IC50 0.0024 µM [5] 
 
ChEMBL448343 Ki 0.0051 µM [8] 
 
16(S) IC50 0.018 µM [5] 
 
16(R) IC50 0.018 µM [5] 
 
9(S) IC50 0.5 µM [5] 
 
9(R+) IC50 0.5 µM [5] 
 
29+ IC50 0.280 µM  [5] 
 
68+ IC50 0.665 µM (*) [5] 
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Table S1. Cont. 
5.  Froestl, W.; Mickel, S.J.; Hall, R.G.; von Sprecher, G.; Strub, D.; Baumann, P.A.; Brugger, F.; 
Gentsch, C.; Jaekel, J. Phosphinic Acid Analogs of GABA. 1. New Potent and Selective GABAB 
Agonists. J. Med. Chem. 1995, 38, 3297–3312. Inhibition of binding of 10nM [3H]Baclofen or 2 nM 
[3H]CGP 27492 (*) to GABAB receptors from rat cortex. 
8.  Alstermark, C.; Amin, K.; Dinn, S.R.; Elebring, T.; Fjellström, O.; Fitzpatrick, K.; Geiss, W.B.; 
Gottfries, J.; Guzzo, P.R.; Harding, J.P.; et al. Synthesis and Pharmacological Evaluation of Novel 
γ-Aminobutyric Acid Type B (GABAB ) Receptor Agonists as Gastroesophageal Reflux 
Inhibitors. J. Med. Chem. 2008, 51, 4315–4320. Displacement of [3H]GABA. 














CGP51776 IC50 6 µM [1]   
 




1.  GABA B receptor pharmacology: a tribute to Norman Bowery; Blackburn, T.P., Bowery, N., Eds.; Advances in 
pharmacology; Elsevier, Academic Press: Amsterdam, The Netherlands 2010; ISBN 978-0-12-378647-0. 
Inhibition of binding of  [3H]CGP27492  
 
+Agonists included in the test set used to calculate the LIA coefficients 
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Table S2 - Inactive compounds. The structure of the inactive compounds. The dataset contains totally inactive 
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